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ABSTRACT
This thesis is divided into two sections. The first section focuses on
developing a better method for the detection of C - reactive protein (CRP) from whole
blood. CRP plays a key role in determining the risks associated with various
cardiovascular diseases. However, detecting this protein is a challenge since it
accounts for < 1% of all known blood proteins. This protein can be detected by using
a sandwich ELISA inside of a microfluidic chip made from Polydimethyl Siloxane
(PDMS). PDMS chips are created that will first remove blood cells and platelets from
whole blood. For the removal of blood cells, different filter papers that specialize in
blood separation are tested based on the volume of filtrate recovered, amount of blood
cells filtered out and whether the cells rupture or not. From these tests, it was
determined that the Vivid Plasma Membranes GX and GR from the Pall Company was
the most suitable filter based on blood cell removal and quality of filtrate.
To further compliment this, these chips need to extract high abundance plasma
proteins (HAP) including human IgG antibody and human serum albumin. These
experiments focused on using protein A as a method for the removal of IgG due to its
high affinity with the antibody. This will be then coupled with IgG that has been preattached to Protein A specifically modified to attach to Human Albumin. Experiments
were conducted in order to obtain the appropriate incubation time needed for removal
of antibody/protein as well as the effects on surface concentration and amount of
incubation reservoirs. The final step was to combine these two aspects in order to
create a microfluidic chip that accurately detects CRP by filtering out blood cells and
removing high abundance proteins. This resulted in a microfluidic chip that was able

to detect CRP from whole blood while filtering out blood cells and removing the bulk
of the high abundant plasma proteins in order to obtain a high signal. This was
performed by the addition of multiple incubation areas for high abundance protein
removal embedded on the chip. Detection was carried out via fiber optic cables and a
standard curve was created that associated a specific CRP blood concentration to an
intensity found via fiber optics. By use of this method, a correlation between the
concentration of CRP in a sample of blood, as well as a limit of detection for the
system could be obtained.
The second section focuses on identifying an antibody fragment as a biomarker against tau protein. Tau protein is a known to play a role in the development
of Alzheimer's disease. This is due to the rapid addition of multiple phosphate groups
attaching to the protein. This section focuses on the identification of antibody
fragments that detect a normal form of tau and one affected by the addition of
phosphate groups. These fragments are recombinant antibody fragments created via
phage display. Antibody phage is inserted into a well, in which the phage that is able
to bind to tau will bind to it. These phages are then injected into an E. coli culture
which will produce antibodies known as single-chain variable fragments (scFvs).
These antibodies are extracted and tested on whether or not they attach to the specific
tau antigens. After performing these experiments, two scFvs have been found that
attach to both forms of tau: one with phosphate groups and one without. Titration
curves and DNA sequences for both antibodies were also created. With these
antibodies, they can be used as an effective biomarker into the early treatment of
Alzheimer's disease.
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SECTION 1

DETECTION OF C REACTIVE PROTEIN IN WHOLE BLOOD

CHAPTER 1

INTRODUCTION

In previous years, in order to effectively detect a disease or a serious condition,
a large sample would have to be extracted and sent into a laboratory. From there,
numerous experiments that would take days, even weeks to complete would have to be
performed. Not only was this work time consuming, but it also could mean the
difference between life and death to a certain individual. Today, testing can be
performed with small chips and paper-based cartridges with little fluids required. This
is a breakthrough in detecting and treating certain diseases and ailments. This is what
is known as Lab-on-a-Chip (LOC). In LOC experiments, large scale experiments are
performed on the small scale with small volumes of sample and reagent, is not only
found in current research, but used in practical applications[1,2]. This can be beneficial
in rapid detection and care of various ailments. One such ailment is heart disease[3].
There are various factors that can cause heart disease which include high cholesterol[4].
However, one important compound is C - reactive protein (CRP). CRP is found in the
blood and is a factor in determining whether or not an individual can be affected by
heart problems[5]. If a certain sample has a level of CRP that is over a certain amount,

1

then this individual would be susceptible to heart disease. Currently, those same
laboratory methods are used to detect CRP, which include extraction of a good amount
of blood and waiting at least a few days for results[6]. The following project will focus
on these aspects of LOC’s in order to better detect CRP.
1.1.

Lab on a Chip

In the previous decade, there has been an effort to make the detection and
treatment of diseases and ailments easier and faster. Currently, the best methods to
detect diseases are in laboratories with expensive equipment[6]. There are various
issues that do come up when performing these experiments. First of all, bulky
equipment is used and a lot of it can be pretty expensive to buy and/or repair. Second,
with this large equipment, it can be certain that large amounts of sample and or
reagent have to be used. This amount can be in the area of a few milliliters. The third
issue is the time needed to perform each experiment. These tests can last for a few
weeks if needed. Because of these issues, a new method needs to be addressed.
Basically, a system for detection has to be designed, that not only is light and portable,
but must also be fast in detection and must take as little fluid as possible.
Currently, there is a new method of detecting ailments with all of these points
in mind called Lab-on-a-Chip, or LOC for short. LOC essentially takes experiments
that can only be done in labs and miniaturizes them onto a small chip[1,2]. Because of
this, all the reagents used would have to be enough to be present in the chip,
preferably in the microliter range. In addition to all of this, because of the smaller
volumes of liquid, the time needed to perform these experiments is greatly reduced.
This allows for better detection that most people can do in a relatively short amount of
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time. This is beneficial not only for home testing, but also for allowing testing to be
performed in under-developed countries, where access to top of the line health care is
all but non-existent[7].
Because LOC devices are relatively new, there are a limited amount of
technological advances that are widely known. The most known system to use all
three of these properties (miniaturization laboratory equipment, small sample and
reagent size and quicker reaction times) are glucose meters. These meters measure the
amount of glucose that is found in the blood[8,9]. Other examples of these include
pregnancy tests[10] and disease testing kits that range from strep throat[10] all the way to
HIV[11]. These devices prove to be beneficial in the determination of something that
does not need a large scale laboratory or a large amount of time to complete.
How can each of those three aspects create a better system for detecting
diseases and ailments? Here, each aspect can be looked at one at a time. The first
aspect is the amount of equipment. As stated previously, the detection of most
antigens are performed in huge laboratories with numerous large and expensive
equipment[6]. With LOC, chips are created using inexpensive materials (polymers and
paper, as a few examples)[3]. These chips include all of the reagents and detection
areas that are needed for the experiment to be performed[8]. Also, platforms can be
made that are either portable or hand held, eliminating the need for a laboratory[8].
The second aspect involves using as little reagent and sample as possible. In
laboratories, it is common to use milliliters of sample and reagent to perform
experiments[6]. But in LOC applications, the amount of fluid used is in the microliter
range[8]. Even in ELISA (enzyme linked immunosorbent assay) experiments, which
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will be explained later, the total amount of liquid used in each experiment could be
upwards to around 1 liter[12]. But in LOC experiments, with the exception of a sample,
the majority of the fluid is in the chip. And with the chip being as small as possible,
the amount of fluid can amount to less than 10 milliliters[1,8]. The third aspect involves
time. In normal laboratory settings, with the previous two aspects, these experiments
can take upwards to a few days to complete. With LOC processes, these same
experiments can be done in the matter of an hour or less with comparable results. For
these reasons, it can be seen that LOC technology is a novel idea as a better way to
detect diseases and ailments.
One source of interest with LOC devices is the method of detection of various
pathogens in blood. Since there are about 4.7 – 5.5 liters of blood in the body and it
reaches virtually every place in the body carrying oxygen, carbon dioxide and
nutrients, it is one of the body's most essential fluids[13]. There are thousands upon
thousands of different proteins and pathogens that can be found in blood, some of
which can be dangerous for people. There have been numerous methods to use LOC to
detect these antigens, but one of the problems with using LOC devices with blood is
that the makeup of blood is very complex[14]. Plus, with the small amount of liquid
used in LOC, it becomes difficult to separate the antigen that is desired from all the
other components in blood[14]. In order to see how complex blood is and the problem
associated with it, the upcoming sections will explain the composition of blood with
comparison to C-reactive protein.
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1.2.

Detection of C-Reactive Protein in Blood

Since CRP is normally found in blood, one of the issues concerning the
detection of CRP on LOC is the amount of interference caused by other components in
the blood. These components not only include large particles, including blood cells
(both red and white) and platelets, but also smaller particles, including various blood
proteins and antibodies[14]. Because LOC applications require the use of minute
amounts of reagents (up to 1 mL), traditional blood plasma separation, which include
centrifugation is not applicable. Also, it should also be noted that because of the need
to these applications to be portable and compact, an on-site separator also has to be
incorporated onto the chip. Because of these reasons, a direct blood plasma separator
has to be integrated onto the chip[15-17]. In the upcoming sections, different methods of
blood separation will be explained and checked in order to see if it is feasible to
integrate these systems onto an LOC device.
One other issue is in the plasma itself. CRP is only one of thousands of
proteins found in blood and these proteins can cause interference with detecting
CRP[18]. Because of this, a method to extract a good amount of proteins before
detection has to be implemented inside of the chip. This can be performed by
incorporating the various channels that transfer the plasma from the cell separator to
the detection site[14]. Using the channels, these proteins have to be removed before
they enter the detection area. There are different methods which can be performed to
accomplish this. These will be explained in the upcoming sections.
One other point to get across is that there are many methods to detect CRP in
blood, including different methods based on LOC concepts[19,20]. This project will take

5

a look at these different concepts and compare them to how well they can be
performed. With all of these concepts, a newer and better method to detect CRP in
blood on a chip will be tested.
1.3.

Removal of Cells and High Abundance Proteins

As previously stated in section 1.2, one of the issues that surround the
capturing of CRP is because of the fact that it is normally found in blood[6]. This
causes a lot of issues because of the amount of other abundant objects in blood[18].
These objects of important not only are of concern on the micro scale (red and white
blood cells, platelets), but also on the nanoscale (plasma proteins). These objects are
able to cause all types of obstruction when they are placed in a detection area that
would be used to capture CRP. Because of this problem, it is essential to remove
these aspects in order to obtain a reliable result.
Starting from whole blood, it is ideal to remove the blood cells and the
platelets first[17]. The reason for this being that it is easier to remove larger objects,
(cells, platelets), compared to the proteins. Since the cells are noticeably larger, they
do tend to interfere with the signal the most. This can be done either by intentionally
blocking the receptors, or by accidental removing of whatever is supposed to bind to
CRP, or whatever antigen is being detected. There are numerous methods to separate
blood cells from plasma, but most involve using large devices and sample amounts[21].
In terms with LOC applications, especially if it is being used in a non-laboratory
setting, it would be ideal to use only a minute amount of blood and basically separate
it on a chip. There have been projects in the past that have focused on using filter
paper as that medium because of its flexibility to be in any shape and size, its low cost

6

and with most papers, its effectiveness in separating blood cells from plasma[16,17].
This project will integrate this method of using filter paper for blood plasma
separation.
The other obstacle in this project is the amount of proteins found in plasma[18].
There are hundreds of plasma proteins at varying concentrations. One of the issues
surrounding this is that like blood cells, these proteins are still able to cause
interference within the detection area. Because of this, like the blood cells, they have
to be removed in order for CRP to be fully detected. However, because of their small
size and that this has to be performed in the chip before detection and after blood cell
separation, current methods of protein removal, which can include centrifugation[21],
cannot be applicable. Instead, there have been studies, including former
investigations[22-24], which use antibodies on surfaces, like an ELISA[12] (EnzymeLinked Immunosorbent Assay) that can capture these various proteins. This project
will focus on these principles in order to effectively remove these high abundance
proteins (HAP).
1.4.

Objective

The objective of this investigation is to create and improve on a LOC process
that would better detect C - reactive protein in blood. This project will be in
cooperation with previous projects that have been used to begin to detect CRP[22-24].
These projects include a better method to filter blood cells, capture HAPs in
blood/serum that can cause interference and use these two methods to implement a
system to detect CRP onto a chip design that was previously used in a few other
projects.
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The first part of the project is to find a better way to filter blood cells. This is
important since they consist of the largest objects in blood and take up the largest
amount of space. There have been previous methods in which to extract plasma from
blood into a microchip[23,24], but a lot of projects do not go into a lot of detail that
explains the need to better filter blood. These reasons include the amount of force it
takes to extract blood into a channel, how much plasma can be extracted from filter
papers and if the paper is sturdy enough to withstand not only the amount of blood
cells on it, but also the force required to effectively extract plasma without ruining the
filter. For this, there will be research performed that will determine the quality of the
filter paper that will be used for the microchip.
The second part of the project is to find a better method of HAP removal. Like
the above section, there have been attempts to effectively remove these proteins[23,24].
However, as will be explained in Chapter 2, there are flaws with these methods. This
is based on the amount of proteins in plasma and how they can affect the detection
area. This is not only because of the amount of the different types of proteins, but
rather the amount the most abundant proteins in blood plasma: human serum albumin,
and human immunoglobulin antibody G. These two proteins account for more than
75% of all the total proteins in blood[18,28]. Because of this, which will be explained in
the upcoming sections, a better method of antibody removal must be performed.
The final part will be to put both parts together in order to better a currently
proposed method for CRP detection in whole blood. With these two parts formed into
one, actual CRP tests in blood can be performed. In the previous projects, most
experiments were not performed with whole blood because of special procedures and
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the uncertainty of the amount of proteins in a certain sample. Most projects either
relied on a buffer solution with CRP in it, or serum with CRP. Because of this, one
could not say whether or not it could be performed with blood. One reason is that
serum does not contain fibrinogen, a protein known for clotting, whereas plasma does.
Also, the previous filter effects have to come into play. It has to be certain that only
plasma can go into the channel, and not either blood cells or hemoglobin, caused by
hemolysis, or blood cell rupturing. These factors have to come into play, in order for
this project to be successful.
Lab-on-a-Chip is a novel idea, where a person can perform diagnostic checks
without the use of a laboratory and a large amount of sample and/or reagent. But the
above topics have to be addressed in order to make certain that it can be justified that
blood can be used for LOC applications. Due to the amount of blood cells and the
amount of plasma proteins, these have to be removed first hand in order to be able to
detect CRP, a known protein that is linked to cardiovascular disease. With this in
place, a better method of detecting CRP on a microfluidic chip can be performed.
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CHAPTER 2

REVIEW OF LITERATURE

2.1.

Types of Lab on a Chip Applications

The first known instance of Lab-on-a-Chip (LOC) was in the December 1979
issue of Electron Devices, where a miniature gas analysis system was implemented on
silicon using photolithography and chemical etching[1]. This was a system used for
gas chromatography and used to detect and separate various hydrocarbon mixtures[1].
However, there has been an increased interest in microfluidics starting in the mid to
late 1990’s[2]. One of the earliest known examples of LOC technology was a project
between the years 1999-2003 at Delft University in the Netherlands where a microchip
was created that allowed for the analysis of different bioprocesses (i.e.
fermentation)[2]. These microchips was created by using glass and used silicon and
glass etching in order to create the channels to allow fluid inside the chip.
One other application for LOC systems is for testing the quality of certain
fluids (urine, semen, blood, water, etc…). By allowing these measurements, one
could find out how healthy a certain environment is. For example, a biochip has been
developed by Siemens that would be able to test the quality of water[25]. This test
would be able to detect certain hormones, antibiotics, bacteria and pesticides. The unit
is roughly the size of a laptop computer and can be able to identify up to 25 known
substances in a 30 minute timespan. This biochip is covered with surface antibodies
that react to corresponding substances contained in the sample liquid. This is followed
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by an electrochemical reaction which emits a signal. With this technology, it would
be beneficial to any industry that handles wastewater on a regular basis (water
treatment plants, hospitals, and even living conditions with horrible drinking water)[25].
However, the most common application of LOCs is in the use of medical
diagnostics. In recent years, there has been a rise in the amount of the need of portable
diagnostic equipment that is easy to use with accurate results. One option that helps
with LOC devices is the integration with point of care testing (POCT). POCT is
testing that is performed at or near the site of where a patient is located. These tests
are important as that they can give direct results to the patient at his or her precise
location[26]. This is both beneficial to the doctor and the patient where that the results
for any diagnostic test can be fast and immediate. Also, since the tests are performed
with the patient at the doctor’s side, there is no need of a laboratory in order to obtain
results. There are many types of POCTs that are currently in use. Some of the most
common tests that require POCTs include testing for pregnancy, the amount of blood
glucose, testing for strep throat and influenza via the throat[10,26]. These are only a few
of the tests that POCTs can deliver.
However, with the advances in medical diagnostics, there is a greater need to
deliver POCT as a method of detecting different conditions and diseases. This is
extremely beneficial in home care, doctors working on site and in places where
modern medical facilities are not readily available. One such use for POCT that has
been on the rise is the use of analyzing blood. Blood contains numerous amounts of
proteins, viruses and compounds that that serve a specific function within the human
body[27,28]. One of the first POCT devices that incorporate LOC technology are
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glucose meters. Here, a small amount of blood is drawn from the body and sent up a
wick coated in glucose oxidase, which is an enzyme that reacts to the glucose found in
the blood sample[8,29]. An electrical current then interacts with the glucose reaction,
which then generates a signal. This signal then is read as a value that corresponds to a
glucose concentration in blood. The higher the signal, the higher the number[29]. This
allows clear, quick and accurate results for people who suffer from diabetes, in order
to make sure that their glucose levels are either healthy or not[8,29]. This is only one
example of an LOC device which is a good POCT tool for blood testing.
Other examples of POCT for LOC devices that uses blood include various
chips that are able to detect a whole plethora of proteins and ailments[30-33]. These
include a device that uses an LED to detect proteins and viruses fixed to a gold
plate[30,31] and a device that could detect conditions that include HIV and diabetes[32].
In the example of the LED and nanoparticles, proteins and antibodies are fixed on an
array and a blood sample is passed over it. After incubation, a gold plate with holes
on it goes over the sample and light is emitted from an LED through the holes and
onto the sample. An imager detects the emitted and reconstruct the image of the
detected chip into intensity values[31]. One final example is a chip which separates
blood cells and analyses the properties of the separated cells[33]. These examples of
POCT chips which use LOC technology are useful in that different viruses and
proteins and can be extracted and analyzed. With this technology, it will not be long
until these detection values will have a correlation to how much of an extent a person
has a certain ailment. However, one thing in common with these LOC devices is not
only that blood is used, but also that blood cells have to be separated from plasma in
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order to obtain accurate results. The next section will explain the makeup of whole
blood, why separation is an issue and what types of separation are there.
2.2.

Whole Blood Makeup

Figure 2-1: Makeup of whole blood[27]
In the human body, there are many factions that contribute to the makeup of
whole blood. The first includes red and white blood cells and platelets. These three
components are the biggest objects that can be found in blood. Red blood cells
transport nutrients and oxygen to the muscles of the body, while also transporting
carbon dioxide to the lungs and waste to the kidneys. They account for 45% of the
total volume of blood. White blood cells are part of the body's immune system, which
fight off foreign pathogens and platelets are used for blood clotting when the blood
canal is ruptured in order to prevent blood from escaping the canal. Both of them
account for < 1% consists of the volume of blood. The remaining 55% is known as
plasma. Plasma consists of water and all the proteins that are common in blood. With
the absence of the protein fibrinogen, which aides platelets with clotting, this fluid is
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called serum[18,27,44]. Figure 2-1 shows a comparison as to how the makeup of whole
blood is constructed.
The issue with blood in an LOC process is that these three components can
interfere with any detection signal when a certain antigen is to be obtained. This is due
to the large size and abundance of the cells. Most proteins have an average diameter
size of 200-400 µm, while blood cells as a comparison have a diameter of 6-8
µm[18,44]. In any experiment in which blood is used, it will cause interference in any
type of detection because of its size. These cells could both act as a barrier and block
certain antigens from being detected or if there is a method of detection already in
place in the chip, it could effectively remove that area of detection. Either way,
because of this disruption, it will be necessary to remove said blood cells and platelets
before the blood goes into the chip. The following section will explain the various
methods of blood filtration and plasma separation.
2.3.

Methods of Blood Cell Separation
2.3.1. Blood Centrifugation

The most common method for blood cell removal and plasma separation is
centrifugation. This involves taking a vile of blood and placing it inside of a
centrifuge. Using centripetal force, the centrifuge spins around at a high RPM and the
cells head towards the bottom of the vial. After about 20 to 30 minutes, a vial that
appears to be red now has three visible layers: a bottom red layer showing the cells, a
small middle layer containing platelets and a clear, almost tan layer containing plasma
or with EDTA, serum[21]. Figure 2-2 on the next page shows two vials with blood
inside of them. The right vial is normal blood without any separation of blood cells
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occurring. The left vial is blood that has underwent centrifugation. Notice the two
distinct layers; while the third layer, the platelets, are not shown due to the amount and
size of them in blood. The bottom of the vial contains all of the blood cells, both red
and white, while the top tannish translucent liquid is blood plasma after the removal of
blood cells.

Figure 2-2: Blood separation via centrifugation (left vial) compared to whole blood
without separation (right vial)
While centrifugation is an ideal method to separate blood cells effectively, it is not an
ideal method of blood separation to use in POCT with an emphasis on LOC
technology. The main reason for this being that external equipment has to be used. In
this case, a centrifuge has to be used. With LOCs and POCTs, it is imperative that all
experiments are performed on the chip. This should include any blood separation
processes where the testing can be performed outside of the laboratory. Since a

15

centrifuge is normally not included on or in an application involving LOC and that
most centrifuges can be big and bulky, this method is not applicable with this type of
process. Also, the amount blood required to be separated is greater than what is
required in LOC applications. In order to effectively see any separation, at least 1 mL
of blood has to be sufficient in order to see this separation of plasma and cells. One
could use less blood, however for most experiments that use blood centrifugation; at
least 1 mL is required in order to effectively separate blood. The most effective
method to separate plasma from blood would be to perform this inside of the chip
itself.
2.3.2. Lab on a Chip Methods
Currently, there are numerous methods for the separation of plasma from
whole blood with volumes less than 1 mL on LOC devices. One of these methods
involves a process known as dielectrophoresis. “Dielectrophoresis (DEP) is a
technique to handle neutral particles in liquid medium using polarization of particles
and medium in an inhomogeneous electric field,” according to Nahashima[34]. This
means that a force is placed upon a particle, in this case blood cells, and moves them
when exposed to an electric field. In this article, blood is inserted inside of the chip
and an electric current is run through the chip, which separates the cells from the
plasma. This is performed by placing electrodes on one side of the chip and
connecting it to an electric current. As soon as a voltage is applied, the cells move
towards the electrodes and plasma is extracted through small channels into a small
reservoir. The result of this being fully separated plasma without the rupturing of
blood cells[34]. Even though this is a good system for LOC applications, it cannot be
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useful for POCT diagnostics. For one reason, this system relies on an outside electric
current in order to separate the cells. This defeats the purpose of having the system
portable and helpful in on site diagnosis. Also, because of the electrodes, it is rather
difficult to integrate it with a system that also accounts for CRP detection. There are
too many electrical parts this can cause interference with the detection system due to
the electric field. One other constraint is that during the fabrication of the chip, the
electrodes have to be fabricated inside of the chip. These are gold electrodes that must
be between glass and epoxy before blood is inserted[34]. This creates a problem in that
the chips are more expensive to make because of the electrodes. For this reason, other
methods for blood plasma separation have to be considered.
One other method that can be considered when trying to filter blood in a
microchip is by building tiny micro structures embedded inside of the chip that can
help separate the blood cells[35]. Based on the research performed by Shim, a
microfluidic chip was created in order to separate blood cells from plasma using tiny
microstructures and packed beads in the chip[35]. Like the previous example, small
channels were etched inside of the chip, but this example does not require the use of
electrodes to separate the chip. Instead, small channels were created inside of the chip
complete with fluid beds to hold the blood in the chip for filtering. These beds were
filled with packed beads which created spacing just large enough for plasma to travel
through, but not the blood cells. Movement throughout the chip was performed by
capillary action in the chip, where the plasma would seek and fill the open spaces
caused by the beads. Plasma was then extracted by way of an opening where air could
be pumped into the chip and forces the plasma out of the chip[35].
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Even though this is a possible method of blood cell removal, in terms of this
project, it is not a viable method to remove blood cells. The reasoning for this is the
fabrication, or building, of the microchip. According to Shim, a nickel plate had to be
coated with a photoresist in order to create the molds. These molds were formed by
exposing the photoresist under UV light and then developing the molds[35]. One of the
experiments on mold creation involves this method, but the technology provided by
the laboratory does not allow the formation of these particular channels. This is due to
the fact that in order to create narrow channels, the UV light source in this experiment
has to be focused and direct in creating these channels. A broad UV light source can
cause errors in creating the channel shape by making the channel widths wider than
what it should be[22]. This will be explained in further detail in chapter 3. Also,
because of the extra step in that beads have to be used; there still can be gaps in which
blood cells can escape. Because of these reasons, this method of blood filtration is not
feasible for this thesis project.
Other methods of blood cell separation include hydrophoretic filtration, in
which high structures inside of the chip inhibit blood cells from passing through[36],
planar microfilters[37], microfilters with agarose gel[38], which does not use external
forces to remove blood, devices that require cross-flow filtration[39] and ones that
utilize the Zweifach-Fung effect, (where particles tend to migrate to an area of a
higher flow rate when approaching a fork in the channel)[40,41], which uses more
external forces upon the blood. Again some of the problems with these devices are the
amount of time, energy and cost to create and the issues of implementation onto a
LOC system. However, with the examples that do not require external forces to
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separate blood cells, this becomes more difficult as a way to extract plasma is needed.
Because of this, there has to be a simpler way to not only remove blood cells, but also
extract plasma into the microchip.
In order to incorporate blood filtration in a microfluidic chip for use in a POCT
device, it not only has to be cost effective in monetary value and labor, but it also must
be easy to set up and integrate without external factors. For this reason, one of the
most effective methods is to use blood filters or membranes that can effectively
separate blood cells from plasma. Filters/membranes are a more logical solution
because of its availability, ease of use and cost. In addition, since the filtration is to be
included in the microchip, the filters can be altered so that it is small enough to either
fit inside or on top of the microchip. However, one does have to look out for the
possibility of potential blockage in the filter paper based on the size of the blood cells
compared to the pores embedded on the paper[42]. Despite this disadvantage, the
restructuring of the chip to encompass the filter will be minimal. Because of the idea
of filter paper, the user will be able to handle smaller quantities of blood (up to 100
µL) and eliminates the need for a centrifuge. Unlike previous Lab-on-Chip methods
that involve small microchannels which filter blood, to include that and have the
experiments on the same chip will require a larger chip altogether. This would require
a redesign of the device that performs the immunoassay in order to adapt to the
changes in the chip design. Because of these reasons, it would be beneficial in
incorporate filter paper as part of the blood – separation process.
Since there are numerous blood filters, it would be essential to test as to how
well each one will fair. While some filters are just a simple filter, others are more
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complex based on its mechanics and how effectively it can filter out blood cells. For
this reason, two separate tests will be conducted for the effectiveness of the filters: a
filtrate volume test, a blood cell characterization test.
2.4.

Plasma Makeup and Protein Removal

One other concern deals with what happens after the plasma fully separates
from the blood cells. This concern deals with the makeup of the plasma. Currently,
there are thousands of known proteins and antibodies in plasma[45], most of which
again interfere with whatever the method of detection system is used. The amount of
these proteins in blood is usually around 8% of the volume of plasma, while the
remaining 92% is water, with dissolved materials which include glucose, vitamins,
minerals, carbon dioxide and urea[43]. While there are hundreds upon hundreds of
proteins that are known to cause interference, three main proteins usually cause the
most interference. The first important protein is fibrinogen, which explained in the
previous section, is the cause of blood clotting along with platelets[18,44]. It is a long
protein that has an approximate length of 45 nm and it is composed of multiple peptide
chains which link together and form this long protein[44]. Compared to the other
proteins that will be mentioned later on, fibrinogen can cause interference with
detecting antigens in blood. Even though the amount of fibrinogen in blood is low
compared to other proteins (4-7% of total plasma proteins)[44,45], they could still be a
factor in obstruction due to their size and ability to form clots. However, most of the
LOC experiments rely more on blood serum. Serum is essentially blood plasma but
without any fibrinogen. Because it does not contain fibrinogen, serum will not easily
coagulate when outside of the blood canal. Despite this, there is still an issue with
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serum due to two other proteins, known as high abundance proteins (HAP): human
albumin and human immunoglobulin antibody.
Albumin makes up roughly 50 - 60% of the total amount of proteins in plasma,
making it the most abundant protein in blood[28,45]. Because of the abundance of
albumin, it does not allow the majority specific proteins to be easily detectable. In
short, albumin acts as a barrier that does not allow antigens to be detected easily.
Natural occurring antibodies, known as immunoglobulin, which comprise of a group
of proteins known as the globulins, which account for 20 – 30% of the total proteins in
the body[28,45]. These antibodies come in various forms including immunoglobulin A
(IgA). Immunoglobulin B (IgB), immunoglobulin E (IgE), immunoglobulin G (IgG)
and immunoglobulin M (IgM). The most abundant of these antibodies would be
human IgG[45]. There are two factors that rise with IgG is a factor when dealing with
assays that require blood. The first of which is their size. Antibodies are normally
larger in size than most proteins, which, like albumin and fibrinogen, represent a
barrier against and sort of detection. The second factor arises in that in many assay,
other known antibodies are used to detect specific antigens. This will be explained
later, but in short, human IgG can force these antibodies out of position, causing a
false signal in the detection area. Because of these two aspects, it would be ideal to
remove them before any detection happens. But since the aforementioned blood cells
also have to be removed and are bigger, it would be easier to remove these proteins
after the removal of the cells. Table 2-2 explains the three different types of HAPs
and the average amounts in plasma.
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Type of Protein

Concentration in Blood
Percentage of Plasma
(mg/mL)
Proteins
Albumin
40 - 45
50 – 60%
Globulins
20 - 25
20 - 35%
Fibrinogen
2-4
4 - 7%
Table 2-1: Ranges of the amount of high abundance proteins in blood[28,44,45]

In laboratory applications, there are various methods to fully separate and
remove these proteins. The most common methods are via precipitation[46] and
ultracentrifugation[47]. Precipitation involves the use of a chemical (trichloroacetic
acid, acetone, ethanol, etc) in order to aggregate certain proteins can clump them
together[46]. This process requires the use of a centrifuge in order to force this
sediment down to the bottom. Another method, known as ultracentrifugation, requires
no chemicals, but still relies on a high-powered centrifuge in order to effectively
separate and remove proteins[47]. These proteins can be extracted via drying of the
precipitate, or extraction of the supernatant (liquid). While this method is shown to
work, there are two drawbacks to these methods. First, with a centrifuge, the use of
performing all the experiments on a chip would be useless, since protein extraction
must be performed before the serum is in the chip. Also, with precipitation, some
chemicals are not as selective in the precipitation of proteins. This means that all
available proteins could be in the precipitate, which can cause problems which
detection. Because of this, a method of HAP removal has to be utilized inside of the
chip and is selective only to those HAPs.
To help further explain the reasoning behind the removal of blood cells and
these abundant proteins, it would be helpful to talk about a protein that is normally
found in the bloodstream. This protein is far less abundant in blood than that of
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albumin and human IgG. Also, this protein is regarded to have a link to various
cardiovascular diseases, diabetes and liver failure. This essential protein is known
commonly as C - reactive protein[6,48].
2.5. About C-Reactive Protein
C - reactive protein (CRP) is a ring-shaped protein that is found in the blood
stream. This is a protein that is used in immune system of the human body. Its role is
to bind to the surface of infarcted, or dead, cells and bacteria and alert components in
the immune system, including macrophages, which in turn, clear these cells. Because
of this property and their role in the body, CRP is normally used as an inflammation
marker[49]. CRP is synthesized in the liver and travels down the blood stream in search
of inflamed areas[49,50]. The first mention of CRP came from William Tillett and
Thomas Francis in 1930 as a pathogen because of its appearance in various
cancers[49,50]. The CRP protein structure consists is of pentagonal shape consisting of
5 monomers with an average weight of 25.106 kDa per monomer (total weight: 125.53
kDa) and has 224 amino acids in its monomer structure[49].
In a laboratory setting, CRP is used as inflammation marker for the
determination of patients that are susceptible of different ailments. For a long time, it
was determined that there was a link between CRP and various cancers, including
colon cancer. However, many studies have shown that CRP is only known to
determine whether a patient has a risk of developing cancer, rather than whether a
patient is at risk of cancer[50]. In recent years however, a link has been found between
CRP and cardiovascular disease. This was shown with patients with high blood
cholesterol content in blood, which can lead to coronary heart disease[49,50]. However,
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since CRP levels can increase with any type of inflammation, it is not very specific in
terms on the immediate risks of cardiovascular disease. However, it can be shown that
there is a link between the two based on sample size and amount of tests performed.
In blood serum, the amount of CRP varies with the individual; however there
are CRP levels that exhibit whether or not due to age, inflammation or heart risk.
Normal CRP concentration in serum is usually between 5 and 10 µg/mL. However,
higher levels can be found in older patients and mild inflammations. This is usually
between 10 and 40 µg/mL concentration of CRP. Over a concentration of 40 µg/mL
CRP is where more active and severe cases of inflammation can occur[6,49]. In the case
of determining a risk of heart disease, the American Heart Association has developed
a quick reference guide. According to them, a CRP level under 1.0 µg/mL correlates
into a low risk category, 1.0 – 3.0 µg/mL correlates into an average risk category and
over 3.0 µg/mL correlates into a high risk category[6]. However, this is based on the
concentration in blood. Since there is a 11:9 ratio of serum to blood cells (54% serum,
45% cells)[27], this scale can be modified to mean that low risk is less than 1.85 µg/mL
CRP concentration of serum and high risk is greater than 5.56 µg/mL CRP
concentration of serum. However, multiple tests have to be confirmed, including a
second CRP test and a cholesterol test to better determine one's own risk[6].
2.6.

CRP Detection
2.6.1. Current Detection Methods

Currently, there are numerous methods in which CRP can be detected.
However most of these do not involve LOC technology. Perhaps the most common
method used is using a blood analyzer[6]. A blood analyzer takes a sample of blood
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and analyzes the sample. The most common method of analyzing is by use of a
nephelometer. A nephelometer measures the particles in a solution by shining a light
into the solution and reflecting the light onto a light detector. Each protein can be
found by either emitting a different wavelength or by seeing the how much or the
angle of light is reflected back[51]. For measuring CRP, there are two types of tests.
The first being a normal CRP test which measures the amount of total CRP in a
sample and the second being a hs-CRP (high sensitivity CRP) test which is more
useful in determining the risk or cardiopulmonary disease[6].
While this is an effect method to measure CRP, it does not work well for LOC
applications. The first of which is its size. This is a machine than can weigh anywhere
up to a couple of hundred kilograms, so most of them are not portable. Second, all of
the experiments are performed on the machine and not on a small chip. The blood
goes into a vial and then into the machine for screening. This brings up the third
drawback. Most of these blood analyzers up to, if not more than, 1 mL of blood. Most
LOC devices use far less fluid than what a blood analyzer uses. Fourth, most of these
analyzers only use plasma or serum. This means that the blood cells cannot be in the
detection area. While all experiments require this, blood must be pre-separated before
it can be placed in the analyzer. This usually involves centrifugation, hence the large
volume required. Finally, time is always a factor. From blood extraction to results, the
time elapsed could be as long as a few days, which does not take into consideration
logging data and bookkeeping. Based on the type of machine, it can take anytime from
a few minute to a couple of hours[4,51]. Even though it is a well-known system, it is not
ideal for LOC applications based on the preceding.
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Other large machines include liquid chromatography, for example, high
performance liquid chromatography (HPLC). Liquid chromatography allows a user to
determine what types of proteins are in a sample by mixing a sample with a solvent
and sending through a column with packing material that separates the proteins in
solution[52]. The detection of specific proteins is good, but there are also drawbacks to
this. Mostly, it can detect proteins, but not the concentration of certain proteins. Also,
all the samples are diluted before they are measured so an accurate measurement
cannot be found. Furthermore, one test run can last up to a day[52]. Because of these
reasons, any liquid chromatography experiments cannot be performed to detect and
measure CRP.
However, in terms of LOC experiments, there have been different platforms
that have been created in order to detect CRP. One platform uses immunoglobulin Y
(IgY) as a method to capture CRP in not only serum, but also in blood. The time taken
to perform this test has been reduced significantly to only a couple of minutes and has
a high detection range[53,54]. Other LOC applications use nanoparticles coated with
anti-CRP antibodies that would attach and allow for accurate detection[19,20]. These are
only a few examples on how far LOC has developed into a well-known method for
detecting CRP in whole blood.
However, while reviewing a few of these products, it is worth noting a few
limitations to them. First, some of the reagents can either be expensive in cost, as in
the case with gold nanoparticles[19], or expensive in time in which to engineer the
reagents[54]. In the case with IgY, there is a stark contrast with it compared to IgG.
IgG is a mammalian antibody that is used cooperatively with the immune system. IgY
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is similar, but it is found in reptilian and avian (bird) blood. This means that is cannot
bind either well or at all to mammalian proteins or antigens[55]. Because of this, these
antibodies need time to be effectively engineered in order to make them more useful
for mammalian experiments. There is one other limitation to these experiments: the
type of fluid used in the experiments.
A number of LOC systems can either use serum or whole blood for analysis.
But this whole blood needs a certain anti-coagulant to be present before it is dropped
onto the chip, for example, with the ABX Micros CRP 200 by Horiba[56] and the CRP
analyzer by Labcompare[57]. The most common anti-coagulant is EDTA
(Ethylenediaminetetraacetic Acid). EDTA is commonly found in laboratories and is
mixed with blood as soon as the blood is extracted[56]. The need for an anti-coagulant
in experiment is that the blood does not curdle during experiments. Over time, due to
platelets and fibrinogen, blood can become more gel-like and solidify[58]. Anticoagulants slow down and occasionally stop this process in order to preserve blood.
This method is still great for laboratory work, but in field work, or a home setting,
where EDTA is not readily available, this can cause some problems. Because of this, a
better method for detecting CRP from a drop of blood directly from the body has to be
considered.
2.6.2. CRP Detection with ELISA
One of the most common methods in detecting CRP is what is known as an
enzyme-linked immunoassay (ELISA). In a basic ELISA, the antigens are attached to
a certain surface, in most cases, the bottom of a micro-titer plate. Afterward, a specific
antibody is attached to the antigen followed by a substrate to detect the antibodies
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attached to the antigen. This is a simple method to be able to detect certain antigens[12].
A full detailed example will be discussed in the upcoming sections. For this part
however, it is essential to know the basics of an ELISA.
There are multiple types of ELISA that can be used for experiments. The first
type, explained above, is known as a direct ELISA. This ELISA is beneficial because
a certain antigen can be detected by the use of antibodies specifically designed to
attach to that antigen[59]. The second type is known as an indirect ELISA. This ELISA
is used to detect an antibody, rather than an antigen. To perform this experiment, a
known antigen is attached to the bottom of a well. An unknown solution that may
possibly contain an antibody that can attach to that antigen is placed into the well.
From there, antibodies designed to attach to that antigen will attach. This antibody is
what is known as a primary antibody. Later, a secondary antibody is used to detect
that first antibody, in which the substrate can detect these secondary antibodies[59].
The third type is what is known as a sandwich ELISA. This type can either be direct,
or indirect, but the main difference being that instead of an antigen binding to a well,
an antibody specific to that antigen binds to the well. Then a solution with many
antigens or proteins (blood serum) is sent though, allowing the antigens that are
specific to the antibody already attached to attach. A second, and sometimes a third is
used to detect that antigen again and also be used to activate the substrate once it
comes into contact[59]. A final type of ELISA is known as a competitive ELISA.
Unlike the first three examples, this type of ELISA uses competing proteins or
antibodies to either detect changes in detection, or to remove/narrow down possible
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choices for unknown proteins or antibodies[59]. Below is a diagram highlighting the
main differences between the first three ELISA types.

Figure 2-3: Diagrams highlighting the differences between a direct ELISA (left), an
indirect ELISA (center) and a sandwich ELISA (right)[59]
Because of the fact that a certain antigen is being detected, it would be better to use a
sandwich ELISA in order to capture and detect CRP. Also, since this project is also
concerned about the concentration of CRP, it would also be helpful to use a
competition ELISA, where more than one concentration of CRP. With these two types
of ELISAs, it would be the most optimal method to detect and calculate the
concentration of CRP in blood. Previous lab projects have combined to obtain a
working microchip that envelops this concept[22-24]. Based on this, work from these
previous models will be brought together in order to create a more modern version of a
CRP detection chip that incorporates blood cell removal and ELISA detection.
2.7.

Previous Lab Work

Over the past few years, there have been systems developed by the URI
microfluidics laboratory that used LOC technology in order to capture and detect CRP.
The first system was developed by Peng Li in order to detect CRP on a microchip.
This system implemented an ELISA detection system and was one of the first systems
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to integrate sequential loading, where all the reagents were inside the chip and the
reagents were fed through the detection area by way of a micropump[22]. This system
accurately detected CRP in buffer. The second system was developed by Michael
Godfrin in order to find a method of detecting CRP in blood serum with the removal
of albumin and human IgG[23]. The third system was developed by Michael Franzblau
as an updated version of the system developed by Peng Li with incorporated both
sequential loading and CRP detection in blood. This system was also novel in that the
detection was automated, rather than relying on human interaction. An example of
this system is found in figure 2-4[24]. Pictures displaying this system is shown below
in figure 2-4. Other projects developed include a hand-held CRP detector developed
by John Jones[60] and an ongoing project in detection of CRP and other reagents on
paper[61,62]. This project encompasses the first three projects mentioned and uses this
to develop a better method to detect CRP. The reason for this is explained below.

Figure 2-4: Prototype of CRP detection POC device created by Michael Franzblau
2.8.

Reasoning for a Modified CRP Lab-on-a-Chip System

In order to better develop this goal of detecting CRP in whole blood, it would
be beneficial to incorporate the projects developed by Li, Godfrin and Franzblau into
an updated and more reliable system. In order to see if there needs to be any
improvements on these systems, a simple experiment combining the chip developed
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by Franzblau[24], the protein removal developed by Godfrin[23] and the detection
system developed by Li[22] to see if this experiment was feasible. Further explanations
of each of the three experiments will be clarified in the next chapter.
In a brief synopsis of the experiments, the chips were first functionalized with
BSA (bovine serum albumin) protein, glutaraldehyde and protein A[22]. This allowed
the removal of the high abundance proteins and the detection of CRP. The chip was
divided into three sections: a top section for removal of IgG, a middle section for
removal of albumin and a bottom section for CRP detection[24]. Anti-albumin IgG in
the middle and Anti-CRP IgG in the bottom were added and incubated for 5
minutes[22-24]. The chip was washed with PBS (phosphate buffer saline) and serum
with CRP was added to the chip. It first incubated in the IgG removal area for 5
minutes, then in the albumin removal area for 5 minutes and finally in the detection
area for 5 minutes. After a PBS wash, anti-CRP antibodies labeled with FIT-C were
added and incubated for 5 minutes. After a PBST wash, PBS was added and detected
using fiber optics[22-24]. A negative control with serum but no protein removal and a
positive control with CRP in PBS buffer were also used in conjunction. This
experiment was performed with 5 and 10 µg/mL concentration of CRP in serum (2.6
and 5.2 µg/mL concentration of CRP in blood)[48-50].
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CRP Detection Based on Previous Projects
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Figure 2-5: Comparison of CRP detection in previous projects
Figure 2-4 depicts the detection of CRP in serum using the previous methods
designed. The center bars show the result given when the experiment was performed.
The values of the signal are based on the intensity, or how much light was adsorbed by
the fiber optics used in detection. To the left are the signal values for the same
experiment with no removal of albumin and IgG. The signal of the tests are
noticeably higher than that of the buffer, but in comparison to the signal of just CRP in
buffer (right bars), it tells a completely different story. The values of the tests were
half that of the buffer experiments. This relates that there was a noticeable presence of
IgG and albumin in the detection area. The probable cause of this would be the
incubation of the removal of IgG and albumin. Five minutes for the removal of the
two most abundant proteins in blood is not an ideal amount of time if there is still a
large amount of antibodies. Also, there was not a significant change in signal as
concentration increased in the experiment as compared to CRP in buffer. One other
thing is that even though it was implied that blood could be used in the experiment,
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there were not enough tests in order to see if this was functional. Because of these
reasons, this method of high abundant protein removal has to be dealt with.
In order to go about fixing this system, each of the aspects from getting from
separating blood cells to detection of CRP has to be looked at. This includes seeing
how well blood cells get filtered out of the chip to seeing as to what is the most
efficient method of IgG and albumin removal. This project will take a look as to how
well IgG attaches to protein A and how it can be bettered. This will help in the
removal of albumin from serum as well. With these aspects, a newer more efficient
method of removing CRP from whole blood can be obtained.
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CHAPTER 3

METHODOLOGY

In order to explain the process behind this project, this section will be broken
up into three different sections. The first section will be about the process of making
the chips. The second section focuses on blood separation. The third section focuses
on the removal of high abundance proteins in order to detect C – reactive protein.
3.1.

Microchip Fabrication

One of the main issues is deciding what type of chip to work with. Different
chips can be constructed by using different materials. Based on the material being
used, these chips can be divided into two categories. This is based on how fluid travels
through the chip. The first category is known as passive flow chips. These chips use
capillary forces to move a liquid down a channel without the need of an external force
to move the chip. The second type is known as active flow chips. These chips use an
external source, such as a pump, in order to move the liquid towards its potential
area[63-65]. The upcoming paragraphs will examine both processes and determine which
process would be better suited.
The first process mentioned is passive flow. This method does not require the
use of a pump, but rather forces in the material, either through diffusion or capillary
forces, drive the fluid to a destination[65]. In most cases, this is performed by wetting
an area for the fluid to go through with a hydrophilic solution, while wetting the
boundary in a hydrophobic solution[64]. The most common materials that are used to
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make the chips are any material that can easily draw water, including paper, twine and
fabric[64]. The advantages to using a passive system are that the materials needed to
make the chip are inexpensive and the design and printing of the chips can easily be
performed on the computer. The disadvantages to using passive systems are that there
is no optimal fluid control since there is no external source other than the chip to guide
and control the flow of the fluid.
The other process mentioned is active flow. This method requires the use of an
external source for the fluid to flow. These sources include pumps, electrical impulses
and magnetic impulses[65]. Basically, if an external force is needed to drive the fluid,
then it is an active flow system. Unlike a passive flow system, where the material acts
as channel for the fluid to flow, in active flow, the channels are formed inside of the
chip, by way of a mold[22-24]. This allows the fluid to easily flow inside the chip and
keep intact and not leave much of a streak or residue behind. These chips are usually
made out of glass, plastic or nay polymer. The advantages for using active flow is that
the user has full control over the liquid in the channel, they are easy to make and fluid
can be easily placed in and taken out of the chip. The disadvantages are that it is more
costly to make, based on the making of one mold, and numerous amounts of polymer
or glass, the process to create the chips usually takes longer than that of a passive
system and external equipment is needed to perform the experiments.
Based on the reasons listed above, it was more beneficial to go with an active
system than a passive system. The reason for this being that the fluid is easier to
control in an active system. The fluid is allowed to stay in one place, which would be
ideal for allowing more CRP to be detected. Also, with a pump or a syringe, the user is
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allowed to move the fluid to all the different parts of the channel. With a passive
system, the best way to move liquid would be to add more liquid to the chip. In the
case of adding blood to the paper, some aspects of the experiments include the
removal of blood cells and high abundance proteins. The issue is that with using a
passive system, if the plasma is in constant flow, then it would be a lot more difficult
to contain it in order to remove all of the high abundance proteins. This will be
explained in full detail later on in the removal of high abundance protein section.
Because of the ability to better control the fluid in the chip, the method of active flow
to detect CRP will be investigated.
3.1.1. Mold Creation
The first part on creating the chip is creating the mold. The mold acts as a
template in order to create the microchannels. Each mold will have an etched side,
where indents will be formed in order to create the channels that the substrate will be
set upon. For this project, the molds were made based on two methods: an older
method using silicon wafers and SU-8 photoresists via soft lithography developed by
Peng Li[22] and a newer method by using aluminum molds via hard lithography
developed by Michael Franzblau[24].
3.1.2. Silicon Molds
To prepare the molds using the first method, the silicon wafers (SI-Tech, Inc.,
Topsfield, MA) have to be pre-treated. This is performed by placing the wafers in a
piranha solution. This removes any debris and organic material on the chip. This
solution consists of a 50/50 mixture of hydrogen peroxide (H2O2) (Ricca Chemical
Company, Arlington, TX) and sulfuric acid (H2SO4) (Acros Organics, Geel, Belgium)
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and is an oxidizer against organic material. These wafers are placed in the solution on
an Orbit Shaker (Lab-Line Instruments, Melrose Park, IL) for about 15 minutes or
until no bubbles are present on the wafer. The wafer is then soaked in distilled water
three times for five minutes per soak. The wafer is then dried using compressed
nitrogen and stored until adhesion of the photo resist.
Once the wafers have been cleaned and dried, the photo resist is then applied to
the wafer. The wafer is first cleaned with compressed nitrogen and placed on the spin
coater (Laurell Technologies, Corp., North Wales, PA). 2 – 3 mL of AP300 adhesion
promoter (Silicon Resources, Inc., Chandler, AZ) is added to the wafer. The wafer is
spun for 25 seconds at 300 rpm and then for 30 seconds at 3000 RPM once to spread
the resist and twice to dry it. Nitrogen gas is blown gently onto the wafer to dry the
wafer. Then, SU-8 2050 photo resist (MicroChem Corp., Newton, MA) is added to the
center of the wafer. The wafer is spun a second time first at 300 RPM for 45 seconds
and then at 600 RPM for 50 seconds. The wafer is removed and placed on a leveling
tray, resist side up and allowed to level off for 1 hour. Finally, the wafer is placed on a
hot plate (HS40A, Torrey Pines Scientific Inc., Carlsbad, CA) in order for the photo
resist to harden. The baking consists of a three part sequence. First, the hot plate must
be at 50°C before the wafer can be on the hot plate. Once the wafer is on, the
temperature will rise from 50°C to 95°C for 23 minutes at a rate of 2°C/min. At 95°C,
the wafer will continue baking for 3 hours. Finally, the temperature is lowered at a rate
of 1°C/min until the plate is at room temperature. These wafers are then stored until a
pattern for them will be etched.
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The next step is to create a pattern to be placed on the chip. This is done by
using Adobe Acrobat. A sheet is made with four black boxes, with white etchings that
relate to the dimensions of each wafer the channels are drawn using white lines, along
with openings for the fluid to enter and a detection area for the immunoassays. Each
document can hold up to four stencils, or photo masks. Examples of the photomasks
used can be found in the Appendix (A.1 & A.2). Once the making of the photo mask
is complete, the document is saved and sent via e-mail to CAD/Art Services, Inc. in
Bandon, OR, which would print the masks on transparent plastic to be used for
etching, with the clear sides being the areas where the channels will be etched. These
examples are shown on the below in figure 3-1.

Figure 3-1: Transparent masks for silicon wafer molds for the channel side (left) and
filter holder (right)
The last step will be to etch the pattern on the wafer. To do this, the photo
mask is placed over the resist, making sure that there is no gap in between them. They
are then placed in a UV-light source (i-line, Karl Suss MJB-3, Suss Microtech,
Garching, Germany), where UV light at 365 nm wavelength will harden the exposed
photo resist, while the covered sections will remain untouched. This exposure will last
approximately 6 minutes for resist thickness of 400 µm. This does not include two 1
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minute rest times in between. In total, for a 400 µm resist thickness, there is a 2.5
minute exposure, followed by a 1 minute break, then a 2 minute exposure, a 1 minute
break and finally a 2.5 minute exposure. The wafer is then placed on a hotplate at
45°C and then ramped up to 85°C at a rate of 2°C/min. It is then baked at 85°C for 40
minutes, before coming back down to room temperature at 1°C/min. Finally, the
molds have to be developed. For this, three solutions have to be used. First, the wafer
is placed in a series of two SU-8 developers (MicroChem Corp., Newton, MA), on an
Orbit Shaker and shaken until the non-exposed photo resist comes off (approx. 10-20
minutes). Finally the wafer is placed in a container of isopropyl alcohol (Fisher
Scientific, Fair Lawn, NJ) for 1 minute and then blown dry. The last step would be to
bake the chip at 150°C for 30 minutes, with a 1°C/min heat up and cool down before
and after[22]. A full protocol can be found in appendix A.3. Figure 3-2 shows the
process and figure 3-3 shows the final molds.
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Figure 3-2: Example of microchip fabrication using soft litography[66]

Figure 3-3: Completed silicon wafer molds used for LOC chip production for multifluid assays (left) and single fluid assays (right)
Even though this is a known and good way to create the molds, there are
drawbacks to this method. The first drawback is the UV light. The light source used in
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the experiment is very broad and dim when etching. This is problematic because the
dimensions of the channels will be larger than what they should be and due to the lack
of intensity, not too high. In the case of more elaborate channels, where this light
source would not create better channels, the wafers and masks had to be sent to the
laboratories at the Massachusetts Institute of Technology in Cambridge, where a
better, more direct light source was used. The second drawback is the repeated use of
the wafers. On average, the wafers are used about a dozen times until they either break
due to the heat and negligence, the photoresists peels off or the wafers become
warped. The third drawback is the various chemicals being used, which are known to
be not only toxic, but can cause skin corrosion. The fourth drawback is that one of the
necessary components, the AP300, was discontinued. The final drawback was that
from designing the mask to finishing the molds, the process took approximately
between 2 to 3 weeks to complete. Because of these issues, a more ethical procedure
in order to create better molds had to be established.
3.1.3. Aluminum and Polymer Molds
In this method of mold fabrication, the channels were all etched out on a small
block of either aluminum or a polymer material. The first step in creating the molds
was to create a design by use of a CAD program (in this case, SolidWorks was used).
The finished program was then translated into a programming language via
MasterCam, which was then relayed to a computer numerical control (CNC) milling
machine where the mold was carved out of either aluminum or a polyetherimide
known as Ultem, which was developed by SABIC. The end result revealed a durable,
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etched block that consisted of the etched channels that would be implemented in the
chips[24].
There were a few things to look out for when creating these molds. First was
that the molds had to have raised structures which indicated where the channels were
supposed to be. Second, the molds had to be designed within the parameters of how
the milling machine could create them. The bits that were used to sculpt the channels
were McMaster-Carr end mills (part# 8832A008) that had a diameter of 203 µm and a
depth cut of 350 µm. Because of this, all the channel heights hat to be at the most 300
µm and the thickness between any two raised structures to 205 µm, in order to stay
within the parameters of the device[24].
However, there are many advantages to using aluminum molds as compared to
silicon molds. One advantage is that the time which the entire process is performed is
cut by, on average, a week. One of the reasons why the silicon wafers take longer is
that the photo masks take up to a week or two to be fully completed. Without that step
and the fact that the chip designs are only converted into code, it takes less time to
make these molds. Second, these molds are more durable than the previous silicon
ones. With silicon molds, there is always the possibility that the molds can shatter and
warp, the photo resists can break off and the molds could easily get lost. This means
that a new mold is usually created after only a couple of months. With aluminum and
polymer molds, on the other hand, there is no need to worry about any of this because
the molds are usually between 0.25” and 1” thick. And since the raised channel
structures are part of the chip, there is no fear in that these structures would break off
from the mold. Finally, unlike the previous molds, these molds can withstand higher
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temperatures. With silicon molds, there is always the chance that warping can happen
on the molds due to heat. Because of this, the chips have to be cooked at 95°C in
order to prevent this. Aluminum molds are more thermal resistant, especially since
they are thicker, so they can withstand temperatures greater than 150°C[24]. Because
of these reasons, it is safe to say that these aluminum molds are an improvement over
the previous silicon molds.

Figure 3-4: Aluminum molds used for LOC chip production for single fluid assays
(left) and multi-fluid assays (right)

Figure 3-5: Aluminum and polymer molds used for LOC chip production for multifluid assays. Clockwise from top: bottom of chip, channel sides (2), blood filter
holder
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3.1.4. Fabrication of the Chips
Regardless as to how the molds were created, the method of making the chips
remained constant. There are many substrates in which chips can be made, based on
the different properties. Etching chips from glass is a common method that is used
because glass can be durable, is transparent and does not react when in the proximity
of biological substances[34]. However, glass is brittle and can shatter, is expensive to
obtain and etching usually requires hydrofluoric acid, which is extremely corrosive.
The best method would be to use polymers as a chip substrate because they are usually
nontoxic, inexpensive, can withstand high temperatures and can be easily liquefied
and solidified. One of the best known polymers is polydimethylsiloxane (PDMS).
PDMS is a transparent silicon polymer that is usually inert under chemical and thermal
changes. It is relatively inexpensive to use PDMS and the fact that it starts as a liquid
with a high viscosity and low surface tension means that the polymer can flow over
the mold in order to make sure all the nooks on the mold are covered.
To make the actual chips a mixture of liquid PDMS (Slygard 184, Dow
Corning, Midland, MI) and curing agent are added in a 8:1 – 10:1 PDMS : Curing
Agent ratio. Depending on the size of the mold and the thickness of the final chip
(between 0.4 and 0.6 mm thickness), the mass of the PDMS mixture varies between 30
and 50 grams. This was found by taking the approximate volume (cross-sectional area
X slab height for one side) and multiplying it by the PDMS density (0.965 g/mL) and
doubling it. The reason for this mass is that this is the total mass for the top side
(channel side) and bottom side (flat side). The liquid mixture is poured onto each mold
in equal proportions. During the mixing and the pouring of the PDMS, air bubbles
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form in the mixture. It is essential that these bubbles are removed as that they cause
irregularities in the channel formation and cause interference in the detection signal.
For this, the molds are placed in a vacuum chamber (Sybron – Nalge, Braunschweig,
Germany) for 1 hour to remove all bubbles from the molds. This process can be
performed quicker by leaving it in the chamber for 15 minutes until all the bubbles
reach the surface and then leaving it outside the chamber for another 15 minutes. Once
all the bubbles are gone from the mold, the mold is placed on a hot plate at 95°C to
bake for 2 hours.
After the PDMS has hardened, they are removed from their respective molds
and trimmed of excess PDMS using a 4” razor blade scrapper (McMaster-Carr catalog
#26765A31). Holes are punched at the channel openings using a 1.5 mm biopsy punch
(Miltex catalog #33-31A) to allow fluid into the chip and tubing to latch into the holes
created. The next step will be to bind both sides of the chip together. This will be
performed by using the plasma asher (Femto, Diener Electronic, Reading, PA). To use
the plasma asher, both sides of the chip are placed on a tray that is then inserted the
asher. The chips are inserted mold side up because they tend to be the clean side free
from air bubbles and in the case of the channel mold, it is where the channels are
located. The process consists of four steps. First, the chips are inserted, the window
between the chips and the outside sealed and air is pumped out the chamber. This
process takes about 3 minutes, in order to make sure no air is in the chamber. Second,
oxygen gas is pumped into the chamber. This step takes approximately one minute.
Third, the chamber is activated, which plasmas a thin layer of oxygen onto the surface
of the chip. This process takes 3 minutes to perform. Finally, once the 3 minutes are
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up, the gas and pump are turned off and air is added to re-pressurize the chamber. The
chips are then taken out and are bonded together with the two sides facing up being in
contact. The chips are pressed together and are placed on a hot plate at 95°C to bake
for 1 hour in order to facilitate binding. If the chip requires a paper pad to be used as a
waste area, the paper is fitted onto the channel chip with the flat chip brought in to seal
them. If a filter is needed, the top of the chip is placed in the asher with the filter
holder and the process continues. The filter is placed on top of the holder, with the
smooth side facing up, then the chip is pressed onto the holder and placed on the hot
plate[24]. The full protocol can be found in appendix A.3. Since there are multiple
chip designs that will be implemented, each upcoming section will explain the
geometries of each chip. Figure 3-6 below highlights the process of making the chips
and 3-7 on the next page shows the equipment used in the creation of the chips.

Figure 3-6: Sample assembly of PDMS Chips[65]
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Figure 3-7: Equipment used to create PDMS chips including vacuum chamber (top
left), hot plate (top right), plasma asher (bottom left) and vacuum oven (bottom right)
3.2.

Blood Separation

In the previous chapter, it was determined that because of the cost,
functionality and easier integration, it was determined that the preferred method of
blood separation would be to use filter paper and membranes. However, since there is
a large selection of filter papers, there has to be a way to sort and narrow down the
search for a proper filter paper. There are numerous tests that one can perform that
include measuring the amount of filtrate and seeing how well they keep blood cells
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out. These methods will be implemented in determining a suitable filter for blood cell
separation.
One of the companies that produce blood filtration membranes is the Pall
Corporation. Pall has a line of membranes known as the Vivid Plasma and the
Cytosep Membranes[68,69]. These are two types of membranes that not only are able to
separate a large amount of plasma, but also show no sign of blood cells rupturing or
escaping the membrane. This is based on the characteristics of the membrane. The
membrane consists of two different sides: a rough upper side and a smooth lower side.
Blood is placed upon the upper side and the liquid migrates to the smoother side.
There are pores in the paper that allow the blood to flow through, but the roughness of
the sides depends on the size of the pores. The rough side has larger pores, making it
ideal for cells to be captured, while the smooth side has pores small enough for the
plasma to seep through, while keeping the cells inside of the membrane[68,69].
It is a highly hydrophilic membrane and unlike some papers which are fibrous,
or made from paper, these membranes are made from a polymer known as polysulfone
in the case of the Vivid Plasma Membrane[68] and of a blend of natural and synthetic
fibers in the case of the Cytosep Membrane[69]. Because of this, it actually can
withstand higher temperatures and pressure forces exerted onto it. Plus, since it is
hydrophilic, the blood can travel readily throughout and stay in the membrane until an
external pressure is applied. This allows for an adequate amount of plasma to remain
on the filter until it is needed to be exerted onto the chip and the amount of plasma can
be high enough to be necessary without fear that blood cells and hemoglobin can enter
the chip[68,69].
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Since these are a few examples of blood filters, it would be essential to test as
to how well each one will fair. There are two main tests that will be used to determine
how effective these filters are. The first will be a test based the amount of filtrate has
been filtered out. This will be performed by just directly measuring the filtrate volume
by using a syringe pump to extract the filtrate until the filter does not allow any more
filtrate to pass through. The second test will be to see how well the filters separate the
blood cells from the plasma. This can be performed with multiple tests including
blood staining and microscopy. An additional test can be performed to see if either
plasma or serum is obtained from the filtrate. From these tests, a suitable filter will be
found that can be used to separate blood cells from whole blood.
3.2.1. Filtrate Volume Tests
The first test involves the volume of the filtrate. The main filtrate that will be
going through the chip should be plasma. As stated previously, plasma accounts for
approximately 55% of the total blood volume. This means that for every 100 µL of
blood, there will be approximately 55 µL of plasma to go along with it. In experiments
that require only a small amount of plasma, it is not a big issue that 100 µL of blood is
used. The issue occurs when for example 15 µL of blood is filtered to yield
approximately 8 µL pf plasma. The reasoning for this that the filter can adsorb a good
amount of plasma and that red and white blood cells, known as the filter cake in this
experiment, can ultimately block off the channel so that no more filtrate can be pulled
into the channel. With this knowledge, it is important to find out if these filters are
even functional to begin with.
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Tests will be performed with the filter to make sure that these filters are
functional. In each experiment, a syringe will be connected via tubing to a PDMS slab.
The tubing will be marked at 1 µL intervals, which will be used to measure the filtrate
volume. A small piece of filter paper will be placed in the slab, where a drop of blood
will be placed. The filter papers being used in these experiments were the Vivid
Plasma Membranes GX and GR from the Pall Corporation (Ann Arbor, MI).
According to Pall, these filter papers are some of the top of the line papers because of
their double-sided nature. The top side has rough openings that can entrap blood cells,
while the bottom has a smooth, yet finely holed surface that allows plasma to escape.
By use of active transport, fluid motion with the aid of an outside influence, in this
case, a syringe pump, the blood would flow through the filter and into the tubing. The
remaining plasma will then be collected, measured and analyzed based on techniques
that are used to characterize and determine the quality of the plasma.
The syringe pump that is used is from the company SyringePump.com from
New Era Pump Systems. The model number of this pump is NE-1010. A picture of
this pump is shown on the next page as well as the setup of the experiment in figure 38. The reason this experiment focuses on active transport is because it is the easiest
method to collect and isolate blood filtrate. The filtrate is collected inside the tubing
due to the movement of the syringe and the vacuum pressure created inside of the
tubing. This forces the plasma through the membrane into the tubing at a steady rate.
The one issue concerning this would be the filter cake that builds up. The cake is
defined as the items that did not effectively flow through the filter (RBC, WBC,
Platelets). This causes a slowdown in filtrate extraction and a buildup in vacuum
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pressure. In addition to this, membrane rupturing and hemolysis can occur. This
causes a problem mainly in the antibody-antigen assay, where hemoglobin can
interfere with the interactions between antigen and antibody.

Figure 3-8: Apparatus of syringe pump (left) and PDMS chip (right) used for plasma
extraction
During each experiment, the main focus would be not only how much plasma
can be extracted, but also if 5-7 µL can be extracted from a blood volume between 25
and 45 µL. This is important because the reservoir for the antigen has a volume of 5-7
µL and through experiments, it will be shown that it is the ideal volume for the
amount of plasma that can be collected, where the risk of hemolysis, or rupturing of
the blood cells is minimal. These values will be graphed and compared with each other
in order to determine which filter is the most ideal filter to use in the system.
3.2.2. Blood Cell Analysis
The second factor with blood filtration involves the clarity of the filters. For
this segment, two aspects are taken into account. The first is whether or not red blood
cells are filtered from the plasma. This is important because in the immunoassay, only
the proteins in blood are important in detection. Since RBC’s have an average
diameter of 6-8 microns[18,44], they can interfere with the proteins while performing the
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immunoassay. Because there cannot be any trace of blood cells in the channels as the
filtrate is added to the serum, it is necessary to see if cells were able to penetrate
through the membrane and into the channel. In order to perform this, microscopy has
to be used. There are two different methods that can be utilized in order to perform
the microscopy. One method is by use of what is known as a Giemsa Blood Staining.
In this method Giemsa Stain is applied to a dried sample and by using microscopy, the
different specimens can be identified based on the color given. One example
performed in the lab used this testing to find the effectiveness of the Pall Membranes.

Figure 3-9: Giemsa Staining of filtrate from different membranes (top, left to right:
whole blood, filtrate from Vivid Plasma Membrane GX, filtrate from Vivid Plasma
Membrane GR; bottom, left to right, filtrate from Cytosep 63, filtrate from Cytosep
62)[70]
As shown in figure 3-9 above, this test was performed on both the Vivid
Plasma and the Cytosep Membranes. Both sets of the Vivid Plasma Membranes
performed well and did not filter through any blood cells. The Cytosep Membranes on
the other hand not only allowed more blood cells to seep through, but some of the
filter paper broke apart in the filtrate. From these tests, it was shown that the Vivid
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Plasma Membranes performed better than the Cytosep Membranes[70]. However, one
of the main issues with using Giemsa stain is that it is very oxidative, meaning that if
not carefully performed, a stock solution of Giemsa Stain can be ruined with a small
amount of oxygen in air and water. Because of this, an alternative method of direct
microscopy of filtrate samples will be performed for this project. This involves
creating chips that hold the filtrate and place them directly under a microscope. Keep
in mind that because of these previous results with the Giemsa staining; only the Vivid
Plasma Membranes will be in use for this experiment.
Another factor is based on whether or not hemolysis has occurred. Hemolysis
is the process where RBC membranes rupture and hemoglobin is released in the
plasma. This can occur either in the filtration process due to a bad filter or a high
pressure caused by the syringe pump, or by using old blood. Normally, if there is
redness in the filtrate, it is either caused by RBC’s or hemolysis. Normally, it can be
seen with the naked eye whether or not it occurs, but it is better to check using a
microscope if there is noticeable redness. This can involve seeing whether or not
blood cells remain in a “reddened” filtrate. This would show whether or not
hemolysis has occurred in the blood and the amount can tell whether it was the filter
or that old blood was used in the system.
To perform the microscopy aspect of this project, slides will be prepared by
using a PDMS chip with 5 microchannels. One microchannel will contain whole blood
as a control and to see the relative RBC size. The other microchannels will contain a
filtrate based on a specific type of filter paper, the dimensions and area of it and
because a syringe pump is used to withdraw the plasma, the rate of extraction. Each

53

blood sample will be of the same volume based on the average drop size and because
the drop needs to soak into the filter paper completely, a common time between
dropping the blood onto the paper and the start of the pump. This method will help
determine what the ideal method is for blood filtration. During each experiment,
various observations will be noted, including total plasma volume, plasma color upon
initial inspection, and volume before possible hemolysis. These observations will play
a vital role in characterizing the filters and help determining the aforementioned
qualities if the filter paper. Microscopy will be performed on a Leica DMLB
microscope (Buffalo Grove, IL). This microscope has the ability to vary in resolution
size, from 5X to 20X and is able to take a snapshot of the channels by way of a
mounted camera connected to the computer. With this camera, pictures can be taken
of the microchip to be used for further processing.

Figure 3-10: Microscope and chip used for blood cell analysis
3.2.3. Clotting Factors: Plasma vs. Serum
One other factor that has to be taken into account is whether or not the filtrate
is plasma or serum. The difference between these two is based on fibrinogen, or
clotting proteins present in the filtrate. Serum contains no amounts of fibrinogen,
which means that even if there is a small amount of fibrinogen in the filtrate, it will
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still be identified as plasma. Since there is not an ideal method to locate fibrinogen
under a microscope, the best method to characterize the filtrate will be to precipitate
the fibrinogen out of solution. This is performed by coagulating the fibrinogen, which
is soluble, into fibrin, which is not soluble. There are different reagents that are able to
perform this, such as thrombin and certain aqueous salts[71]. This project however will
focus on using ethanol for fibrinogen aggregation[71]. By adding ethanol into plasma,
fibrin will precipitate out of solution, leaving only serum in liquid form. If this
experiment does not perform, then it will be clear that fibrinogen is left behind in the
filter and serum is yield in the filtrate. However, if even only a small amount of fibrin
is recovered in the filtrate, then the only possible way to classify it is to say that these
filters will filter out plasma. If this happens, then further research will have to be
conducted as to how serum can be extracted using these filter papers.
3.2.4. Design of a Microchip that Incorporates Blood Filtration
Ultimately, this new chip design will incorporate a one-touch system, where
the user will use a drop of blood onto the filter and the micropump will draw the
plasma into the chip and perform the immunoassay with only the touch of a button.
The filter will be embedded inside the microchip to allow for filtration without the
need for an external source. Because filters come in all shapes and have different
microstructures and properties, they have to be taken into account. From all of this, a
microchip that enables both sequential loading and blood microfiltration will be used
to perform immunoassays in order to detect various diseases found in the blood.
This chip will encompass the idea of sequential loading, where a reagent is
transported into a detection area one at a time by use of a micropump. Along the way,
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different projects will encompass the focus of the main project. These projects include
finding a suitable method for microfiltration, finding out how much plasma or serum
can be extracted by using this method of filtration and checking the quality of the
plasma based on the number of blood cells filtered out. From these results, a suitable
design for the sequential loading microchip that encompasses microfiltration will be
designed.
However, in order to make sure that blood filtration and sequential loading can
be easily combined into one chip, a prototype filtering chip has to be introduced. This
chip would only involve the direct separation of plasma from blood. This is just to
make sure that not only the filter can be embedded inside the microchip, but the
plasma can easily flow into the microchannel without the risk of hemolysis or a
sudden increase in the vacuum pressure. In order to perform this, a PDMS slab will be
used to hold the filter in place. This slab will have an indent, which will act as a
mechanism to hold the filter in place. To make sure that this procedure works each
time, the filter has to be cut at precisely the exact dimensions to fit in the chamber
properly. If the filter is too small, the blood would run over the sides. However, if the
filter is too big, the PDMS slabs will not stick together properly. In order to figure out
the appropriate size of the filter paper, tests will be performed by dropping different
amounts of blood onto different filter paper sizes. This will be based on the design
specifications of the filter paper, which was given by the manufacturer. By knowing
this and that a drop of blood should be in the volume range of 40 – 50 µL, the
appropriate size filter will be found based on these characteristics.
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From these specifications, moldings of the filter will be made in order to place
it between two slabs. Ultimately, the new chip will have multiple layers, instead of the
two layers that were on it previously. Before the new design, the chip had only two
layers: a channel layer and a blank slab. This new design will include one additional
layer: to hold the filter in place. In total, the new chip will comprise of three layers,
which is shown below.
3.3.

CRP Detection and HAP Removal
3.3.1. Surface Functionalization

Surface functionalization or modification is when a surface has to be coated in
order to change its properties[22]. This can mean by changing the surface of the
channels by either making them either more hydrophilic or hydrophobic, or by
allowing proteins or other antigens to bind more easily to the surface. For these
experiments, because of the surface structure and the hydrophobicity of the PDMS, the
antibodies used in the ELISA cannot bind to the surface of the channels well.
However, there are certain known proteins that can readily bind to IgG antibodies.
One certain protein is known as Protein A, which has a high affinity to IgG
antibodies[72]. However, this protein cannot be stand alone in the channel. The reason
for this being that even though the antibody would still bind to the protein, the protein
could bind to other impurities in the chip or that the antibody would bind to the
channel in a way that is not beneficial to the experiment. This type of binding is called
non-specific binding. To circumvent this, a blocking agent has to be placed on the
surface beforehand. One known protein that is able to do this is bovine serum albumin
(BSA). BSA is a non-reactive protein that can be used in order to coat the surface
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before protein A can be inserted into the chip. However, since BSA does not react and
proteins usually do not bind with each other, there has to be a linker that can be able to
connect both proteins. One known linker is glutaraldehyde (C5H8O2). Glutaraldehyde
is a 5 carbon single chain with two aldehyde (one carbon attached a hydrogen and a
double-bonded oxygen). With these two aldehyde groups, it is used as an aminereactive crosslinker, in which it can easily link two proteins together. This would
enable a tight link between the blocking agent BSA and the capturing agent protein A.
3.3.2. Method of Surface Functionalization
To functionalize the PDMS, each chip is first checked to make sure that no
leaks occur in the chip due to improper sealing. PBS (phosphate buffer saline) (Fisher
Scientific) is inserted into the channel to clean out the channels and to make sure
leaking does not occur. Once the PBS is removed from the channel, a mixture of BSA
(Sigma Aldrich, St. Louis, MO) and PBS (1.5 mg/mL) is inserted in the chip. The
chips incubate at room temperature for 4 hours in order for the BSA to attach to the
channel. The BSA is removed from the chip and PBS is inserted and removed to wash
the chips and remove excess BSA. The channels are aerated in order to remove excess
liquid. A mixture of glutaraldehyde (Sigma Aldrich) and water (0.4% v/v) is inserted
into the chip. The chip is then incubated at room temperature for 1 hour. The
glutaraldehyde is removed and the chip is washed with PBS and aerated a second time.
Protein A (Sigma Aldrich) in PBS (50 µg/mL) is added in the chip and incubated at
room temperature for 1 hour. The protein A is removed and the chip is washed with
PBS and aerated a third time. A storage buffer consisting of 10 mM Tris in distilled
water, 0.05% BSA (w/v), 0.05% Proclin 300 (v/v) and 5% Glycerol (v/v) is inserted
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into the chip and the chip is stored at 4°C until the chip is ready to be used[22-24].
Below is the finished schematic of the functionalization process. The protocol for this
procedure can be found in appendix A.4. A completed functionalization diagram is
found on the below in figure 3-11

Figure 3-11: Diagram of protein A functionalization on the channel surface
3.3.3. CRP ELISA and Detection
This section will explain the process of performing the ELISA inside the
PDMS chip. This process will be exclusively for the detection of CRP. Later
modifications, including the addition of the filter and the antibodies for albumin
removal will be explained the upcoming sections. This section will only focus on the
detection area. To begin, the storage buffer is removed from the microchip. PBS is
then inserted inside the chip, which will remove the excess buffer. In the case where
the chip only includes the detection area and not any other channels for protein
removal, an additional aeration step will be required after every wash in order to
remove any excess fluid. In the case of multiple liquids, the fluid will be moving slow
enough so that there is no accumulation of excess fluid on the surface of the channel.
After the PBS has been removed, the captured antibodies are inserted into the
detection area. The capture antibodies being used are Mouse monoclonal anti-human
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CRP IgG antibody (Abcam, Cambridge, UK) at a concentration of 200 µg/mL in
Protein A/IgG binding buffer (Thermo Scientific, Rockford, IL). These antibodies are
incubated in the channel for 7 minutes. The antibodies are removed from the chip and
PBS is inserted to wash the channels. The CRP (Fitzgerald Industries, Acton, MA) is
then inserted into the chip. In terms of the type of protein, it is unclear on whether or
not the CRP is in the pentagonal form, or the monomer based on the Fitzgerald
website[73], but it can be assumed it is the pentagonal form because it is the most native
form and the CRP has to go through a dissociation process in order break into
monomers[74]. The protein is mixed with either a solution of PBS or serum that does
not contain any CRP (Fitzgerald). Because of this, different concentrations will have
to be added to the solution. For these experiments, the CRP concentration in either
PBS or serum will be between 0.7 and 100 µg/mL. Also, depending on the type of
experiment, the protein will have various incubation times associated with it.
However, for normal detection of CRP, an incubation time of 5 minutes will be used
for each experiment. This will not have an effect on whether or not buffer or serum is
used.
Once the incubation of the protein has completed, it is removed and washed for
a third time with PBS. A mixture of the detection antibodies in PBS (50 µg/mL) is
then inserted into the chip. The detection antibodies used are Goat polyclonal antihuman CRP IgG antibody labeled with FIT-C (Abcam). The antibodies will then
incubate for 5 minutes. After the incubation, the antibodies are removed and a final
was step is required. This time, instead of PBS being used for the wash, PBST (1X
PBS + 0.5 µL Tween 20 per 1mL PBS) will be used. This is a stronger wash than PBS
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and it will remove more of the improperly bound antigens. After 5 minutes of
incubation, the PBST is removed from the chip and PBS is then inserted in order to aid
in detection. This is also shown in the protocol in appendix A.4. A diagram of the
sandwich ELISA is pictured below in figure 3-12[22-24].

Figure 3-12: Diagram of completed sandwich ELISA for CRP detection
Detection is performed by using fiber-optics. The detection area consists of a
spectrometer (Ocean Optics, USB4000, Dunedin, FL), which is hooked up to a
computer. To perform the detection, the fiber-optic cables are inserted into the
openings of the chip next to the detection area. The chip with the fiber-optics is placed
inside the detection box. To activate the antibodies, the power is turned on, which
activates an LED (light emitting diode) (Quadica Developments, Brantford, ON,
Canada) in order to excite the FIT-C. The light will travel through a series of bandpass
filters that will filter the incoming light to give off a wavelength of 470 nm (Edmund
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Optics, Barrington, NJ). This filter that was used has a bandwidth of 10 nm, a
minimum transmission of 45% and an optical density (OD) of 3. This enabled the
filter to block excess light that would interfere with the detection area and eliminate
most of the background noise in the system. Detection and readings are performed by
using the Ocean Optics program Overture. The wavelength is adjusted to 200 nm and
the reading will be read at 493 Hz. This is where the spike will appear on the screen.
The higher the spike, the more “full” the detection area will be. The absorbance level
will be recorded and then plotted using Excel against the concentration of the IgG[2224]

. The experiment setup is shown below in figure 3-13 and example plots for the

experiments will be available in appendix A.5.

Figure 3-13: Front view (top) and top view (bottom) of fiber optic test are for CRP
detection
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3.3.4. High Abundance Protein Removal
One of the main issues with performing a LOC with using blood plasma or
serum is the abundance of proteins in the blood. There are numerous proteins that can
be found in plasma that are known to cause interference in an ELISA-type assay.
These proteins not only can block the attachment areas in the assay, but also can
remove the antibodies that are used to capture CRP. The best way to overcome this
would be to remove the high abundance proteins already after the blood cell filtration.
In order to do this, it would have to come after the blood cell filtration site and the
detection site, since the blood cells can cause havoc with the detection for the same
reasons stated above.
Since there are many abundant proteins in serum, it would be most beneficial
to focus more on the most abundant proteins: human serum albumin and human IgG.
The reason for this being that they are the two most abundant proteins in plasma and
serum, they tend to cause the most interference when trying to perform experiments
that deal with plasma. There are other proteins that can cause interference, but these
two proteins are by far the most abundant and since there are multiple proteins, the
chip would have to be restructured in order to integrate multiple protein areas.
The preferable method to remove these proteins would be before the detection
area, but after the blood cell filtration. This means that there has to be a method of
protein removal in the microchannels inside the chip. There are different methods to
remove the proteins, but they involve using different outside sources and expensive
methods. These methods include electrophoresis[75], which was explained in the
removal of blood cells[34], a mixture of trichloroacetic acid and acetone[76] and
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different kits that are designed to remove albumin from serum[77]. While these
processes are effective, in terms of use on a microfluidic scale, it is rather difficult to
integrate due to the size limitations on the LOC system. However, one easy method is
utilized already in the chip: protein A. Protein A already has a high IgG affinity, which
is why it is already used in the detection area as a method to capture the capture
antibody. The same principle can be used in order to effectively capture IgG already in
a mixture like plasma. The channels of the chip can be coated by way of the same
method that was used in the ELISA. Also, since there are also anti-albumin IgG
antibodies on the market, they can be developed the same way as the capture
antibodies are used in the detection area. Except these antibodies will be used to
remove the albumin that is in serum. The antibodies used in these experiments are
Goat polyclonal anti-human albumin IgG antibody (Pierce-Antibodies, Thermo, #
PA1-29338). Two diagrams showing highlighting these methods are demonstrated
below in figure 3-14 and on the next page in figure 3-15.

Figure 3-14: Schematic of Human IgG removal from Blood with by way of protein A
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Figure 3-15: Schematic of Human Serum Albumin removal from Blood with by way
of protein A and anti-albumin IgG
There have been various methods to test in order to see how the removal of
albumin and IgG will help in CRP detection and there have been designs and
experiments performed that test this theory. However, most tests come to a conclusion
of having the serum flow into a removal site, allow IgG to leave the solution, move to
an albumin detection site, allow albumin to leave, and then flow to the detection site.
While this theory may work well, there is one flaw to this theory: the amount of IgG
and albumin is much greater than that of CRP. This creates the problem that even if
there is one removal area for each protein, there would still be too much in solution so
that it will cause interference. Because of this, a false reading can be taken and it
would incorrectly portray the CRP in a solution.
3.3.4.1.

Indirect Measurement of HAP Removal

To see how this method can be better develop, one has to look as to how well
the protein – antibody interaction is. This can be demonstrated by measuring the
concentration before and after each removal process. This is what is known as an
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indirect measurement. During an indirect measurement, the serum is sent into the
functionalized channel incubated to remove the high abundance proteins, removed
from the chip and collected for concentration sampling. This will help determine not
only how much of the HAP still remains in solution, but also with basic subtraction,
how much was taken by the protein. To perform this experiment, a nanodrop
specrtrophotometer was used to record the concentration. The nanodrop used was a
NanoDrop 1000 from Thermo Scientific. This was performed at the INBRE
Laboratory, URI College of Pharmacy. A drop of the reagent (~2 µL) was placed on
the center of the sample area. This works similar to the fiber optic detection system,
in which a light of a specific wavelength detects the particles in solution[22]. The
experiments will first focus on the removal of a pre-determined amount of IgG in PBS
buffer and if that is successful, the removal of albumin in buffer.
3.3.4.2.

Direct Measurement of HAP Removal

The other method will be a direct measurement of HAP removal. This
involves the same procedure as the indirect measurement, but instead of measuring the
amount of HAPs still remaining in solution, it will measure the amount of HAP
captured on the channel. This method will be performed by using the same fiber optic
detection method as with the ELISA. The solution that will be used is a mixture of
IgG labeled with FIT-C (detection antibodies) in PBS buffer. With this method, it will
be easy to see how well the IgG will attach to the protein A and come to a conclusion
as to how well this process is.
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3.3.5. Chip Designs for Protein Removal
In terms of what type of chips will be implemented, there are four main chip
designs that will be implemented. The first design is a one channel chip with two
ports and a hexagonal detection area. This design will be used to implement not only
how well blood can enter the chip, but also how can IgG attach directly to protein A.
This will both be performed with the indirect and direct IgG detections. Also, this
chip will be used to measure the CRP detection based on the positive (CRP in PBS
buffer) and negative (CRP in serum without protein removal) controls.
The second design is a modified first design, where there is a longer end of the
channel between the two ports. It still will encompass the detection area, but on the
bottom part of the chip. This design is for the tests that will implement the IgG
removal. The whole chip will be functionalized in the same manner as in the previous
chip, only the upper channels will be used as the IgG removal areas, and the hexagonal
area will incorporate the detection area.
The third design will incorporate multiple IgG removal areas. This design
expands on the premise of the first design. In this design, there are three separate
chambers above the detection area that will incorporate more of the capturing of the
IgG antibodies. The bottom area below the detection area incorporates a waste area.
No detection / IgG capturing will be performed in this area. All this area serves is that
the fluid will just enter this area after it passes through the detection area. All of the
channels of the chip will be coated with BSA, while the detection area on up will
include the protein A on the channels.

67

The final design comes from the Franzblau design of the final microchip, since
this would eventually be integrated in this system[24]. In this design, the same concept
as the third design will be encompassed, but there are noticeable changes. Starting at
the top, there are holes that will lead to a channel which head towards the main
channels. This is where the inlet for where the blood / plasma / serum will enter the
chip. This is due to the fact that all the reagents will be present on the chip before
blood plasma is introduced to the chip. Above that junction where the two channels
meet will be the storage for the reagents used after the plasma enters the detection
zone. In order are, from bottom to top, PBS, detection antibody, PBST, PBS. Below
this are the reagents used before the plasma enters the channel. They are, from top to
bottom, PBS, anti-albumin capture IgG, anti-CRP capture IgG. Notice that the
detection area now is the width of the channel. This is to allow a better signal within
the confines of the chip. Below this is the waste area, where channels have been
replaces by paper. This is to better the movement of the fluid in the chip, without
adding a delay in starting and stopping. Full pictures of the chips will be presented in
the figure on the next page.
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Figure 3-16: Chips used in serum/blood experiments. Clockwise from top left:
single-channel detection area, single channel with IgG depletion area, multichannel
with IgG and albumin depletion areas, multichannel with multiple IgG depletion areas.
3.3.6. Combination of Cell and Protein Removal
Using all of the methods described above the final steps will be to combine all
of this into a LOC device that is able to detect CRP from whole blood more
effectively. All three aspects, blood filtration, high abundant protein removal, and
CRP detection will be implemented in this new chip. With many methods of detecting
CRP in laboratories and with LOC processes, this new chip would not only have a
simple to use design, but also detect CRP with the upmost accuracy. The experiments
will show the most ideal method of removing blood cells, remove the majority of the
high abundance proteins and be able to detect real-world levels of CRP from any
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person. With this, testing for the risk of heart disease will be faster, easier to use, more
available outside of the lab and more accurate.
3.3.7. Limits of Detection and Quantification
Based on the results of the experiments with serum and blood, titration curves
will be created which display the comparison between CRP concentration in blood
/serum and intensity detected by the fiber optics. This diagram will be useful in that at
a specific intensity value, a CRP concentration value can be founded. This is useful in
testing and in homecare use, but it would be ideal to find how well this system can
effectively detect CRP, especially at low concentrations. In order to see the
effectiveness of the system, the limit of detection has to be implied. The limit of
detection (LoD) is the amount of, for example CRP, that can be effectively be detected
in which there is a distinct signal (in which background noise is not a factor)[78,79].
With the LoD, one can find out the minimum CRP concentration that is allowable for
accurate detection.
There are different ways to find the LoD. This project will focus on 3 methods
to calculate LoD. The first is what is known as a visual evaluation. This involves
creating a titration curve and checking to see where at low concentrations the graph
begins to level off to where a constant signal occurs. This is usually good for
estimation, but there are two other methods in which LoD can be easily detected.
The second method is what is known as a signal-to-noise calculation[78]. This
is a comparison between the amounts of the desired signal compared to the
background noise. This means that for a certain amount of signal that is produced,
there is an amount of noise that goes along with it. In any detection experiment the
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amount of signal detected should be greater than the amount of noise detected.
However, in order to obtain an accurate signal, the signal must be significantly higher
that then background noise. In most cases, a 3:1 ratio of signal to noise would be
adequate in order to obtain an optimal reading. However, there is a limit known as the
limit of quantification (LoQ) in which the obtained signal is adequate without any
objection. This is usually a 10:1 ratio. Both of these measurements can be easily
calculated using the titration curves[78].
In order to calculate the LoD and LoQ, one has to plot the concentrations and
signals for the lower end of the curve, usually near or past the point when the signal is
concentrated at the zero point. This plot is ideally linear and will give a slope (SL).
The next step will be to obtain the standard deviations (SD) for each signal omitted.
This is to see how far from a signal can the reader emit. This is usually about 95% of
the mean signal. In Microsoft Excel, the STEYX formula is useful for this because it
relates the standard deviations at each intensity for a given concentration and predicts
the standard error of all values. With the slope and standard deviation, the following
two equations can be used to calculate the LoD and the LoQ respectfully[78]:
(1)
(2)
The third method, based from Armbruster and Pry, calculates LoD based on
the limit of blank (LoB)[79]. The LoB is the highest expected amount that can be
obtained where no antigen (CRP) is present in the system. Even though there is no
CRP in the detection area, a signal can still be obtainable. For this, reason, a blank
sample has to be taken into account. To calculate the LoB, separate measurements of
71

the blank have to be measured. From these measurements, the mean blank
measurement and the blank standard deviation has to be calculated. The LoB can be
found using the following equation:
(3)
Once the LoB is found, a sample with a low amount of analyte is measured and
the standard deviation is recorded. The LoD can then be found using the following
equation[79]:
(4)
The LoQ can also be calculated based on the following method by rearranging
and combining the standard deviation / slope ratio[78]:
(5)
Rearranging the right side obtains the approximation:
(6)
For this project, the limits of detection and quantification will be examined
using these three methods and compared against each other.
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CHAPTER 4

FINDINGS

4.1.

Blood Cell Filtration

After many tests with the vivid plasma membranes, it was shown that they
were effective on removing RBC’s from whole blood. During each run, the syringe
withdrew the plasma at a constant flow rate into the tubing until either an air gap was
present, or the filters became clogged. Plasma was then collected in separate vials and
analyzed using a microscope. This provided the basis for the removal of blood cells.
Since the pores of the filters effectively allowed plasma to flow through, it was
assumed that the proteins also flowed through the filter as well. This was further
exemplified during the experiments for fibrinogen detection.
4.1.1. Evidence of Blood Filtration
In order to make sure that the following experiments can even be performed it is
important that plasma can even be filtered out of solution. The following pictures give
an example as to if this process can even work. For each test, piece of filter paper was
placed on a slab of PDMS connected to tubing which connected to a syringe. In this
example below, a piece of filter paper was sandwiched in between the channeled chip
and a PDMS slab designed to hold the filter paper. 45 µL of blood was inserted in an
opening that allowed filtration. A syringe pump was enabled at a pull flow rate of 100
µL/min. The filter paper used in this example is the Vivid Plasma Membrane GX
from the Pall Corporation.
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Figure 4-1: PDMS chip with Vivid Plasma Membrane GX with blood first inserted
onto the paper (top left), spreading throughout the paper (top center), the underside
after the blood spreading (top right), plasma extracted into the chip (bottom left) and
filtrate inside of the tubing (bottom right)
As seen in figure 4-1, the blood is added onto the chip and is able to migrate
through the filter paper. Note that the inlet into the channels is on the opposite side
from the inlet to the paper, as to avoid tearing of the paper due to the force of the
syringe pulling. After two minutes, the paper is concentrated with blood and there is
noticeable separation in the membrane. This is given off by that there is a tannish
color on the paper between the edge and the area of red blood cells. Normally, this
paper is white as seen in the top left of figure 4-1, but because this area is darker, it is
assumed that this would be the filtrate. The top right shows the underside of the chip.
Here, the blood has covered the entire area of the filter with it being red, in order to
show that there are blood cells that are attached to all points of the filter paper. It is at
this point that the syringe pump is turned on in order to effectively draw the filtrate
into the chip.
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The bottom left shows that chip with the filtrate already extracted into the chip.
The filtrate is the light tan fluid in the channels of the chip. It might be a little difficult
to see the filtrate inside of the chip, so bottom right includes the filtrate inside of the
tubing that is connected to the syringe. It is here that one is able to see very clearly
that the filtrate is being pulled into the tubing, which means that the filter paper is very
effective in obtaining a good amount of filtrate. Also, it is worth noting that the
filtrate has no red in it at all. This means that the filter has both effectively separated
the cells not allowed hemolysis to occur. Because of this, it can be stated that the
Vivid Plasma Membrane GX is an appropriate filter for separating cells from plasma
in small quantities of blood. The analysis of the blood will be investigated in section
4.1.3. The next section will explain how much filtrate can be exacted with the
Membranes GX as well as the GR.
4.1.2. Filtrate Volume
The two filter papers that this project is concerned with are the Vivid Plasma
Membranes GR and GX. The main difference between the two, according to the Pall
website, were the amounts of whole blood it can filter out per one square centimeter of
paper. The GX can handle roughly 20 – 30 µL of blood, while the GR can handle 40
– 50 µL of blood[66]. This is due to the void volume of the filters, where the GR has a
larger pore space than that of the GX. Based on this information, the following graphs
detailing the average filtrate volume are shown below (Figure 4-2 for the GX and
figure 4-3 for the GR). Each initial blood sample was set at 45 µL. Each test was run
until the filtrate stopped moving due to the blockage caused by the blood cells. Four
tests were compiled based on the rate of extraction (50 – 100 µL/min) and by shape of
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the filter (100 mm2 square vs 96 mm2 rectangle, based on whether or not the paper
would break during extraction)

Average GX Filter Test (45µL Blood
Initial)
Filtrate Voiume (µL)

20
50 µL/min - 10 mm x 10
mm Area

15

100 µL/min - 10 mm x 10
mm Area

10

50 µL/min - 12 mm x 8 mm
Area

5

100 µL/min - 12 mm x 8
mm Area

0

Figure 4-2: Average Filtrate Volume from the Vivid Plasma Membrane GX with 45
µL of blood
Based on figure 4-2, the average filtrate volume did not vary significantly. The values
stayed around 13 – 16 µL filtrate, regardless of the filter shape and flow rate.
However, in figure 4-3 below, a different story applies.

Average GR Filter Test (45µL Blood
Initial)
Filtrate Volume (µL)

25
20

50 µL/min - 10 mm x 10
mm Area

15

100 µL/min - 10 mm x 10
mm Area

10

50 µL/min - 12 mm x 8 mm
Area
100 µL/min - 12 mm x 8
mm Area

5
0

Figure 4-3: Average Filtrate Volume from the Vivid Plasma Membrane GR with 45
µL of blood
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With the GR filter in place, there is a noticeable 5 µL increase with the higher
flow rate. This is mainly due to the fact that more filtrate can be extracted without
environmental factors that include evaporation and the drying of the filter cake. This
did not show up in the GX due to the fact that the GR can handle 25% more liquid
than the GX. But other than this, there is no difference in the filter papers at the lower
end of the flow rate. With both types of filter papers, and both dimensions, it was
apparent that up to 15 µL of filtrate can be extracted, or up to 35% (rounding)
extracted from the original amount of blood. Based on the estimation that 55% of
whole blood is plasma, this amounts to an estimation of up to 68 – 70% of plasma
recovered. A table of values showing each volume extracted as well as percentages
for total blood and plasma volume recovered for both papers is show below.
Blood Vol. (µL)

50
50
100
100

Blood Vol. (µL)

50
50
100
100

Dim. (mm x mm)

Average Vol. (µL)

Blood %
Recovered

Plasma %
Recovered

10 x 10
16.5
36.37
67.90
12 x 8
13.25
29.44
54.52
10 x 10
15.5
34.44
63.79
12 x 8
17.17
38.15
70.64
Table 4-1: Values of filtrate volumes from Vivid Plasma Membrane GX
Dim. (mm x mm)

Average Vol. (µL)

Blood %
Recovered

Plasma %
Recovered

10 x 10
15.13
33.61
62.24
12 x 8
14.56
32.36
59.93
10 x 10
20.88
46.39
85.91
12 x 8
18.94
42.08
77.93
Table 4-2: Values of filtrate volumes from Vivid Plasma Membrane GR

Based on these findings and the fact that only about 5 - 7 µL is to be extracted,
either the Vivid Plasma Membrane GX or GR is acceptable. However, for the
upcoming experiments, based on the amount of blood that can be withstood, a few
tests will be conducted with the GX membrane. Even though the GR membrane could
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handle more blood, it should be noted that the final chip design calls for two inlets:
one for blood and one for the reagents. Because of this, the blood inlet has to be
sealed in order for the reagents to flow through the chip. Because only a few
microliters of blood are need and that the blood cells have to plug up the filter, it
makes more sense to use the GX membranes.
However, it is crucial to find the limit of what these filters can take. The first
test that demonstrated this was performed was with a larger sample size of blood (75
µL). Based on the previous experiments, it was assumed that the results would be the
most plasma that could be extracted from that size of filter paper, since it was
dependent on the recommended size for that specific blood volume. For this
experiment, since the amount of blood being used was about 1.5X the original amount,
it would be best to use a filter area 1.5X that as well (150 mm2). Also, the opening
into the chip was on the opposite end of where the majority of blood cells would be
filtered. Based on this experiment, it was shown that a large amount of filtrate was
extracted, with more extracted at a higher flow rate. This satisfied the findings on the
proportionality of the paper, where about 35 - 37% of the total blood volume was
extracted (compared to 33 – 35%), which resulted in an overall percentage of filtrate
extracted being between 68 and 70%. The figure and table for this experiment is
shown on the next page.
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Filtrate Voiume (µL)

Average GX Filter Test (75µL Blood
Initial)
30.5
30
29.5
29
28.5
28
27.5
27
26.5
26
25.5
25

50 µL/min - 10 mm x 15 mm
Area
100 µL/min - 10 mm x 15
mm Area

Figure 4-4: Average Filtrate Volume from the Vivid Plasma Membrane GX with 75
µL of blood with a filter area of 150 mm2
Blood Vol. (µL)

Dim. (mm x mm)

Average Vol. (µL)

Blood %

Plasma %

50
10 x 15
27.00
36.00
66.67
100
10 x 15
30.17
40.22
74.49
Table 4-3: Values of filtrate volumes from Vivid Plasma Membrane GX with 75 µL
of blood with a filter area of 150 mm2
However, with the same filter dimensions, but with the original starting
amount of blood, it was shown that less filtrate could be extracted. In the first
experiments with the GX membrane, about 15 µL out of a total of 45 µL could be
extracted. Here on the other hand, only an average between 8 µL at 50 µL/min and 12
µL at 100 µL/min could be extracted. This relates to 30% of the total blood yield and
about 58% of the total plasma yield. It was possible to extract 15 µL, but only at a
rate of 150 µL/min. It should also come to be known that at 10 µL/min, only 4 µL of
plasma could be extracted. The graph and table explaining this is located on the next
page.
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Average GX Filter Test (35µL Blood Initial)
16

Filtrate Voiume (µL)

14
10 µL/min - 10 mm x 15 mm
Area

12
10

50 µL/min - 10 mm x 15 mm
Area

8

100 µL/min - 10 mm x 15
mm Area

6

150 µL/min - 10 mm x 15
mm Area

4
2
0

Figure 4-5: Average Filtrate Volume from the Vivid Plasma Membrane GX with 45
µL of blood with a filter area of 150 mm2
Blood Vol. (µL)

Dim. (mm x mm)

Average Vol. (µL)

Blood %

Plasma %

10
10 x 15
4.00
8.89
16.46
50
10 x 15
8.54
18.98
35.15
100
10 x 15
12.75
28.33
52.47
150
10 x 15
15.08
33.52
62.07
Table 4-4: Values of filtrate volumes from Vivid Plasma Membrane GX with 45 µL
of blood with a filter area of 150 mm2
Due to these findings, it is important to relate the amount of blood being used
and the dimensions of the filter paper. Since the assays would likely be handling
plasma or serum volumes less than 10 µL, it should be noted that coming from a
starting blood volume between 40 and 50 µL, a filter area of 100 mm2 should be
sufficient in not only extracting that amount of filtrate, but making sure that the port to
allow the filtrate to enter the chip is sealed due to the filter cake. For this, either the
Vivid Plasma Membranes GX or GR are suitable with a total filter area of 100 mm2
based on concerns for the filtrate volume.
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4.1.3. Blood Cell Observations

Figure 4-6: Microscopic view of using Vivid Plasma Membranes for blood filtration
(top left: membrane GX – 5X, top right: membrane GX – 20X, bottom left: membrane
GR – 5X, bottom right: membrane GR – 20X). The dark channel represents whole
blood and the four light channels represent filtrate

Based on microscopic observations, it has also shown that there were no
amounts of RBC in all but two of the filtrate samples. The reason for the amounts of
RBC in the filtrate was based on sample mixing due to a bad microchip. Other than
that, it was shown that there were hardly any traces of RBC in the filtrate. The redness
in the samples explained above was caused by hemolysis either due to the age of the
blood, or the RBC during filtration. As stated previously, even though there were trace
amounts of redness in each filtrate, due to the force trying to obtain another 2 µL after
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about half the possible plasma was recovered, there was no sign of RBC’s anywhere
after filtration. This satisfies the second focus of the study.
To show that there was filtrate in these samples, figure 4-7 shows a
microscopic sample of what happens when there is a tear in the membrane. Blood
cells do rush into the channel, but not at the amount found in the control channel with
whole blood.

Figure 4-7: Microscopic view of using Vivid Plasma Membranes for blood filtration
with blood cells entering the channel (left: membrane GX – 5X, right: membrane GX
– 20X)
4.1.4. Plasma vs. Serum Tests

Figure 4-8: Centrifuged extracted filtrate with ethanol for plasma/serum tests (left),
fibrin remaining after serum extraction (right)

82

Figure 4-9: Centrifuged serum with ethanol for plasma/serum tests. Note that the
middle vial had no ethanol added to it
Concerning the presence of fibrinogen, 10% ethanol by volume was added to
each filtrate sample and frozen overnight to allow for coagulation. Each sample was
then centrifuged for a half hour to see if there was sediment. The results of this shown
in figure 4-8 has shown that there was significant coagulation and sediment for each
individual filtrate. In comparison, figure 4-9 shows the same experiment performed in
serum. In figure 4-8, there is a more noticeable amount of precipitate and it is more
tannish-red than white, as shown in figure 4-9. Furthermore, in figure 4-9, the middle
vial is serum without any ethanol added and it is similar to the serum with ethanol
added. Therefore, it can be said that each sample was plasma, not serum. In order to
make it so that these filters release serum instead of plasma, further research has to be
conducted in order to design a filter that separates serum from plasma.
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4.1.5. Creation of a Blood Separation Chip

Figure 4-10: First Prototype of blood-separation chip
In terms of the chip design, the first design, pictured above in figure 4-10, was to be a
two layer chip. The bottom layer consisted of the channels used to direct the fluid,
while the top layer consisted of an open filter at the top. The dimensions for this chip
are shown in the schematic. The filter was to be held into place using a thin layer of
glue. While testing, this prototype, there was one main fault with this design. This
was caused by the glue on the filter. The glue seeped throughout the filter, which
made it so that the blood could not flow through the filter and into the chip. Because
of this, a new prototype had to be created.
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Figure 4-11: Second Prototype of blood-separation chip
This new design consisted of three layers. The bottom layer is just a flat
PDMS layer, the middle layer is where all the channels are located and the top layer us
where the filter is held. The plasma asher is used to bind all three layers. The
channels will be bound as normal, but the filter holder will be bound to the top of the
chip, with the filter in between the both of them. In this scenario, the filter holds up
pretty well and blood flow is not obstructed. An example of the prototype can be
found in section 4.1.1 with the figures depicting the blood separation.

Figure 4-12: Modification of second prototype of blood-separation chip
Over the course of this project, this design has been modified in order to
maximize the effects of blood separation. For example, in the first update, a second
inlet channel was added in order to effectively filter out more blood from both sides of
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the filter paper[23,24]. A second update makes the filter paper circular in order to not
allow white area and to cover the filter completely with blood[23,24]. These two adages
will be implemented with the new sequential loading chip being used to detect CRP
with whole blood.
4.2.

Removal of IgG
4.2.1. Indirect Measurement of IgG

Concentration (mg/ml)

IgG Removal with Nanodrop
Measurements
4
3
2
1
0
0

2

4

6

8

10

12

Incubation Time (min)

Figure 4-13: Representation of indirect IgG capturing with varying incubation times
The first method used in the removal of IgG was to detect IgG that remained in
the plasma. Based on the results of these tests, it was determined that the evidence in
finding the amount of depleted IgG was insufficient. There was a good amount of IgG
depletion during the early stages with shorter incubation times; however, the
concentration was shown to be rising as the incubation time elapsed. There not a large
amount of change between 0 and 2 minutes, but around 5 minutes, there was a huge
spike in the amount detected and in the opposite direction. There are numerous factors
that can explain this phenomena happening, which include improper mixing of the
antibody before the tests and additional proteins/antibodies in the solution. This can be
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caused by improper binding either to the protein A or the channel and during the wash,
where improper binding can wash into the solution. Another issue is at larger
incubation times, protein A can become over-saturated with IgG that it cannot handle
all the binding and can break off from the glutaraldehyde. The nanodrop does not
include these factors in its measurement and therefore, will count these rogue agents
as a part of its total concentration. Because of these reasons, this method of indirectly
measuring IgG is not useful. A direct measurement of IgG has to be helpful as to how
well IgG can attach to protein A. Because detection antibodies labeled with FIT-C are
used in the ELISA, and since protein A has a high affinity to IgG, these antibodies are
able to attach to protein A and one can be able to use these antibodies to see how well
they attach to protein.
4.2.2. Capturing and Direct Measurement of IgG

Protein A Absorption of IgG
Intensity (counts)
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Figure 4-14: Representation of direct IgG capturing with varying incubation times
In these experiments, the capturing of IgG was performed with the focus how
effectively IgG binds to protein A. In the following graphs, a similar trend occurs.
From the start of the experiment to about 2 to 3 minutes, there is a steady increase in
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the signal of the IgG. However, after this time frame, the signal stays constant.
However, after 5 – 6 minutes, the signal declines. From the data, this is what can be
made from it. First, the protein has a rapid rate of capture and it can readily capture
IgG. However, as expected, there is a limit as to how much antibody can be on the
protein. This is apparent between 2 and 5 minutes, where the detection is relatively
level and the same within that time frame. One other thing to keep aware of is that the
longer the incubation time is (> 6 minutes), the signal decreases. The main reason for
this being that there the protein can become over-saturated when there are too many
antibodies on the protein that the protein can likely fall off the glutaraldehyde and out
of the detection area.
This is extremely important because once the experiments use serum or
plasma, it is necessary to remove a great amount of IgG and later on, albumin, so
knowing how long it takes in order for the protein to become saturated is important.
Based on these experiments, the optimal time to remove IgG successfully up to
saturation would be between 3-5 minutes based on the layout of this chip. To be on the
safe side, it will be the most ideal to have the incubation time set at 5 minutes, which
would make sure that the majority of the IgG that will be able to attach to the protein
can be achieved without fear of it breaking away and causing a disruption in the
detection area.
Based on this information, one can see how well IgG can readily attach to
protein A. But how does this help in CRP detection? Both antigens are found in serum
so it would be best to see how well they can CRP be detected in a buffer that also
contains IgG. To do this, two variables will have to be considered: First, how
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incubation time can affect detection. For these trials, multiple incubation times were
used, which ranged from 0 minutes to 5 minutes. Second, how IgG concentration can
affect detection. For these trials, IgG concentration varied between 0X to 4X the
concentration of CRP in solution. This should give an idea as to how well CRP can be
detected before serum, which contains a larger amount of IgG, can be used.
4.2.3. CRP Detection with IgG in Buffer
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Figure 4-15: Representation of CRP detection with IgG present with dependence on
incubation time
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Figure 4-16: Representation of CRP detection with IgG present with dependence on
IgG concentration per CRP concentration
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In these experiments, the capturing of IgG was performed with the focus of
two variables: the change in incubation time and the change in IgG concentration.
Based on the results of these graphs, two things can be said. First, as incubation time is
increased with the IgG concentration the same, the signal also increases. This is to be
expected since as less IgG is in the detection area, the less interference it causes,
which means that the CRP signal will be greater. Second, as IgG concentration
increases, with the incubation time kept constant, the signal also decreases. This is
based on the fact that there is so much IgG in the system and a limited amount of
protein A on the channels. There is a lot more interference in the detection area,
which attributes to the drop in absorbance. This is helpful because in these
experiments, the ratio to the amount of IgG to CRP varied between 0:1 and 4:1. In
human blood however, this ratio is much higher than that of the buffer. Because of
this, there has to be a way to increase the amount of signal that is comparable to that of
buffer.
There are various ways to try to increase the signal such as increasing the
concentration of protein A and the surface area of the incubation channels. However,
it is assumed that the channels are fully concentrated in protein A and in order to
increase the surface area, the chip would have to be redesigned completely. However,
based on the structure of the chip and the dimensions, there is a large amount of space
utilized for the storage and movement of the fluid compared to the amount of fluid
used. Because of this, multiple incubation areas can be utilized for the capture of even
more IgG. The reasoning for this being that up until a certain incubation time (5-7
minutes), the incubation area will become saturated with IgG that there will still be a
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significant amount of antibody in the detection area that interference will occur. To
make it so that this does not happen, multiple IgG capture areas will be integrated in
order to see if there is a rise in protein A detection. The amount of detection areas will
vary between 0 and 3, based on the limitations of the design of the chip.
4.2.4. CRP Detection in Buffer with Multiple Incubation Areas
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Figure 4-17: Bar graph of 10 µg/mL CRP detection in Buffer with 2X the
concentration of IgG mixed with 0 – 3 incubation areas
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Figure 4-18: Bar graphs of 10 µg/mL CRP detection in Buffer with and 4X the
concentration of IgG mixed with 0 – 3 incubation areas
The data above shows the detection of CRP with multiple incubation areas.
Note that only 3 incubation areas are used due to the amount of liquid and the
limitation on the chip design. Based on these results, it shows that as the number of
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incubation areas increase, the intensity detected will also increase. This is to be
expected since the amount of IgG has been depleted due to the multiple incubation
areas, which allows for less interference in the detection phase. One thing to be aware
is that the highest IgG:CRP ratio used here is 4:1. One has to take into account the
amount of IgG is a lot greater in that of serum and that albumin will also cause
interference. So even though this data is high, it still cannot compare to a real world
use as with serum, as shown in the upcoming experiments.
4.2.5. CRP Detection in Serum with Multiple Incubation Areas
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Figure 4-19: Bar graphs of 10 µg/mL CRP detection with IgG removal in specified
removal areas
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The graphs on the previous page show the same experiments above, but with
serum instead of buffer. Note that the light source runs on batteries, which explains
the low CRP in PBS signal. The above chart shows two experiments with serum with
a CRP concentration of 10 µg/mL and with incubation areas that vary between 0 and
3. For the most part, there is a noticeable increase in intensity as the number of
removal areas increase. However, once the third incubation area is added, there is no
noticeable rise in intensity. It is not as easy to see with the second chart, as that there
is an increase with the additional incubation area, but in the first chart, it is noticeable
as that these two values are identical. This may stem from the fact that because the
amount of IgG is decreasing, the fact that there could be just too little that it either
makes no difference in the actual assay, or that at every 5 minute incubation areas,
there is just too little IgG left in solution that grabs on to the protein. Regardless of
this, it would be beneficial to observe this with other concentrations.
100 µg/mL CRP Detection in Serum with IgG Removal Areas
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Figure 4-20: Bar graph of 100 µg/mL CRP detection with IgG removal in specified
removal areas
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5 µg/mL CRP Detection in Serum with IgG Removal Areas
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Figure 4-21: Bar graph of 5 µg/mL CRP detection with IgG removal in specified
removal areas
In the case with 100 µg/mL concentration of CRP in serum, this follows suit as
previously stated. However, with 5 µg/mL concentration of CRP in serum, there is a
different trend that shows. The experiment follows the same pattern up to 2 IgG
removal areas, but once the third removal area is reached, there is an issue because this
value is a lot lower than that of 2 areas. This can be from the fiber optics not receiving
a signal, or that something happened to the detection area that did not allow the
ELISA to function properly. Regardless of this, it seems that the highest levels of
detection occur with two IgG removal areas. The following graphs give a comparison
to how well CRP is detected at these three concentrations, and would allow seeing the
difference in intensity for all three concentrations.
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Comparison of CRP Detection with IgG Removal
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Figure 4-22: Line plot of CRP detection comparison with 2 IgG removal areas
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Figure 4-23: Bar graph of CRP detection comparison with 2 IgG removal areas
As shown in the graphs, blue represents detection of CRP in PBS, green
represents CRP detection in serum without any IgG removal and red represents CRP
detection in serum with two IgG incubation areas. This was performed with 3 CRP
concentrations: 5, 10 and 100 µg/mL. In terms of both the bar graph and the line plot,
there was a significant increase across all concentrations with IgG removal. However,
the amount detected was still considerably low compared to the amount found in PBS.
This means that there is interference caused by albumin in the sample. For this reason,
it is safe to assume that the removal of IgG is prevalent, however, the fact that albumin
still has to be removed has to be brought to attention.
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4.3.

Introduction of Albumin Removal
4.3.1. Order of Incubations

Intensity (counts)

Order of Removal
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then IgG
Albumin
Removed
Removed

Figure 4-24: Bar graph representing how order of removal is affected
Once it was discovered that the removal of IgG was effective, the integration
of anti-albumin IgG had to be considered. The first issue of this is in what order
should the removal be (albumin → IgG or IgG → albumin). The reasoning for having
the removal of albumin first is that there is more of it in serum than IgG, whereas the
reasoning for the removal of IgG first is that IgG in serum can cause interference and
can break away the IgG already used in capturing albumin. To perform this task, two
runs were produced where CRP was detected in its normal fashion and the integration
of protein removal was used. Each run was different as to the order of the removal of
the protein. The first run consisted of the albumin removal first, followed by IgG
removal, whereas the second run was the opposite: IgG removal followed by albumin
removal. Intensity measurements were performed after each removal stage to see how
well the CRP can bind in the detection area. A negative control which contained no
removals and a positive control containing CRP in buffer were also used as a
reference.
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The results on the previous page show that when the albumin was removed
first, there was as slight increase in signal. There was also a slight increase when the
IgG removal came later. However, when the IgG was removed first, a higher signal
was present, that basically was about the same as the signal obtained when albumin
was removed, followed by IgG. A stronger signal was emitted when the albumin was
removed after the IgG. Compared to the CRP in PBS detection, it was still not up to
that level, but a stronger signal was found. The results from this experiment show that
the preferred order for HAP removal would be the removal of IgG, followed by the
removal of albumin. This follows the same reason as in Godfrin and Franzblau[23,24].
Figure 4-30 on the next page shows the completed chip with the areas highlighted for
each fluid and where the areas for IgG and albumin removal would be. Keep in mind
that even though one area is highlighted for each removal process, the number of
incubation steps in each area will vary based on the experiment.

97

Figure 4-25: Microfluidic chip including blood separation and areas where IgG and
albumin removal zones are located
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4.3.2. Introduction of Albumin Removal Areas
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Figure 4-26: Bar Graph representing the addition of albumin removal areas
The graph above shows the comparison as more albumin removal areas are in
place. The first experiments were performed with 1 IgG removal site, followed by an
increasing amount of albumin removal areas, from zero to three, including one with
just serum without any removal and one with CRP in PBS. The first experiments were
performed with a CRP concentration of 10 µg/mL, represented the red bars. The
initial response was that this performed well because the signal increased with the
number of detection areas. However, a second experiment was performed with 5
µg/mL concentration of CRP and even though the signal also increased, the difference
between the two concentrations was too small. This means that if one was to measure
a CRP in this manner, for a specific intensity, the intensity range for those two
concentrations would be too small to tell. Compared to the example of CRP in serum,
there needs to be a wide range of intensity values for these two concentrations
To solve this, two more experiments were performed to see the reasoning
behind this. Based on the highest experimental results (1 IgG and 3 albumin areas), an
additional removal area was added to both experiments (one had 1 IgG and 4 albumin,
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and the other had 2 IgG and 3 albumin). Based on these experiments, there now was a
noticeable difference between the two concentrations. Each produced a high signal
and each concentration was close to that of the buffer. This can be tied in with the
previous experiments, where even with one round of IgG removal; there was still a
large amount of IgG remaining in the solution. Because of this reason, and that the
intensity increased during this round of experiments, the new flow method for the
removal of IgG and albumin will be 2 IgG removal areas, followed by 3 albumin
removal areas.
4.3.3. CRP Detection in Serum
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Figure 4-27: Linear comparison of CRP removal with 2 IgG and 3 Albumin removal
areas for 5, 10 and 100 µg/mL
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Figure 4-28: Bar comparison of CRP removal with 2 IgG and 3 Albumin removal
areas for 5, 10 and 100 µg/mL
The above graphs show the results of the serum tests with this new protocol. In
this run, 3 different concentrations of CRP were added to the CRP free serum: 5, 10
and 100 µg/mL. Each of the graphs show that a different amount of CRP can be easily
identified based on whether or not serum or buffer is used. This is shown based on the
different color lines on the graph. From here, we can see that a different value/range
can be associated with each amount of CRP that is added.
One other thing to note is that the difference in adsorption between 5 and 10 is steeper
than that of 10 and 100. This means there is a greater difference in whether or not
serum has 5 or 10 versus whether or not serum has 20, 50 or 100. For this reason, it is
essential to see if values can be associated with values between 10 and 100.
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Figure 4-29: Linear representation of CRP detection in Buffer, Serum with high
abundant protein removal and Serum without High abundant protein removal
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Figure 4-30: Bar representation of CRP detection in Buffer, Serum with high
abundant protein removal and Serum without High abundant protein removal
Based on the diagrams above, there is still no change in intensity at 50 and
even at 25. However, there is a slight drop when the 15µg/mL level is reached. It is at
this point where an accurate measurement of CRP can be determined. It can also be
seen that the detection area is fully concentrated, which means that no more CRP can
be added to increase the signal. Because of this, one can see that the CRP detection
area is idea for identifying samples of CRP at low concentrations, but not ones with
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high concentrations. However, his can signify a good yes-no marker on whether or not
a person has a high risk of cardiovascular diseases, but not an extent as to how the risk
factors are.
CRP
Signal in Serum
Signal in Serum
Signal in Buffer
Concentration
(no removal)
(IgG and Alb.
(µg/mL)
Rem)
0.7
1300
2166.4
2373
1
1840
2563.5
2685
2.5
3017.6
4747
5156.4
5
6007
9004.2
10316.43
10
6959
11486.4
12067.53
15
7215.75
11779.2
12467.53
25
7384
12088.6
13223.25
50
7618.5
12989.4
13894.83
100
7570
13010.6
13811.9
Table 4-5: Signals of varying concentrations of CRP in Serum (with and without IgG
and albumin removal) and in Buffer
The following table depicts values obtained when the assays are performed
with different combinations. The second column represents the signal in serum with
no albumin or IgG removed (represented by the green line in the graph), the third
column represents the signal in serum with IgG and albumin removed (represented by
the red line in the graph) and the fourth column represents the signal in buffer
(represented by the blue line in the graph). These numbers represent the signal
emitted at specific concentrations. These vales show what has previously been stated,
but in a numerical format. This shows the rise in signal compared to the rise in CRP
concentration and how it varies between the three solutions. This still shows the same
issue that once higher CRP concentrations are met, the signal becomes more linear due
to the design of the detection area and the incubation time in said area.
Also, it shows where this change from a rise to a linear plot likely occurs. This
was shown to be around 10 – 15 µg/mL for all three curves. From this, a table can be
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made where these two areas should meet. This was based on dividing the graph into
two sections and adding a quadratic trend line on the left side and a linear trend line on
the right. The graph showing one example is below and the table with the list of
values is also below.

Intensity (counts)

Comparison of CRP Detection
y = 16.538x + 11609
R² = 0.7628

16000
14000
12000
10000
8000
6000
4000
2000
0

y = 1804.1x + 695.75
R² = 0.9923

0

10

20

30

40

50

60

70

80

90

100

CRP Concentration (µg/mL)

Figure 4-31: Plot representing where the change of signal in concentration occurs
(trend lines for serum with stops)
Type of Curve

Eq. for Left Side

Eq. for Right Side

Concentration (@
Intensity)
Serum w/out
Y = 1809x + 560.51
Y = 5.5865x +
6.224 µg/mL
Stops
7126.1
(@7161)
Serum w/ Stops
Y = 1804.1x +
Y = 16.538x +
6.122 µg/mL
695.75
11609
(@11710)
Buffer
Y = 1870.3x +
Y = 17.541x +
6.243 µg/mL
824.5
12391
(@12500)
Table 4-6: Concentrations indicated where a rising signal turns more linear
This was based on the fact that the signal started to become concentrated
around 10 µg/mL. As a result of this, it was shown that with the increase of
concentration, the signal started to become stagnant around 12000. This was easily
associated with CRP concentrations less than 10 µg/mL. This was not due to the
removal of HAPs, but more to do with the detection area itself. The time taken to
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capture CRP in the detection area was five minutes. This was based on the previous
experiments where at this time, there surface was already concentrated with CRP that
no further binding could occur. This method worked well for CRP concentrations
under 10 µg/mL but over 10 produced this linear correlation whereas the concentration
of CRP increased, the signal would either increase slightly, or not at all. Perhaps the
signal would be better if the incubation time was increased, but with the fact that the
detection site can become saturated with CRP, this would be unlikely. The best
solution to see that there can be an increase in signal would be to increase the surface
area of the detection area to accommodate this problem. This method could be
investigated further in order to see if this holds true. In the meantime, it can be said
that at CRP concentrations under 10 µg/mL, this method is preferred, but at or greater
than 10 µg/mL, there is a high signal, but no clear and concise differences between
concentrations, especially at concentrations over 25 µg/mL.
4.3.4. CRP Detection in Blood
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Figure 4-32: Graphical Analysis of CRP detection in whole blood compared to the
serum results
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After a few experiments in which a normal blood sample was used, a number
of conclusions can be reached. First, the filter filtered of the plasma well. This meant
that there was adequate amount of plasma in the channel during the experiment. Also,
there was an absence of not only red blood cells, but also hemoglobin. This allowed
the plasma to be a clear liquid, or a light tan liquid, which eliminates the obstruction
caused by the blood cells.
Also, the points above on the graph were based on a trend line with the red line
as the basis for the trend line. This line is a rough estimate as to how far outside the
previous experiments were. This graph however does not take into account a point
where no signal occurs. For this, a second plot was created at a CRP concentration
that is close to 0 µg/mL (around 800 for intensity).
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Figure 4-33: Graphical Analysis of CRP detection in whole blood compared to the
serum results with an estimate point at a CRP concentration of 0 µg/mL
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In this graph, there are two considerable differences in the trend lines. The
first is that two different concentrations of CRP in blood are given. The table on the
next page highlights the two differences.
Graph

Signal Emitted

CRP Plasma
CRP Blood
Concentration
Concentration
4-37
9416.875
5.2323 µg/mL
2.8254 µg/mL
4-37
9629.125
5.4570 µg/mL
2.9468 µg/mL
4-38
9416.875
4.7377 µg/mL
2.5584 µg/mL
4-38
9629.125
4.8526 µg/mL
2.6204 µg/mL
Table 4-7: Values of CRP in whole blood based on experiments and figures 4-32 & 433
Even though the values represented in figure 4-33 are less than that of figure 4-32,
they do represent the curve better since they are more likely to be found on the red line
than in the figure 4-32. This makes this second figure more ideal in estimating the
value of CRP in blood. However, the first graph is better at estimating values greater
than that of 5 µg/mL concentration. For this reason, in order to accurately see what
kind of plot can be obtained from these experiments, the two equations created from
the trend lines were set in order to solve for the intersecting point that was accurately
depicted on the plots. From this, it was shown that the two trend lines intersected at a
concentration of 3.856 µg/mL at an intensity of 7816. Any values lower than this was
fitted with the trend line form figure 4-33 and values greater than this was fitted with
the trend line from figure 4-32.
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Figure 4-34: Representation of possible CRP detection in Serum
The graph above shows the possibilities of the detection of CRP as each
specific concentration is associated with an intensity value. However, these values are
for serum alone, which was in the detection area. In order to see the values of CRP in
blood, all the serum values would have to be multiplied by 0.54 since 54% of the total
volume of blood is serum. The graph for the blood is shown below, which is nearly
identical to that of serum, but with a different X-axis. The two black dots represent
the two experiments with blood being used as a fluid.
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Figure 4-35: Representation of possible CRP detection in Blood
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The following table on the next page represents the intensity values associated with
the graph at various CRP concentrations.
Intensity

CRP in
Serum
(µg/mL)

CRP in
Blood
(µg/mL)

Intensity

CRP in
Serum
(µg/mL)

CRP in
Blood
(µg/mL)

1605.66
2337.37
3197.06
4142.88
5136.75
6144.37
7135.25
8008.91
8631.87
9183.60

0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0

0.27
0.54
0.81
1.08
1.35
1.62
1.89
2.16
2.43
2.70

9668.31
10090.20
10453.49
10762.37
11021.05
11233.74
11404.64
11537.95
11637.89
11708.65

5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
10.0

2.97
3.24
3.51
3.78
4.05
4.32
4.59
4.86
5.13
5.40

Table 4-8: Values of CRP in serum and whole blood based figure 4-40
On the graph, it is worth noting that all CRP concentrations in blood greater
than 5.5 tend to converge at 12000. Based on the previous experiments with serum
only, the signal can get over 14000, but this requires a blood CRP concentration
greater than 10 µg/mL. However, from the introduction and the literature review, a
high risk of cardiovascular disease occurs at 3.0 µg/mL concentration of CRP in blood
(5.56 µg/mL in serum), this chart works well in the acceptable range of an individual
with either a low or a moderate risk of cardiovascular disease. For more extreme
cases however, it is still functional, but there is known error due to the small spacing
between the intensity values and CRP concentration. Therefore, according to the table
and chart, a reading of under 4000 means that a patient has a low risk of
cardiovascular disease, a reading between 4000 and 10000 signifies a moderate risk
and a reading over 10000 signifies a high risk. According to figure 4-40, the blood
samples gave off a reading of about 9500, which translates to a CRP blood level of
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2.87 µg/mL concentration of CRP in blood (5.3 µg/mL concentration of CRP in
serum), which translates to a moderate risk of cardiovascular disease.
Since there is no definitive method of checking to see if removal of IgG and albumin
has occurred in the channel, it would be best to detect the amount of CRP in the
plasma and then compare it to the amount taken by the graph made in the previous
experiments. In this case, the fiber optics recorded a signal for two measure
measurements of blood of 9416 and 9629, which correlates to a CRP plasma
concentration of 4.78 µg/mL and 4.91 µg/mL, respectively. In order to obtain the
blood concentration, since the mass of CRP is constant and adding cells increases the
volume, a good estimate would to take the concentrations and divide by the amount of
plasma in blood (54%). This will give CRP blood concentrations of 2.58 µg/mL and
2.65 µg/mL respectively.
This shows that it is in the normal range of serum as in the previous tests.
However, one thing of noting is that fibrinogen could still be in the plasma. This could
still cause some interference within the detection area and/or the incubation areas. In
order to see if this experiment is performed well, this has to be taken into account.
This will be talked about in more detail in the upcoming section. Other than this, it
was shown that the plasma was filtered well and that a respectable signal could be
found with the addition of blood in the detection of CRP.
4.3.5. Limit of Detection
This section will explain the different methods for limit of detection that were
used in this thesis. The first method implemented was the use of direct observation.
Using the experimental curve with the IgG and albumin removal, it was found that the
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lowest limits in which CRP that can be detected in which there was a persistent
increase in intensity was at 0.7 and 1.0 µg/mL. This was shown in figure 4-34.
Averaging these two values together gave a limit of detection of 0.85 µg/mL CRP in
serum, or 0.46 µg/mL CRP in blood.
The second method implemented was the signal to noise method of
determining limit of detection. The four lowest values that were detectable were
plotted and a linear trend line was also plotted in order to show the correlation
between these values. The standard deviation was also calculated for all the points
and this was placed with the slope in equation 1 in chapter 3. The result of this was a
limit of detection of 0.7 µg/mL CRP in serum and 0.39 µg/mL in blood. Using
equation 2, the limits of quantification for both serum and blood respectfully were
2.12 and 1.17 µg/mL. The graph displaying the slope is shown below in figure 4-36.
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Figure 4-36: Trend line for limit of detection using signal-to-noise
The final method implemented was performed using the limit of blank. In this
method, assay tests were recorded with no CRP or antibody signal. The mean and
standard deviation was recorded and placed into equation 3. The result of this was a
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limit of blank of 0.82 µg/mL. This was placed into equation 4 with the standard
deviation of the lowest measurement (0.7) and a limit of detection was found to be
1.10 µg/mL for serum and 0.61 µg/mL for blood. The limit of quantification was
found using equation 6 to be 3.31 µg/mL for serum and 1.82 µg/mL for blood. Table
4-9 summarizes the methods and values obtained for LoD and LoQ. The discussion
about the limit of detection will be addressed in chapter 5.
Method
LoD Serum
LoD Blood
LoQ Serum
LoQ Blood
Observation
0.85 µg/mL
0.46 µg/mL
2.55 µg/mL
1.38 µg/mL
Signal:Noise
0.70 µg/mL
0.39 µg/mL
2.12 µg/mL
1.17 µg/mL
Limit of Blank
1.10 µg/mL
0.61 µg/mL
3.31 µg/mL
1.82 µg/mL
Table 4-9: Summary of limits of detection and quantification for blood and serum
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CHAPTER 5

CONCLUSION

5.1.

CRP Detection

Based on the results of the previous experiments, there are a number of
conclusions that can be made. The first conclusion is that minute amounts of blood be
effectively filtered and have no trace of blood cells anywhere. This is due to the
construction of the filter membrane in that it is very hydrophilic and has pores large
enough to allow plasma to pass through and keep blood cells out. Also, there was no
sign of either blood cells escaping or hemolysis occurring. This means that all of the
filtrate entering the chip was plasma. This by itself eliminates the majority of objects
that can cause obstruction with the ELISA in the detection area. Because of this, a
chip was created that was able to incorporate blood filtration by using separation
membranes.
In addition to this, it is possible to detect CRP in any medium, including
buffer, serum and whole blood. It is even possible to detect it without the extraction of
small proteins. However, because of the interference between the capture antibodies
and high abundance proteins, it was shown not only to be more difficult, but there is
no variance between different amounts, as compared to detecting CRP with buffer. It
is also worth noting that protein A can effectively capture human IgG in serum. One
thing though that has to be pointed out is that there is a limit as to how well protein A
can hold on to IgG. Usually over 5 minutes of incubation time, the protein becomes
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too saturated with antibody that the antibodies start to fall off the protein or the protein
breaks off completely from the channel. This should explain why the signal is lower at
incubation times over 5 minutes. This was one of the reasons why multiple incubation
areas had to be included on the chip. The other reason being that the amount of IgG in
serum is far greater than that of CRP (coupled with the amount of human albumin). In
order to obtain a better signal, a method of removal of more proteins/antibodies has to
be used.
Based on the design of the chip, two incubation areas were originally created:
one for IgG removal and one for albumin removal. The channels in the chip between
the filter and the detection area can hold about 50 microliters of fluid at one time.
Since 5 microliters of serum are only needed for each experiment, it would be best if
multiple incubation areas were introduced. This would be performed for both the IgG
and albumin incubation areas. In the following experiments, it was shown that the
signal for CRP did increase with each additional incubation area, but it is also
important to know that the rise in signal between 2 and 3 areas is lower than between 1
and 2. It is best to say that there should be at least two incubation areas just for IgG
removal. Also, before any experiments are performed with albumin, it is safe to say
that there should be at least 2 incubation areas for albumin based on the fact there is a
greater concentration of albumin than there is of IgG.
The next experiments involved seeing whether or not removal of IgG or
removal of albumin would come first, based on this assessment, it was determined that
the removal of IgG would come first because there would not be any interference
between the IgG in the serum and the IgG already on the protein A. This is based on
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the graphical data, where there was a higher final signal with IgG then albumin than
the other way. From the previous experiments, it was then time to test the effects of
albumin with one base sample (10 µg/mL concentration of CRP). This first
experiment increased the amount of albumin detection spots, which came after 1 IgG
incubation area. The results showed that as the amount of incubation areas increased,
the signal in the system also increased. The same theory applied when a lower
concentration was used (5 µg/mL). The experiment revealed that the signal also
increased. However, when the two results were compared there was no clear
separation in the intensities. There was a difference in the intensities, but it would not
be considered great. In order to make sure that this is functional, there has to be a large
enough gap between 5 and 10 µg/mL of CRP. One of the reasons for this being that
there is only one IgG incubation area. This causes interference not only in the
detection area, but also with the anti-albumin IgG. Because of this, a second
experiment was performed, with 2 IgG and 3 albumin incubation areas, and 1 IgG and
4 albumin areas.
It was also shown that with concentrations of 5 and 10 µg/mL of CRP, there
was a distinct difference in the levels in intensity. This difference in intensity was
between 1500 and 2500 for 5 and 10 µg/mL. This was provided that there had to be 2
IgG removal areas, followed by 3 albumin removal areas. Because of this, it would be
essential to remove as much IgG in serum before albumin can be removed. For this to
occur, at least two IgG incubation areas have to be established in order for this
interference to be mitigated.
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As a comparison between the two previous tests, a higher concentration was
performed (100 µg/mL). The results of this test showed that there was a rise in signal
with the increase in concentration. However, the rise in concentration was not as high
as compared to the lower concentrations. The reason for this being either the
incubation time in the detection area is too low or the detection area is too
concentrated with CRP. Because of this, it would be ideal to see what the maximum
concentration that the detection area can hold. As it turns out, with different dilutions,
it was shown that a decrease in the signal occurred at15 µg/mL in serum. This is not
very high considering that this is around the lowest concentration in which the CRP
level is in the “danger zone”. Because of this, this detection system can inform the
user whether or not his CRP level is too high, but not to the extent of how high it can
go. However, it can give the level of CRP in a healthy person accurately.
The results of the previous experiments resulted in a curve that can be used as
a correlation between intensity and CRP concentration. This is shown as the red line in
the graphs in chapter between the blue line representing CRP in buffer (positive
control) and the green representing CRP in serum without protein removal (negative
control). As shown in the graph, the red line is very close to the blue line, which
means that the process of IgG and albumin removal before the detection of CRP
worked well. Compared to the line for CRP in serum without any removal, it is on a
level about 2 times that. Is it possible to achieve a higher signal compared to the
previous experiments, yes, but that will require another incubation area (either a third
for IgG or a fourth for albumin), and even then, this does not factor in other proteins in
serum. Even with the extra incubation area, the intensity would only go up by a few
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hundred. The important thing is that there is a reasonable curve that can be used to
detect an amount of CRP in serum, even though it can only accurately detect
concentrations less than 15 µg/mL.
As for the tests with whole blood, the experiments worked well from top to
bottom. There was an ample amount of blood that was filtered well into the chip
without any blood cells entering or rupturing. The plasma did go through all 5
incubation areas in the chip and CRP was detected (there was a detection signal
emitted) in the detection area. One thing to point out is that the signal shows a
concentration, compared with a trend-line that was less than 5 µg/mL concentration.
The addition of a 2.5 µg/mL test has shown that there was a decrease in intensity by
about 3000. However, with tests at 1 µg/mL, the decrease was around 1200, with an
addition 500 decrease around 0.7. This shows that while it is possible to detect low
amounts of CRP, at concentrations under 1 µg/mL, it becomes more difficult due to
the relative amount of CRP compared to IgG and albumin. While this test shows that
it is possible to detect CRP in whole blood, there are still three issues that have to be
dealt with. First, the blood that was used was from one source. If multiple sources
were tested, one could see that there could be varying patterns between the different
blood types. It is not as easy as inserting a fixed concentration of CRP because one
would have to account for the CRP that is currently in the blood. Second, this is CRP
detection from a planned detection system. If it could be possible, an actual
measurement of CRP would have to be performed to see if this method would hold
water. Finally, the previous tests used serum as a medium for CRP. This new test used
plasma as a medium. The main difference between the two is the presence of

117

fibrinogen. Fibrinogen is not as abundant as albumin, but it is a larger protein and it
can cause blood to coagulate when it is outside of the human body. One set of future
experiments could be to insert a sixth incubation area that removes fibrinogen and see
if the CRP detection changes.
From the results of these experiments, a few advantages and disadvantages can
be pointed out. The first advantage is that not only is CRP detectable in serum and
blood, but it is within the area of using CRP in a buffer solution with the same
detection. This means that a wide range of signals that are normal can be found and
there can be different absorbance values associated with them. The second advantage
is that blood that was either not de-coagulated with EDTA or diluted worked in the
system. This means that the system can be used outside of a laboratory setting where
a prick on the finger for blood extraction can be performed. One final advantage is
that this can qualify as an LOC – POCT device, in which patient care can be
performed on the spot and the amount of blood that can be obtained is less than 50 µL
per patient.
However, there are a few disadvantages to this process. The first of which
being the time taken to perform the assay. It takes on average between 50 and 60
minutes to perform the assay, with the majority of the time spent on IgG and albumin
removal. It is true that the majority of the IgG and albumin can be removed within 2 3 minutes per incubation, but this experiment used 5 minutes as a time in order to
effectively fill the channel surface effectively with IgG or albumin. If a 2 – 3 minute
incubation time is used, it might make the time elapsed half of what this experiment
calls for (20 – 30 minutes). A second disadvantage is the detection area. As
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performed in the experiment, a titration curved was created for the detection of CRP in
serum and blood. Unfortunately, any blood CRP concentration greater than 5 – 6
µg/mL kept the curve stationary, meaning that the same signal was still going off.
Because of this, there is no way to determine the extent of detection for high CRP
patients without a simple yes or no. In order to fix this, either a better detection area
has to be created, or another incubation area time has to be utilized. One final
disadvantage is that multiple tests still have to be performed on a patient. This is due
not only due to the fiber-optic signal, but also that CRP levels can vary from person to
person within a few days. Because of this, multiple readings have to still be
implemented in order to obtain a good reading. Despite these disadvantages, this
method has shown that for normal CRP levels, this method of CRP detection from
whole blood is ideal.
In terms of the limit of detection, it has been shown that this system is able to
detect minute amounts of CRP in whole blood (< 0.5 µg/mL in whole blood).
However, both the signal-to-noise and the limit of blank methods display two different
values. This is due in part to the signal achieved due to the blank. Without a chip in
place in the system, the level of intensity is around 800. This is fine for the method of
signal-to-noise because it assumes a intensity of 700 at no CRP concentration (see
figure 4-41), but in the case of limit of blank, it has been shown that with a blank,
there is still an intensity level of 1900 that has been detected, with a standard deviation
of around 150. The lowest experimental level is at 0.7 µg/mL and the intensity values
have shown have a value of around 2100 and a standard deviation of around 300.
With the calculations, it was shown that the limit of detection was doubled using the
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limit of blank. As a comparison, a second signal-to-noise ratio was conducted, as seen
in figure 5-1.

Signal to Noise LoD
5000
4500
Intensity (counts)
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3500
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y = 1170.7x + 1639.6
R² = 0.9368
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0
0
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2.5

3

CRP Concentration (µg/mL)

Figure 5-1: Signal-to-noise LoD calculation with emphasis on the blank point
This time, this calculation was based on the blank measurement. The result showed
that LoD for serum and blood were the same as with the LoB method (1.11 µg/mL &
0.61 µg/mL respectfully). Because of the blank intensity being that high, this was
shown in the LoD calculations.
As a comparison for this project, it would wise to take a look at the results
from Godfrin[23]. In his set up, only there was only one incubation area for each HAP
removal. These incubations was only for 7 minutes each, whereas the incubations for
this report were for only 5 minutes based on the protein A experiments. Also, his
included a blocking step where BSA was used to eliminate any non-specific binding,
whereas this project did not incorporate it, since it relied more on the protocol from
Li[22] and Franzblau[24]. Furthermore, the CRP incubation time was longer than the
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one used in this report (10 min as compared to 5 minutes). Because of this, the
majority of time used in CRP detection in Godfrin[23] whereas the majority of the time
was used in HAP extraction. The table below highlights the times needed to perform
each step.
Incubation Step
Time via Godfrin (min)
Time via Pytka (min)
Capture Antibody
7
7
Blocking w/ BSA
5
0
IgG Removal
7 (1 @ 7min)
10 (2 @ 5 min)
Albumin Removal
7 (1 @ 7 min)
15 (3 @ 5 min)
Sample (CRP)
10
5
Detection Antibody
5
5
PBST
5
5
Rinse, Pumping &
4
8
Detection
Total
50
55
Table 5-1: Comparison between CRP detections based on the Godfrin[23] and Pytka
systems
Even though these differences apply, the system used in this report was only 5
minutes longer than the one used by Godfrin. Knowing that less than 5 minutes was
an acceptable time for the incubation, if this was implemented, it amount of time for
the process would decrease by about 20%. Also, it would be ideal to look at the
comparisons graphically, which are shown in figures 5-2 to 5-4.

121

Intensity (counts)

Comparison of CRP Detection in Buffer
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
0.1

1

10

100

CRP Concentration (µg/mL)

Figure 5-2: Comparison of CRP detection in buffer graphs between the Godfrin[23]
project (top) and this project (bottom)
The first comparison is the CRP detection in PBS buffer. Based on the results
of these graphs, it was shown that both graphs are similar not only in shape, but also in
the intensity values. Based on this, both graphs can be used as a bench mark for a
comparison with serum and blood.
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Figure 5-3: Comparison of CRP detection in serum graphs between the Godfrin[23]
project (top) and this project (bottom)
In the serum tests, there are a few key factors to point out. First of all, the
Godfrin test used a diluted serum (10:1 PBS:Serum) in order to test the functionality
of the system[23]. This report, on the other hand, did not use diluted serum, which
means that the normal IgG and albumin concentrations in serum were kept intact.
Even with this modification, it was still shown that the rise in intensity in the Godfrin
experiments were not as great as the experiments in this report. This could be partially
based on the amount of HAPs still in the serum. There was a rise in the intensity as
concentration increased, but compared to the values to the bottom graph, it was not
high enough and did not compare to the increase in intensity based on the CRP in
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buffer curves. The bottom graph, on the other hand, matched almost exactly the buffer
curves. Table 5-2 on page 118 shows the percentages of CRP detected in serum
compared to the buffer curves for both experiments.

Comparison of CRP Detection in Blood
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CRP Concentration in Blood
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Blood Test 2
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Figure 5-4: Comparison of CRP detection in blood graphs between the Godfrin[23]
project (top) and this project (bottom)
For the results based on whole blood tests, keep in mind that the CRP
concentration in serum is larger than that of whole blood. This is due to the removal
of cells that contribute to 45% of the total volume in blood. This is important because
the Godfrin tests used blood doped with a certain CRP concentration[23], whereas this
project estimated the CRP concentration by multiplying the concentration CRP in
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serum by 0.55. Because of this, only the lower end values for the Godfrin graph apply
here. The Godfrin graph shows a rise in intensity based on the CRP concentration, but
it still was smaller than that in diluted serum (see figure 5-2) for each concentration.
The blood values obtained in this project used the assumption the only difference
between the serum and blood graphs were the loss of 45% of the blood volume. Thus,
taking a look at both graphs, up to 5 µg/mL concentration, there is a substantial rise in
concentration in both graphs, but the Godfrin plot is too low compared to the plots in
this project. Tables 5-2 and 5-3 shows the specific CRP concentrations of both
projects and compares them to that of the concentrations for each one in buffer.
Godfrin Project
Pytka Project
Conc.
C (Se)
C (Bu)
% Det.
C (Se)
C (Bu)
% Det.
0.5
405
2200
18.4%
2166
2373
91.3%
1.0
510
2250
22.7%
2564
2686
95.5%
5.0
700
7500
9.33%
9904
10316
96.0%
10.0
930
14000
6.64%
11486
12067
95.2%
Table 5-2: Comparison of detectable CRP in serum amounts and percentages detected
for both projects
Godfrin Project
Pytka Project
Conc.
C (Blood) C (Buffer) % Det.
C (Blood) C (Buffer) % Det.
0.5
490
2200
22.3%
2337
2373
98.5%
1.0
450
2250
20.0%
4100
4300
95.3%
5.0
590
7500
7.87%
11600
12000
96.7%
Table 5-3: Comparison of detectable CRP in blood amounts and percentages detected
for both projects
The Godfrin plots can only detect normal CRP in the intensity range of 450 –
600. This system on the other hand, can detect CRP in the intensity range of 1600 12000. This means that because of the high range, there is a small window of error
between two distinct concentrations (for example, a 1.0 µg/mL difference in
concentration). Even though there is still error in this new system, it only varies about
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0.5 µg/mL compared to 1.0 µg/mL. Even though the CRP could be detected
accurately with a concentration less than 5.5 µg/mL concentration in blood, this is still
within the range of normal CRP levels in blood. This difference is due to the amount
of HAPs still in the serum during CRP detection. This was shown in the amount of
CRP recovered in each of the experiments. The Godfrin experiments only recovered
about 20% of the available CRP, and then decreased for each additional concentration.
Whereas this project saw the percentage of captured CRP did not drop below 90%.
This was due to the addition of multiple incubation areas in the chip. Because of this,
a better method of accurate detection of CRP in whole blood was possible.
One final thing to point out is the comparisons of the limit of detection. The
method used in the Godfrin experiments was a variation of the limit of blank. In this
case, the LoD was found by taking the average signal at the blank and adding it to
three times the standard deviation of the blank. Using this method, this LoDs in this
thesis were 0.93 µg/mL and 0.50 µg/mL for serum and blood respectfully. In the
Godfrin thesis, the same LoDs were at were 0.14 µg/mL and 4.54[23]. The reasoning
for the smaller LoD in serum is that, again, diluted serum was used for the
experiments, and that the zero concentration intensities were a quarter of the
experiments in this thesis. As for the blood LoD, because of the amount of HAPs still
in the system, it was not accurate in low concentration areas. This is the reason for the
high LoD for blood compared to the method in this thesis. Because of this, it was
shown that the addition of multiple HAP incubation areas not only could accurately
capture and detect low amounts of CRP in blood, but also detect amounts less than 0.7
µg/mL in blood.
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5.2.

Further Work

Even though the previous experiments performed well and had shown that
CRP can be detected with whole blood, there are a few more experiments that can be
performed in order to make the system better. The first experiment could be the
addition of a fibrinogen incubation area. As discussed previously, the blood plasma
tests were assumed that the fluid behaved similarly to serum, when in actuality, the
main difference is that serum does not include fibrinogen. Fibrinogen is a relatively
large protein that is used in clotting and solidification of blood. The reason that this is
an issue is that fibrinogen can act like albumin in that it can cause interference in the
detection area. Even though there is not a large concentration of it, in comparison to
albumin, it is a larger protein and it can cause more havoc. If there was any
interference due to fibrinogen in the chip, the intensity would be a lot lower than what
it should be. In order to get a better estimate as to the level of CRP in a sample of
blood, it might be essential to include a fibrinogen incubation area either before or
after the albumin incubation area.
The next experiment would be the addition of various samples of blood. Each
individual has a different level of CRP in their blood and the previously experiments
only used one type of blood. With multiple samples, it would be efficient to see where
these samples lie on the curve in order to show how well various CRP levels can be
detected in blood. One other issue is the lack of an official CRP measurement. The
previous experiments were an estimate as to how much CRP is in the blood, but the
accuracy of this system cannot be verified until an official measurement can be
obtained for comparison.
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Even with those experiments being performed, there is a possibility for future
work. The first possibility is the integration for automation. The previous experiments
were done manually with either a syringe or a syringe pump. There have been attempts
to integrate this into an automated system. A previous Master's and PhD project
included developing machines that perform this automation[22,24]. This new method
would involve rewriting a code that would enable the fluid to move automatically and
account for the multiple incubation areas.
The second possibility would integrate a better detection system for CRP
detection. The main system used for detection is by way of fiber-optics. While it is a
good method for detection, there are various short comings associated with using
fiber-optics. These include polishing the optic wires for better detection, the fact that
they can easily break and be expensive to repair and replace, and are bulky for a
portable system. One good detection system would be the use of a charge-coupled
device (CCD). Previously, CCDs were tested as a measurement for detection when it
comes to immunoassays[60]. A CCD acts much like a camera where a snapshot of the
detection area is taken and that photo is analyzed using imaging software
processing[80]. This method is less bulky and cheaper to maintain than fiber-optic
cables. The help of a CCD can be beneficial for more accurate and more sensitive
detection.
A third possibly would be a new method of chip design and creation.
Typically, chips take on average 1 – 3 days to create, with an additional 1 – 2 weeks to
create the molds. Also, with the proximity of volatile chemicals and the fact that the
molds could be damaged, a better chip could be constructed. One method is the use of
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paper as a substitute for PDMS. Channels can be made in the paper which would
allow fluid to travel through it[81]. Also, special areas can be set up for incubation and
detection[81]. It would be cheaper to produce the chips on paper and in a shorter time.
Finally, no fiber optics will be used in detection. The main source of detection will
come in the form of image processing. The only downside is that fluids cannot be
stored on a paper chip like a PDMS chip can. But small vials can be used for each
reagent. With that aside, a paper-based chip would be useful for the next step in better
tuning this current chip.
One final future project would be the detection of other antigens in the blood.
There are many different proteins found in human blood and each protein has a
specific function associated with it. In addition, various antibodies have been created
for capturing and detecting these antigens. They can be integrated in the chip in order
to determine how much of a specific antigen does this person possess. An example of
an antibody that has been created to detect and attach to a specific protein will be
discussed in the next section. With these advancements, it would be possible not only
to better detect CRP in blood, but also other proteins and viruses that could be
detrimental to human life. In conclusion, a better method of detection C – reactive
protein from whole blood using lab-on-a-chip methods was found by using filter
membranes for blood filtration and the introduction of protein A and multiple
incubation areas for the removal of high abundance plasma proteins. This method not
only produced a high array of signals, but was also accurate in detection.
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SECTION 2

CREATION OF A RECOMBINANT ANTIBODY AGAINST TAU PROTEIN

CHAPTER 6

INTRODUCTION

6.1.

Alzheimer's Disease

One of the most common ailments that can affect a large percentage of the
older generation is Alzheimer's disease. Alzheimer's is a neuron-degenerative disorder
characterized by memory and cognitive loss, dementia and a rapid reduction in brain
matter[82]. According to the Alzheimer's Association, there are currently more than 5
million Americans with a form of Alzheimer's and a new case developing every 67
seconds. It is the 6th leading cause of death in the United States with approximately
500,000 individuals dying each year[83]. Currently, there is no cure for Alzheimer's
and no method of either prevention or of slowing the disease. If trends like this
continue, by 2050, the amount of patients with Alzheimer's would triple from 5
million to just over 13.8 million[83].
The basic methods of detection of Alzheimer's include determination of
memory loss, difficulty completing ordinary tasks, problems with speaking and
writing, misplacement of goods and mood changes, to name a few[84]. But this only
helps in determining whether or not someone has Alzheimer's, not a method of early
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detection. This has to be performed by various tests in the blood and in the spinal
cavity[85]. While there is no set method to detect Alzheimer's early on, there are
relationships in body functions that can relate if whether or not a patient could be
diagnosed with Alzheimer's early on.
6.2.

Tau Protein

One such relationship is the interaction of Tau protein. Tau is a rod-like protein
found in the brain and the spinal column that helps to stabilize other proteins known as
microtubules[82] and by relaying messages throughout the body. Tau performs these
tasks by undergoing a process known as phosphorylation, which allows the protein to
interact with phosphates and break up and send messages to other parts of the
brain[86,87]. However, if too much of this occurs, the brain area can start to degenerate
and exhibit symptoms of Alzheimer's based on CAT scans of different patients[88]. It
has recently been discovered that tau may be the culprit of the main effects of
Alzheimer's disease[85]. Because of this, there have been new developments as to how
tau can be detected.
6.3.

Antibodies against Tau

One method of the detection of tau protein would be the use of antibodies that
attach to tau[89,90]. This was explained in the first section where CRP was detected
using antibodies. These antibodies can be used for immunoassays in order to
determine the risk of Alzheimer's based on the concentration of phosphorylated tau
(pTau)[89]. However, tau is a long protein with little known antibodies, especially in
places where phosphorylation can occur[91]. Because of this, it would be ideal to
create antibodies specifically to bind to those areas of tau. The most common method
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to create antibodies is to inject antigens from multicellular organisms and extracting
them[92]. However, since using multicellular organisms is a huge liability, there has to
be another method in which antibodies against tau can be extracted. Fortunately, there
is a method called phage display which uses a known antibody library packed into
phage, which is a virus, which can attach to tau antigens. In this method, the phage
injects the antibody library into bacteria and from there, antibody fragments can be
produced in the bacteria[93]. Even though these fragments are more basic than IgG,
they still contain the necessary parts that can bind to tau. The upcoming sections will
explain why an antibody for Tau has to be found and how using bacteria and phage
display, these antibody fragments can be created.
6.4.

Phage Display

Antibody phage display allows the generation of e.g. human antibodies in
vitro. In antibody phage display, an antibody fragment, in this work the single chain
fragment variable (scFv), is displayed on the phage surface and the corresponding
genetic information for this scFv is encoded on a phagemid which is packaged in the
phage particles. Therefore, the genotype and genotype are coupled. In the phagemid,
the scFv gene fragment is fused to the phage gene III (gIII), encoding phage protein III
(pIII). This allows the expression of a fusion protein: scFv::pIII. During phage
assembly in E. coli, the fusion protein will be incorporated in the phage particle and
the phagemid will be packaged in the phage resulting in an antibody phage[92-95].
Antibody fragments can be selected by a process called panning. An antibody phage
library (HAL7/8 in this work) can be incubated with the desired target molecules (Tau
peptides in this work). The non-binding antibody phage will be washed away and the
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bound antibody phage particles will be eluted. E. coli will be infected with the eluted
phage particles and with the help of helper phage; new antibody phage particles will
be produced. These amplified phage particles will be used in a next panning on the
desired target to further increase the fraction of target specific antibodies. These
panning rounds will be performed 3-4 times[94,95].
Single bacteria colonies, infected with the antibody phage particles of the last
panning round, will be cultivated in micro titer plates and soluble monoclonal
antibodies will be produced. These monoclonal antibodies fragments will be tested by
ELISA to identify monoclonal binders. Subsequently, the scFv encoding gene
fragments can be analyzed by DNA sequencing to identify unique binders and for
further analysis. Finally, these antibody fragments can be recloned in any antibody
format (e.g. IgG) for further production and biochemical analysis[94,95].
6.5.

ELISA

In order to test if these antibodies are beneficial, assays have to be completed
in order to make sure that these antibodies bind to the specific proteins. The tests
performed are known as Enzyme-linked Immunoassays (ELISA). As explained in
chapter 2, these tests use a series of antibodies to capture proteins and antigens and a
second set of antibodies to detect said proteins and antigens. A substrate is then used
to detect these antibodies[12]. Multiple types of ELISAs exist, which, as explained in
chapter 2, include direct (where a protein is unknown and antibodies can detect it),
indirect (where the antibodies are unknown, and the protein is known), sandwich
(where an antibody specific to a certain antigen is first placed onto the bottom of a
well), and competition (where competing proteins/antibodies are used to “compete”
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with the main ELISA). These types can be integrated into two main ELISA
experiments: screening ELISAs, where different clones can be found, and titration
ELISAs, where the overall strength of detection is found[92]. These two experiments
can be integrated in order to create an antibody that can easily detect tau protein.
6.6.

Objective

The focus of this investigation is the creation of two recombinant antibody
fragments that attach to two specific types of tau as a biomarker for Alzheimer's:
phosphorylated tau (tau with phosphate groups attached (pTau)) and nonphosphorylated tau (tau without phosphate groups attached (Tau)). These two
antibody fragments are beneficial in that they would be able to attach not only to
healthy tau, but also tau that may be a factor in Alzheimer's disease.
The first task of the project is the creation of the fragments. This will be
performed by the use of phage display. This method will reveal the proper fragments
that will attach to the protein. Even though only a small antibody fragment would be
obtained, it is a cost effective and safer procedure than obtaining IgG
(immunoglobulin G) from a multicellular organism. Plus, these same fragments have
all the proper sequencing that is normally found in IgG in which it attaches to the
antigen. This sequencing is what allows the antibody to attach to the protein. Using
phage display, one antibody fragment can be obtained from a library of different
antibody possibilities by injecting DNA into bacteria and creating multiple colonies.
After three or four panning rounds, one antibody fragment for both Tau and pTau will
be obtained.
The second task of the project is the detection and strength of the antibody
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fragments. This is where the ELISAs will come into play. Using ELISA, these
extracted antibody fragments will be detected and checked if they are able to bind to
the antigens. This process is crucial because it has to be made certain that different
antibodies can be created. Also, there will be many clones that can attach to the
protein. Therefore, tests will have to be performed to check if these fragments are
identical and are able to bind well. This will be performed again by ELISA in order to
see the limits of concentration that these antibodies can be detected. Also, since there
are many clones, these fragments will have to be sequenced. This means that the DNA
structure has to be checked to see if either multiple clones have the same structure, or
that multiple different clones are able to attach to the same protein. This is important
because there can be an instance where two antibodies, with different sequences can
still attach to the same protein.
The end result for this investigation will be the creation of two distinct
antibody fragments that will be able to attach to a section of tau: one that attaches to
pTau and one that attaches to Tau. These two antibody fragments will be useful to
diagnose an early onset of Alzheimer's. Since tau is a long protein (350-450 amino
acids)[91], and since there are antibodies that can already attach to parts of tau, this
project will focus on one section of tau that is prone to phosphorylation and does not
have an antibody associated with it. With this method, it can be possible to in the
future, use this antibody as a diagnostic tool and to map out the entire protein in a
cost-effective manner, in order to see which antibodies are able to attach to it.
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CHAPTER 7

REVIEW OF LITERATURE

7.1.

Alzheimer's Disease

One of the most debilitating diseases today is Alzheimer's disease. Alzheimer's
disease is classified as a dementia usually associated with problems with memory and
behavior[82]. Dementia is described as a neurological ailment that is associated with
memory lost. While older patients do experience some sort of memory loss, it can
only be described as dementia if this memory loss affects normal everyday activities.
This not only includes loss of memory, but also problems in communication, the
ability to stay focused and a lower sense of judgment and reasoning[84]. Alzheimer's is
the most common form of dementia, with roughly 5 million affected people and a new
case every 67 seconds. Each year, more than 500,000 Alzheimer's patients die and at
current trends, the number of Alzheimer's patients will triple to approximately 13
million by 2050[83]. With these numbers, it is important to see how large of a factor
Alzheimer's will be in the upcoming decades.
There are various known symptoms for Alzheimer's that affect patients.
According to the Alzheimer's Association, there are 10 warning signs as to check
whether or not a person has Alzheimer's. These 10 signs are listed on the next page[84].
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1: Memory loss that disrupts daily life
2: Challenges in planning or solving
problems
3: Difficulty completing familiar tasks at
home, work or leisure
4: Confusion with time or place

6: New problems with words in speaking
or writing
7: Misplacing things and losing the
ability to retrace steps
8: Decreased or poor judgement
9: Withdrawal from work or social
activities
10: Changes in mood or personality

5: Trouble understanding visual images
and spatial relationships
Table 7-1: The 10 signs of Alzheimer’s disease[84]
One known issue that is important is that currently, there is no known cure for
Alzheimer's. Most patients that have been diagnosed with Alzheimer's will die due to
complications with Alzheimer's. Not only that, but there is no known method to either
prevent or to slow down the process[96]. This means that at this time, once a patient is
diagnosed with Alzheimer's there is no efficient method to help slow down the time
length from diagnosis to death. Due to this issue and the fact that more people will
develop Alzheimer's in the upcoming years, it is important that there is a method to
detect and try to treat Alzheimer's early on before these 10 factors quickly come into
play.
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7.2.

Known Alzheimer's Factors

Figure 7-1: Comparison between a normal and Alzheimer’s affected brain [88]
The figure above shows a sketch of a human brain. The left side shows a
normal fully functioning brain, while the right side shows a brain based on the effects
of Alzheimer’s. The most noticeable trait is the difference in size and in structure.
The Alzheimer’s brain is noticeably smaller in size and shows more rapid decay. This
was demonstrated back in 1906, when Dr. Alois Alzheimer noticed that one of his
patients was suffering from dementia and had issues with rapid memory loss,
unpredictable behavior and the need to be depended on others for normal everyday
activities. When this patient died, he examined this person’s brain and found that the
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overall size had reduced and, especially in the cerebral cortex and hippocampus,
where learning and memory takes place and large gaps or ventricles[88]. This can be
seen in the cat scans below in figure 7-2.

Figure 7-2: CAT scans of a healthy and Alzheimer’s affected brain[88]
Currently, it is unknown as to what causes this decay in the brain, but there are several
factors that associate with this. Some of these factors include beta amyloid, a protein
found in plaque areas around the brain[97,98], and tau protein, known tubules, in which
fragments can be found the blood and spinal fluids of patients[99,100]. Even though
there is no known concrete evidence that these two proteins cause Alzheimer's, they
are still regarded as a links into how the disease is formed and what is happening in
the brain area. The upcoming sections will explain the proposed roles of both beta
amyloid and tau in Alzheimer's.
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7.3.

Beta Amyloid

Beta Amyloid (aβ) is a protein that commonly shows in patients that have
Alzheimer's. This protein is a relatively short protein (consisting of about 40 amino
acids) and is often the result of proteolysis, or protein breakdown, of the large
Amyloid precursor protein (APP)[101,102]. There is little known about the function of
APP, but there has been research to suggest that to bind proteins and/or cells together,
and that it helps to direct the migration of neurons during early development[103].
Other theories suggest that APP is used in the formation and repair of synapses, which
join nerve cells and transmit neurons[104,105]. Whatever the function of APP has in the
body, it breaks down to form aβ. However, in patients that exhibit all the symptoms of
Alzheimer’s, one noticeable trait is that plaques of aβ are found in the brain regions.
This is from the result of the breakdown of APP and that certain forms of aβ proteins
can coagulate into obscene proportions[102,106]. Below is a diagram that shows this
result.

Figure 7-3: Sketches of neurons in a healthy brain vs. neurons in an Alzheimer’s
brain. Note the abundance of aβ plaques in the brain affected by Alzheimer’s[107]
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The breakdown of APP to aβ performed formed by cleaving a portion of the
APP into smaller structures around 40 amino acids in length[102]. There are two
common forms of aβ that APP can break down into: aβ40, the most common form and
aβ42, the form most prevalent in Alzheimer's. The 40 and 42 recognition only
corresponds to the length, or number of amino acids. Also, aβ is made up of a chain of
hydrphobic and hydrophilic areas in both the middle and ends of the protein. Aβ
attaches readily to each other in its hydrophobic areas but since aβ40 is a smaller
molecule, there is a maximum amount copies it can attach. Aβ42 has two more amino
acids on it, which are hydrophobic. While there can be mutations, where some
hydrophilicity can occur in this area, for regular aβ42, these are all hydrophobic.
Because of this hydrophobicity, more aβ42 can aggregate and form larger clusters,
which can send the brain into a “repair mode”. This can explain the aβ plaques found
on Alzheimer's patients as well as lessening of the brain matter. These reasons show
how important aβ is to the study of Alzheimer's[106].

Figure 7-4: Differences between aβ40 and aβ42 aggregation. Notice that aβ40,
bottom, cannot aggregate more than four times its size, while aβ42, top, can aggregate
to greater proportions[108]
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7.4.

Tau Protein

However, there is another protein that is now factoring into the possibility of a
probable cause of Alzheimer's: Tau Protein. According to Stoothoff, “tau was first
discovered in 1975… as a protein that co-purified with microtubules through cycles of
assembly and disassembly and was called tau for its ability to induce tubule formation.
[109]

” The role of tau protein will be explained later on in section 7.5. Right now, here

is general description of the structure of tau. Tau is a long rod-like protein that is
located in the brain and nervous system, mostly found in the neurons[91,100]. There are
6 main isoforms of Tau based on the number of binding domains and inserts. The
binding domains, known as repeats, are located in the C- (carboxyl) terminal of the
protein and are positively charged, which allows it to bind to any microtubule, which
are negatively charged. The number of domains can vary between 3 (3R) or 4 (4R),
where the second domain is missing from the 3R. In terms of location on the protein,
this report will explain in terms of length based on the number of amino acids. These
domains are located at a length at amino acid 166 in the case of the shortest isoform
and at amino acid 244, in the case of the longest isoform. The more domains the
protein has, the better it is at stabilizing microtubules. Also, there are inserts located at
the N- (amino) terminal, which help send messages to the C-Terminal. The number of
inserts can range from zero to two (0N, 1N and 2N). These inserts are located at amino
acid 45[91,100]. A diagram of an isoform of tau, the longest, and a table explaining all 6
isoforms of tau can be found on the next page.
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Figure 7-5: Tau Protein showing the locations of the domains (pink) and inserts
(red)[91]
Tau Isoform

# of Domains

Tau 0N/3R
Tau 0N/4R
Tau 1N/3R
Tau 1N/4R
Tau 2N/3R
Tau 2N/4R

3
4
3
4
3
4

# of Inserts

Protein Length (#
of Amino Acids)
0
352
0
383
1
381
1
412
2
410
2
441
Table 7-2: Different tau isoforms[91]

Based on this table, the lengths for each tau isoform vary between 352 amino
acids for the shortest isoform to 441 amino acids for the longest isoform. Also, it can
be seen that each binding domain consists of 31 amino acids and each insert consists
of 39 amino acids[91]. Furthermore, it is worth noting that all forms of tau contain the
same 352 amino acids that are on the shortest isoform. The only variation is the
amount of domains and inserts[91]. The diagram on the next page shows all six
isoforms of tau and the locations of these variations. The inserts are located at the 2nd
and 3rd exons, or sections. The orange represents the first insert and the green
represents the second insert. The black bars on the right represent the domains. The
pink is where this change in the number of domains occurs. In this case, all changes
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occur at the second domain (from the left).

Figure 7-6: Differences in the tau isoforms[91]
Tau protein is an interactive protein, in which it regulates and stabilizes
microtubules. It does this by interacting with tubulin, which forms microtubules in the
brain[91,110]. To clarify, tubulin is a group of globular proteins, which are globe-like in
appearance, that come together to form microtubules. There are 5 known types found
in the human body: alpha-, beta-, gamma-, delta- and epsilon tubulins, with the most
common being the alpha and beta types[111]. The process in which this happens is
known as phosphorylation and it will be explained below.
7.5.

Phosphorylation

Phosphorylation occurs when phosphate groups (PO4) attach a protein, which
can alter the specific function or role of the protein. In this method, certain biological
processes can be altered without needing to create or destroy more proteins[112].
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Enzymes or molecules known as kinases are responsible for phosphorylation of
proteins, which can change the entire structure and function of the protein. Kinases
only add phosphate groups to three amino acids: serine (S) (HO2C2H(NH2)CH2OH),
threonine (T) (HO2C2H(NH2)CH(OH)CH3) and tyrosine (Y)
(HO2C2H(NH2)CH2(C6H4)OH)[113].

Figure 7-7: Phosphorylation occurring at serine (left), threonine (center) and tyrosine
(right)[113]
Phosphorylation is what is known as a regulatory process, in which multiple
vital actions can occur in the body[87,114,115]. This also include the removal of
phosphate groups, known as dephosphorylation[115]. Some examples of where protein
phosphorylation is essential in the human body include the regulation of the activities
of enzymes and the interactions between different proteins[115]. In the larger scale,
these regulations and interactions include various metabolic processes, gene
regulation, cell cycle control, transport in the cell and cell adhesion[115]. In short,
protein phosphorylation is an important regulatory process in the human body.
In the case with tau protein, phosphorylation is performed in order to promote
the assembly of and regulate the stabilization of microtubules[91,109]. Microtubules are
hollow cylinders that have a diameter of about 24 nm made up of tubulin[110,116,117].
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They are involved in various processes, which include cell division, and are utilized in
the structure and transport throughout the cell[118]. Because microtubules are essential
to the human body, in order to help stabilize these tubes, tau is brought in and how it is
stabilized depends on the phosphorylation of tau[91]. The amount of phosphate groups
on Tau depend on how stable the microtubule is. The more phosphate groups on the
protein, the less stable the tubule is[91,109]. This process is a relatively common process
in the body and it actually allows the formation of new protein tubes. However, one of
the main factors that Tau is a link to Alzheimer's is known hyper-phosphorylation,
which will be explained in the upcoming section. Below is the process in which tau
helps assemble and stabilize microtubules.

Figure 7-8: How unphosphorylated tau (left) and phosphorylated tau (right) help
stabilize molecules[118]
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7.6.

Hyperphosphorylation and the Focus on Tau Protein for
Alzheimer’s

One of the main reasons why tau protein is a link to Alzheimer’s is the process
of hyperphosphorylation. This is when phosphate groups attach to the Tau at a faster
pace and break down microtubules at a quicker pace. This in turn causes aggregation
of filaments which in turn forms neurofibrillary tangles, one of the key components to
the disease[91,118-120]. This breakdown can be so rapid that, because of the inability to
stabilize microtubules, this can result in the decrease of brain matter, as attributed to
figure 7-1. This theory of the hyperphosphorylation of tau has only been researched in
the last twenty years and it has only been since recently that more evidence suggests
this[121]. This can be better shown in figure 7-9. Figure 7-9 displays tau with the
known phosphorylation sites. There are about 100 known sites, with 1/3 to 1/2 of
them being sites for normal brain activity (green). The remaining sites show where
phosphorylation and Alzheimer’s have a connection with tau (red and blue)[91].

Figure 7-9: Phosphorylation sites on tau for normal brain activity (green),
Alzheimer’s activity (red) and both (blue)[91]
However, 20 years ago, this was not the case. Previously, the focus of source
of Alzheimer's has been the fact that aβ plaques could be found on patients. This
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created the assumption that aβ was the main suspect in causing Alzheimer's[121,122].
This shift in the focus from aβ to tau comes in large part due to how Alzheimer's is
first detected and study as the disease progresses. In most cases, it is easier to see that
aβ can be found in increasing numbers as the person develops Alzheimer's. However,
that is not the case with Tau, in that Tau is the driving force for the cognitive decline,
which will result in memory loss[121,122].
According to Dr. Melissa Murray of the Mayo Clinic in Jacksonville, FL, “Tau
can be compared to a train track that brain cells use to transport food, messages and
other vital cargo throughout neurons...In Alzheimer's, changes in the tau protein can
cause the tracks to become unstable in neurons of the hippocampus, the center of
memory. The abnormal tau builds up in neurons, which eventually leads to the death
of these neurons[122]”. This means that because of the affected tau not being the
stabilizers that they are, this is the cause of the loss of cognition and memory.
This was performed by studying at least 3,500 brains, in which 1 out of 3 were
Alzheimer's confirmed. Each brain varied as to what stage of dementia it was in when
the patient died, so that it could give a time-line of brain degeneration. Each brain was
not only looked at for tau severity, but also for amyloid severity. The results showed
that it was tau, not amyloid, that predicted the onset of cognitive decline, duration of
the disease and the deterioration of mental health. Also, when the research looked at
amyloid, it was discovered that the brain-specific amyloid observed a signal from the
brain scans, and not the amyloid in vessels. Furthermore, this did not correspond to
tau pathology, as similar brains with similar tau effects, which led to Alzheimer's, did
not lead to similar amyloid effects. It was found that some brains with a large amount
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of tau influence had only a small amount of amyloid influence, and vice versa. This
can show that amyloid can be found in individuals even if they have not experienced
cognitive decline. Based on this reasoning, it should be pointed out that tau is now a
major influence in Alzheimer's[122].
However, one cannot overlook amyloid as a cause as well. There has been
research to suggest that beta amyloid can be a factor in hyperphosphorylation of
tau[121,123]. Research has suggested that amyloid can cause an excessive flow of ions
into neurons. This in turn can activate kinases that would undergo phosphorylation on
tau[121]. One such kinase is known as AMPK (5’ adenosine monophosphate-activated
protein kinase). AMPK normally responds to stresses that deplete essential supplies,
including low glucose and heat shock by direct phosphorylation of a number of
enzymes[124]. Because of this, it can be said that beta amyloid can play a large role in
the development of Alzheimer’s. But in terms of finding a source and early detection,
it is more reasonable to take a look into the hyperphosphorylation of tau protein.
7.7.

Antibodies for Detection against Tau

Now that it is clear that tau is the main factor in cognitive degeneration, it is
important to find a method of early detection of rogue tau. As explained in the
previous part, there exists assays that can detect proteins by use of specific
antibodies[19,20]. Because of this, antibodies can be created that will help in capturing
tau. There have previous antibodies that have been created that have been used to
detect certain areas of tau protein[90,91]. This is shown in figure 7-9 with yellow
arrows. These arrows represent the different antibodies that already have been created
in order to attach to tau protein[91]. These antibodies can be helpful in the identification
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of tau protein in terms of both its phosphorylated and unphosphorylated forms.
However, there have not been advances in terms of the number of antibodies created.
Tau is a long protein and there are certain sections of it that are not associated with an
antibody[91]. Because of this, there has to be a method of creating antibodies for all
parts of tau.
There are numerous methods to create and extract different forms of antibodies
from organisms. Some of the most popular organisms to use are mice, goats and
monkeys[92]. However, this project is more concerned about seeing how antibodies
can attach to tau protein. Because of this, and the severe liability risks of using
animals as test subjects, it is not recommended that live animals would be used.
Instead, another method has to be implemented. This method uses bacteria/E. coli in
order to create antibodies. This was because of the availability of bacteria, the ease of
working with it and the relatively cheap cost of using it. However, because such a
simple one-celled organism is used in the creation of antibodies, these antibodies will
be known as antibody fragments and would be the simplest form in which it still can
detect tau[92]. Even though they cannot be properly be used in normal immunoassays,
they are nevertheless important because they create the foundation for an antibody
library and are the basic entities that attach to the desired antigen[92]. This will be
further explained in section 7-9.
7.8.

Reasoning for an Antibody against Tau Protein.

Since Tau is one of the proteins that were linked to Alzheimer's disease, it
would be good to create antibodies in order for it to be used in immunoassays as a
biomarker. This is done by connecting the antibodies to the surface of the protein via
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the amino acids on both the protein and the antibody[92]. The diagram on the next page
shows the model of the longest Tau isoform (Tau 4R 2I) at 440 amino acids long.

Figure 7-10: Diagram of tau protein where the specific antibodies will be created[91]
The two inserts are at sections 2 and 3 and the domains are located at sections
10, 11 and 12, were the second domain is the difference between 3R and 4R. The
numbers at each amino acid spot indicates where phosphorylation can occur. Green is
during normal brain activity, while red is observed with patients with Alzheimer's.
Blue indicates both and black is unknown. Based on this diagram, there have been 14
known antibodies that have been discovered, based on the yellow lines. The majority
of these occur at the front and the back of the protein. For example, antibody T46
corresponds with the amino acids from the 420 to the 441 area (S422, T427, S443 &
S436)[91]. While there have been some antibodies that have been discovered, the
majority of the sites do not have an antibody associated with it. For this reason, this
project will focus on finding antibodies for the first binding domain (1R). This
domain is common in all tau isomers and is located on 256-262 range. The peptide, or
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protein section, that this project will focus on will be the area from 251 to 270, where
known phosphoylation occurs at S258 and S262.
7.9.

Types of Antibodies

For the basis of this project, the antibodies that are the main end product are
known as single-chain variable fragments (scFvs). This form of antibody fragment is
the smallest form of immunoglobulin that still retains its function in antigenbinding[125]. These small antibody fragments consist of a heavy chain (VH) and a light
chain (VL), which are connected together by a peptide linker [92,125]. Compared to
immunoglobulin (Ig) antibodies, they are about 1/6 in size (scFv ~ 25 kDa, IgG ~ 150
kDa)[92,125,126]. However, they are still able to attach to antigens as well. If one takes
a look at the structure of an IgG antibody, one would notice the tips of the branches
are where the antibody would bind to the antigen. These branches are known as the
variable fragment region (Fv). This is similar to the scFv in that the same two chains
are used in order to attach the antibody to the antigen. The only difference between
the two in structure is that the scFv includes a linker, which allows the two chains to
act as a single chain in name, whereas the Fvs are two separate chains that are located
on the tips of the IgG. Nevertheless, both the scFv and the Fv regions of the IgG
contain the same genetic sequence that allows them to bind to the same antigen. This
is shown below in figure 7-11.
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Figure 7-11: Diagran showing the difference between the IgG (left), Fv regions (top
right) and scFv (bottom right) antibodies/antibody fragments[126]
Other types of antibody fragments include the antigen-binding fragments (Fabs)[93,127],
dimetric single chain variable fragments (di-scFvs)[128] and single domain antibodies
(sdAbs or VHH)[127-129]. Even though these examples are important in antibody
construction, they do not hold relevance in this report because they were not fully used
this study. Instead, scFvs were produced in order to find antibody fragments that were
specifically designed to attach to tau protein. The upcoming sections will explain the
use of recombinant antibodies and the method used to create them: phage display.
7.10. Recombinant Antibodies and Phage Display
Because of the previously described methods used in order to create antibodies,
a new method of antibody creation has to be performed. In the last 20+ years, a new
method of creating recombinant antibodies has become popular. Some of the benefits
of creating recombinant antibodies are that these experiments are performed with the
use of animals, which means a reduced risk of contamination due to the disease that
the antibodies are being built for, they can be modified to be created for a specific
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organism in mind and they can be designed to be modified for uses that would
normally not occur naturally, for example, targeting cancer cells[92]. One of the most
common methods is the use of phage display. In phage display, phages, a virus, help
to select and replicate antibodies for a specific protein[92,94,95,130]. An example of a
phage and its structure is shown below.

Figure 7-12: Diagram of phage with scFv fragment[131]
A single scFv fragment is displayed on the surface of the phage and the
corresponding genetic information is encoded on a phagemid and packed inside of the
phage particle. In the phagemid, the scFv fragment is fused to the phage gene III
(gIII) which encodes phage protein III (pIII). This then allows the expression of a
fusion protein: scFv:pIII. The fusion protein will be incorporated in the phage particle
and the phagemid will be packaged in the phage during phage assembly. This results
in an antibody phage[94,95,130-132]. The method of phage display is explained below on
the next page.
The first step of phage display is the in vitro selection of antibody phage
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particles. This is what is known as panning[94,95]. In this step, antigens in which are of
importance, in the case of this thesis, tau peptides are attached to a well of a micro titer
plate. An antibody phage library, in this case, HAL7/8, is incubated with these desired
peptides. The antibody phage of importance binds to the peptide, while the unbound
phage is washed away. The bound phage then goes through a process, known as
elution, in which the phage is collected. This phage then infects an E. coli culture.
Here, the phage is amplified in the cell and new antibody phage is produced with the
help of helper phage. This new antibody phage will then be used in a new
panning[94,95]. The reason for this is that each antigen is likely to be attached to the
micro titer plate using a biotinylated linker, which is attached to streptavidin, which is
in turn coated on the plate. This allows for better binding between the antigen and
phage than having the antigen bind to the well due to the fact that the antigen is more
intact. Because of this, there might be some phage that will actually bind with the
streptavidin and the linker. By performing multiple sets of panning rounds, an optimal
amount of phage and antibody that binds directly to the desired antigen will be found
and a high concentration of it will be produced[92,94,95,130-132]. Each run through of this
process is known as a panning round. A diagram highlighting a panning round is
found in figure 7-13 on the next page.
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Figure 7-13: Diagram describing an example panning round[131]
In most cases, 3-4 panning rounds would have to be performed in order to
obtain a satisfactory amount of antibody phage. During the final round (either the 3rd
or 4th), soluble monoclonal antibodies will be produced. These antibodies will be
tested via ELISA (enzyme-linked immunosorbent assay) in order to identify positive
monoclonal binders. Furthermore, the scFv encoding gene fragments can be analyzed
via DNA sequencing in order to determine unique binders and the antibody fragments
can be recloned into any antibody format (IgG) for further production and biochemical
analysis[92,94,95,130].
7.11. ELISA and DNA Sequencing
Once an appropriate number of clones have been created, the next step is to
make sure that there are active binders for each antigen. To test this out, an ELISA
(enzyme-linked immunosorbent assay) is performed. Back in chapter 2, the different
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types of ELISAs were pointed out. These were a direct ELISA (where the antibody is
attached to an unknown antigen on the bottom of a well), an indirect ELISA (where an
unknown antibody is attached to the antigen), a sandwich ELISA (where the antigen is
attached to a capture antibody before being detected) and a competition ELISA (where
the ELISA is in direct comparison to a competing ELISA)[59]. These ELISAs share a
basic construct: an antibody is used to detect an antigen and that antibody is detected
via a substrate[12,133]. Because of the amount of clones that will be made based on the
phage display, it would be a good idea to find scFv fragment that can attach to tau by
using an ELISA. This can be performed in order to narrow down the amount of clones
that have been made, in order to find an antibody fragment that will properly attach to
tau. This is what is known as a screening ELISA. In this screening ELISA, clones are
picked out and the scFvs are extracted from the E. coli culture. These fragments are
then placed in a micro titer plate with the antigen already in place. After the fragments
have incubated and attached to the protein, detection antibodies are applied and
incubated for some time. The substrate is then applied and clones are then taken into
account based on the signal given off. This is due to the color change in substrate.
The darker the color, in most cases, the higher the signal[12,59,133,134]. From there,
clones that have shown to emit a high signal can be removed. An example of a
screening ELISA is found on the next page.
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Figure 7-14: Diagram of the steps for a screening ELISA. Top represents a well with
a desired antigen signal, bottom represent no antibody signal[134]

Figure 7-15: Example of a completed screening ELISA. Note that the dark blue well
represents a strong signal[135]
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Sometimes even the screening ELISA can produce more clones than needed as
well. This means that there might be multiple clones with the same structure. If this is
the case, it would be necessary to perform a BStN digest. This digest is a type of
electrophoresis by using an agarose gel. In this digest, fragments are separated and
sorted by size through a gel by the use of an electric field[136-138]. Because each
fragment has a different make up and a different size, they can flow through the gel at
different speeds. The larger the particle, the slower it will move through the gel[136138]

. This will create bands in the gel when exposed to UV light. Based on these

bands, it can be determined what would be the makeup of these fragments. Similar
fragments should look the same under the light, while different fragments should have
bands[136-138]. From there, the number of possible clones can be further lowered. An
example of this digest is shown below.
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Figure 7-16: Example of a BStN1 digest[139]
Once a suitable number of clones have been found, the next step would be to
create titration curves for these fragments. This is in order to make sure that not only
these fragments are able to attach to their specific antigens, but also to find out the
strength of each antibody fragment. This is performed by using a titration ELISA[140].
In this ELISA, the concentration of antigen or antibody fragment is decreased along
the length of the micro titer plate. When substrate is then added to the wells, the color
should gradually become lighter as the concentration of antigen or antibody fragment
decreases[140,141]. An example of this can be found in figure 7-17. From this, the
overall strength of the antibody or antigen can be determined and how much of each
would be needed in order to produce a successful signal.
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Figure 7-17: Example of a titration ELISA[141]
Once both ELISAs are performed and there are clones that have been chosen
based on these two ELISAs, these fragments are then broken up through a process
known as DNA sequencing. This allows the DNA strand on the fragment which
attaches to the antigen to be read in order to figure out its binding structure. One of
the most common methods is known as the Sanger Method[142]. In this method, the
fragments are broken into plasmids. These plasmids are then denatured by using heat.
This turns the plasmids into single strand structures of DNA. Next, a primer, or a
chain of 3 nucleotides is added to the ends of each strand. The strands of DNA are
then separated into one of four tubes containing dideoxynucleotides, one for each of
the four bases: adenine, thymine, cytosine and guanine. Each tube also contains DNA
polymerase, which attaches the nucleotides to the DNA. In each tube, the nucleotides
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will attach to the strands until the specific nucleotide for that tube attaches to it. From
there, the four tubes will go through gel electrophoresis, in which each strand is
separated and the sequence can be read from top to bottom[142]. An example is shown
below in figure 7-18

Figure 7-18: Example of DNA Sequencing using the Sanger Method[142]
Since this process is more involved, for the purposes of this project, the DNA
sequencing will be performed offsite. The main goal for this however is to see how
the antibody fragments attach to the tau and if there are multiple fragment clones that
attach, either more than one clone with the same structure, or more than one clone
with different structures. From DNA sequencing, it will be determined how these
fragments can attach to the desired proteins. In the upcoming sections, the procedure
for these experiments will be presented.
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CHAPTER 8

METHODOLOGY

8.1 Phage Display
8.1.1. Panning using Agar Plates
To begin with the experiments, it is important to mention the tau that was used.
The tau peptides that were used are located in the area shown in orange in figure 8-1.

Figure 8-1: Tau protein with DNA sequence with peptide area highlighted in orange
and phosphorylation sites in red[98].
Above is the sequence for tau protein, length 441. The box highlighted in
orange shows where on the tau the peptides used for this project come from. This
peptide is located between amino acids 251 and 260. It is 20 amino acids in length
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and has phosphorylation areas at site 258 (S) and 262 (S). These are of importance
because they are phosphorylation areas in which Alzheimer’s is prevalent. In this
project, two types of peptides will be used: a peptide without phosphate groups at
those sites (Tau) and a peptide with phosphate groups at both sites (pTau). Also, two
forms of each peptide will be used in these experiments. The reason for this being that
micro titer plates coated with streptavidin will be used to carry out the phage display
and the ELISA for the peptides to attach to the well rather than capture the fragments.
For this reason, each peptide will be attached to one of two biotinylated linkers. The
reason that two linkers will be used is that each linker has its own set of amino acids
connecting between the biotin and the peptide. Because of this, it is possible for the
phage/scFv to attach to the linker. Because of this, each peptide will either have what
will be known as linker 1 (L1) or linker 2 (L2). With multiple panning rounds, each
round will alternate between the two linkers so that no phage/scFv that attaches to the
linker will be detected. The following table lists the four different peptides that will be
used.
Peptide
Name
Linker
Sequence
Number
1
Tau L1
eBio-bAbAbAbAbAPDLKNVKSKIGSTENLKHQP
2
Tau L2
eBio-GGSGGSPDLKNVKSKIGSTENLKHQP
3
pTau L1 eBio-bAbAbAbAbA- PDLKNVKpSKIGpSTENLKHQP
4
pTau L2
eBio-GGSGGSPDLKNVKpSKIGpSTENLKHQP
Table 8-1: Peptides used in project with sequence (p – phosphate group) and linkers
There are four total experiments for this project, each with the same
procedures. The only difference between them is the types of peptides being used.
The first two experiments focus on obtaining an scFv fragment by alternation. This
will be performed with Tau only for experiment 1 and pTau only for experiment 2. In
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these experiments, peptides 1 & 2 (Tau L1 & Tau L2) and peptides 3 & 4 (pTau L1 &
pTau L2) will alternate for each panning round. In experiment 1, peptide 1 will be
used in rounds 1 & 3 while peptide 2 will be used in round 2. The same can be said
for peptides 3 & 4 in experiment 2 (peptide 3 for rounds 1 & 3, peptide 4 for round 2).
This method will not only make sure that only the selected phage at the end of the
experiments will only bind to the peptide, but also with the additional third round, be
in greater numbers. With this method, a scFv clone can be found that only attaches to
the peptide.
The other two experiments focus on competition. This will be performed with
the L1 peptides for experiment 3 and the L2 peptides for experiment 4. In these
experiments, pTau peptides are in competition with the Tau peptides with the same
linker. This means that before the phage comes in and attaches with pTau, some of the
phage that either attaches to Tau or the linker will be removed. This is done in order to
find phage that will attach to pTau at a simpler rate due to the fact that less phage is
located in the solution. This can be reversed in order to locate phage for Tau with
pTau in competition, but for these experiments, only phage against pTau will be
considered.
8.1.2. Panning using Agar Plates
The first part of this project is to perform the panning rounds in order to
retrieve the scFvs used for detection. There were two different methods used to
perform the panning rounds. The first and easier method is to use agar plates to
cultivate E. coli cultures to extract scFvs. To perform this experiment, a total of three
panning rounds were performed to maximize the amount of cultures created. In this
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experiment, this procedure was taken from the protocol “Panning Ab-libraries:
Panning mit biotinylierten Oligopeptiden (Panning with biotinylated oligopeptides)”
developed by Michael Hust of the Institute of Biotechnology, TU Braunschweig,
Braunschweig, Germany[143] (see appendix B.1 for a English translation). To begin the
first round of panning, 1 well of a NUNC Streptavidin plate (Item no: 436014, Lot no:
123305, Roskilde, Denmark) was coated with 1 µg (1µL) of tau peptide diluted in 150
µL of PBS (Phosphate Buffer Saline). This was used as the coating well, which was
used as the main site for the phage to antigen binding. A second well was coated with
350 µL 2% mPBS (PBS + milk powder). This was the pre-adsorption well, which was
used to remove phage that bound either to the streptavidin or to other antigens. This
plate with these wells was stored overnight at 4°C without shaking. Diagrams
showing the steps are found below in figure 8-2.

Figure 8-2: Diagrams showing the panning process with the Streptavidin on the well
(left), addition of 2% mPBS for blocking (center) and the addition of biotinylated tau
peptide (right)
In conjunction with this, a 50 mL 2×YT-T (Yeast Extract Tryptone Medium
with 20µg/mL tetracycline) overnight culture inoculated with E. coli XL1blueMRF'
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(LOT#00016047973 (Patrick Droste), Institute of Biotechnology, TU Braunschweig,
Braunschweig, Germany) was also prepared and incubated overnight at 37°C at 250
RPM (INFORD Thermotron High Temperature Shaking Incubator, Rose Scientific
LTD, Edmonton, AB, Canada). This was the first bacterial culture that was used to let
the phage attach itself to the E. coli. After incubation of the bacteria culture, 40 ml of
2xYT (Yeast Extract Tryptone Medium without tetracycline) was inoculated with
37°C overnight culture. From there, the optical density (OD) was measured. To
ensure that optimal growth occurred, the solution was inoculated until the OD reached
0.1. It was then incubated at 37°C and at 250 RPM and measured for OD until the OD
reaches 0.5. This process took about 1.5 hours.
While this process was going on, the incubation and phage sorting on the
streptavidin plate was being performed. These incubation steps were performed on a
shaker at room temperature. The first step was to wash the wells three times with 350
mL with 1X PBS with 0.05% Tween (PBST) using a microplate washer. The washer
that was used was a TECAN Columbus microplate washer (Männedorf, Switzerland).
Afterward, the pre-absorption wells were coated with 350 µL Panning block (2%
mPBS + 2% BSA), while the coating wells were coated with 350 µL 2% mPBS. It
was then incubated for one hour. The next step was to remove the panning block from
the pre-absorption wells and add 150 µL Panning block with 5X1011 clones of the
antibody phage library to it. This was performed with the HAL 7/8 library and the
total volume of the library added was between 4 and 6 µL. An additional 5 µL phage
was added to the well to eliminate further binding to the streptavidin. This was then
incubated for one hour. Afterwards, the panning block and phage were removed from
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the pre-absorption wells and placed in separate vials to be used in the next part. The
wells were then washed three times with 350 mL with 0.05% PBST. After this, the
phage was then added to the coating wells incubated for two hours. The wells were
then washed ten times with 350 mL with 0.05% PBST. This was to remove all signs
of possible excess phage and leave only phage that stuck to the antigen. After
washing, 200 µL Trypsin was added to re-suspend the phage in solution. This was
incubated at 37°C for 30 minutes (Memmert Incubator, Memmert, Schwabach,
Germany). The phage was then collected to be eluted and coated on agar plates.
Figure 8-3 highlights the addition of phage into the wells.

Figure 8-3: Diagrams of wells with phage entering and binding to the tau peptides
(left) and after removal of unbound phage (right)
The next part is to create and grow the bacteria cultures that will create the
scFvs. For this part, two sections will be performed. The first is to create the main
culture. For this step, 100 µL Phage was added to 20 mL 2YT Medium and incubated
at 37°C for 30 min. After incubation, this solution was centrifuged (Eppendorf
Cenrtrifuge 5810 R, Eppendorf, Hamburg, Germany) at 4000 RPM for 10 minutes.
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The supernatant was then decanted and the remaining pellet was re-suspended with
250 µL 2YT medium. This solution was spread on a 15 cm 2YT-AG agar plate and
incubated overnight at 37°C.
The second section was the elution of the phage. For this section, 10 vials
were set up it create the dilutions. In five of these vials, PBS was added: two with 900
µL, one with 990 µL, one with 60 µL and one with 10 µL. After this was performed,
10 µL of a positive control (pHAL14-HT186-D11) was added to a sixth vial. Once
this was completed, 10 µL Trypsin + Phage was added to the vial with 990 µL PBS.
This dilution was 1/100 of the original. From there, two more dilutions were made. A
second dilution was created when 100 µL of the first dilution was added to 900 µL
PBS, which created a 1/1000 dilution. A third dilution was also created when 100 µL
of the second dilution was added to 900 µL PBS, which resulted in a 1/104 dilution.
From there, 10 µL of each dilution was added to three more reaction caps, creating a
further drop in dilutions. To perform this, 10 µL was taken from the 1/104 dilution to
create a 1/106 dilution, 10 µL was taken from the 1/1000 dilution to create a 1/105
dilution and 10 µL was taken from the 1/100 dilution to create a 1/104 dilution. From
there, the incubated XL1 culture is then added to these vials. The following vial had
50 µL added to it: the 1/104 dilution, the 1/105 dilution, the 1/106 dilution, the positive
control and the vial with 10 µL PBS. An additional 60 µL was added to an empty vial.
After this, the following vials were incubated for 30 minutes at 37°C: the 1/104
dilution, the 1/105 dilution, the 1/106 dilution, the positive control, the 60 µL XL1
culture, the 60 µL PBS and the 50 + 10 µL XL1 + PBS. After incubation, the three
elutions were then spread on three separate 10 cm 2YT-AG agar plates, while the
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remaining four were added drop wise onto a fourth plate. These plates were then
incubated overnight at 37°C.
After incubation, each plate was checked for bacterial growth and all colonies
on the small plates were counted (see appendix B.3 for total counts). After this step,
the amplification of the phage began. In this stage, the scFvs are extracted from the
bacteria and are placed inside phage again for another panning round. To begin with,
the 15 cm plate was washed with 5 mL 2YT-AG (2YT Medium + 1:1000 ampicillin +
1:20 glucose) medium. From there, the suspension was mixed with a 40 mL solution
of 2YT-AG Medium until the OD of the solution was at 0.1. The remaining
suspension was stored at 4°C. This solution was then incubated at 37°C at 250 RPM
until the final OD was around 0.5. Depending on the solution, this could take between
2 and 5 hours. This is because during incubation, there is some bacterial growth, then
decay and then growth again. Once the solution reaches an OD of 0.5, 5 mL (~ 2.5 X
109 cells) was extracted and infected with a 1:20 ratio of M13K07 (5 X 1010 pfu)
helper phage. This was then incubated twice: once for 30 min at 37°C without
shaking and again for 30 min at 37°C at 250 RPM. Once incubation was complete,
the culture was then centrifuged at 4000 RPM for 10 minutes. After, the supernatant
was decanted, the pellet was re-suspended with 1 mL 2YT medium and the total
solution is added to 30 mL to 2YT-AK (YT Medium + 1:1000 ampicillin + 1:1000
kanamycin) medium. This was incubated overnight at 30°C at 250 RPM. After
incubation, the solution was filtered and stored in separate vials. This ended the first
panning round[143].
The remaining panning rounds (second and third) were performed in a similar
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fashion as the first with some notable exceptions. First, different antigens were used
during each panning round. This will be explained later on in the procedure. Second,
the antibody library that was placed in the pre-adsorption well was from the previous
panning round. This amount was 150 µL that was added without panning block. This
was for both the second and third rounds. Third, the final was increased after
complete incubation. The number of total washed in the final wash was the round
multiplied by 10 (first round: 10 washes per well, second round: 20 washes per well,
third round: 30 washes per well). The final variation was during the elution step. This
step occurs normally as before, except with one additional part: amplification. In this
part, 9 vials were used to create amplification. In four vials, 990 µL PBS were added
and in two additional vials, 900 µL PBS were added. In the first 990 µL vial, 10 µL
Trypsin + Phage was added to create a dilution that was 1/100 of the original. From
there, five more dilutions were made. A second dilution was created when 10 µL form
the 1/100 dilution was added 990 µL PBS, which resulted in a 1/104 dilution. This
was repeated with the remaining 990 µL PBS vials resulting in a 1/106 dilution and a
1/108 dilution. Then 100 µL was added from the 1/108 dilution to a 900 µL PBS vial,
creating a 1/109 dilution and that was repeated with the last 900 µL vial to create a
1/1010 dilution From there, 10 µL of each dilution was added to three more reaction
caps, creating a further drop in dilutions. To perform this, 10 µL was taken from the
1/1010 dilution to create a 1/1012 dilution, 10 µL was taken from the 1/109 dilution to
create a 1/1011 dilution and 10 µL was taken from the 1/108 dilution to create a 1/1010
dilution. From there, 50 µL incubated XL1 culture is then added to these vials. Then
three 10 µL samples of each were dropped on a 10 cm agar plate and incubated
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overnight at 37°C. The following day, each sample was counted for bacteria
cultures[143].
8.1.3. Panning using Micro Titer Plates
Using micro titer plates during the panning rounds is seen as a faster method
than the straightforward method of using agar plates for panning. During the first
panning round, the same methods used to find phage for scFvs up to when the bacteria
are added to the phage. Instead of using different sized agar plates, the bacteria
cultures were placed in small amounts in micro titer plates for growth and cultivation.
In this experiment, this procedure was taken from the protocol “Panning Ab-Libraries:
Panning in Immunotubes (MTPs)” developed by Michael Hust of the Institute of
Biotechnology, TU Braunschweig, Braunschweig, Germany[144] (see appendix B.2 for
an English translation). To perform this, the exact same procedure for the first
panning round was used (see 8.1.2. Panning in Agar Plates) until it was time to
perform the elution. To perform the elution, 50 µL of Phage was added in one well of
a micro titer plate, along with 130 µL of 2YT-XL1 Culture. This was then incubated
at 37°C for 30 min. Added to the well after incubation was 20 µL of 10XGA (2YT +
1:20 Glucose + 1:1000 Ampicillin) medium to the culture. This was then incubated
overnight at 37°C at 850 RPM (LabNet VorTemp 56 Shaking Incubator, LabNet,
Edison, NJ).
Amplification of the phage was also different than in the previous experiments.
To begin amplification, 5 µL overnight culture was added to 180 µL 2YT-AG medium
in one well in a new micro titer plate and 10 µL was added to 180 µL 2YT-AG
medium in a second well in that same plate. This was then incubated at 37°C and 850
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RPM. The remaining culture was stored at 4°C. The OD was then found and
recorded. This was found by using a TECAN Sunrise microplate reader (Männedorf ,
Switzerland). However, in previous experiments, the OD was measured at a
wavelength of 600 nm. In this experiment, the wavelength was measured at 620 nm.
To find the optimal OD, the following measurement had to be used: an OD620 between
0.3 and 0.4 is around an OD600 between 0.4 and 0.5. The incubation time varied
between 1.5 and 2.5 hours. After incubation, 10 µL M13K07 helper phage was added
to each well and the cultures were incubate at 37°C without shaking for 30 min and at
37°C and 850 RPM for 30 min. Each culture was centrifuged at 4000 RPM for 10 min
and the supernatant was decanted. 180 µL 2YT-AK medium was added per well and
the cultures were incubated overnight at 30°C and 850 RPM. The next day, the
cultures were centrifuged for 10 min at 4000 RPM. 100 µL of supernatant were
collected in vials and were used in the next round of panning, where the 100 µL of
supernatant was added to the pre-adsorption wells as in the previous experiment. This
was repeated during the second round of panning. However, the third round of
panning, agar plates were used again during the colony growth for use in the
upcoming screening ELISA. This procedure was shown in the previous section[144].
8.2.

ELISA and scFv Detection
8.2.1. Screening ELISA

During the Screening ELISA, the scFv clones go through a process where they
are attached to a piece of antigen and and then detected with detection antibodies to
see if they attached to the antigen and how strong the signal is. In all ELISA
experiments, the procedure was taken from the protocol “ELISA” developed by
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Michael Hust of the Institute of Biotechnology, TU Braunschweig, Braunschweig,
Germany[145]. To begin this section, cultures were picked from the cultivation plates
from the panning round and placed in a well of one of two 96 well Costar micro titer
plates (Corning Inc., Corning, NY). Each well was filled with 180 µL 2xYT-AG
Medium. In total, 92 wells had a clone culture, 2 wells (H3 & H6) were left blank for
the negative control and 2 wells (H9 & H12) had a positive control (pHAL14-HT186D11) inside. Each plate was incubated overnight at 37°C at 800 RPM. There were
two plates that were used because of the amount of colonies that were found after the
third panning round. After incubation of the micro titer plates, a second set of plates
were used for bacterial growth of the overnight cultures. In these plates, 170 µL of
2YT-AG Medium along with 10 µL of the overnight culture was added per well. The
remaining clones were stored at 4°C. These new plates were incubated at 37°C at 800
RPM for 2 hours. After incubation, the solutions were centrifuged at 4000 RPM for
10 minutes. The supernatant was then decanted and a solution of 180 µL 2YT-AI
(2xYT Medium + 1:1000 ampicillin + 1:20000 IPTG (Isopropyl β-D-1Thiogalactopyranoside)) medium per well. These plates were incubated overnight at
30°C and 800 RPM.
At the same time, the ELISA plates were set up. For one micro titer plate that
had picked colonies inside the wells, 2 ELISA plates were used during the run. One
plate was used as the positive control, where there the antigen used in the phage
display will be used in the experiment to see if the scFv bound to the antigen. The
other plate contained no antigen and was used to see if that scFv bound to the
streptavidin. Both ELISA plates were coated with streptavidin, (100 µL at a
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concentration of 2 µg/mL), except for the positive controls, wells H9 & H12, which
were coated with 100 µL of 1 µg/ml MucI. These plates were then stored overnight at
4°C to allow for coating of the wells.
After the overnight incubation for the ELISA plates, the streptavidin was
discarded and both plates were blocked with 350 µL of 2% BSA in 0.1% PBST. This
was incubated for one hour. Then the plates were washed three times with 0.05%
PBST. The next step was to add 100 ng of the tau antigen in 100 µL PBS to each well
of the one of the plates. This was added for all wells, except for the positive controls,
where 100 µL hMucI was added to wells H9 & H12. This plate was used as the
positive control during the ELISA. In the other plate, only 100 µL of PBS was added
to each well, except again for the two wells used as the positive control. This plate
represented the negative control during the ELISA. Both plates were incubated for an
hour and washed three times with 0.05% PBST.
During this part of the experiment, the overnight cultures were centrifuged at
4000 RPM for 10 minutes. After centrifugation and the ELISA plate washing, the
scFv clones were transferred to the ELISA plates. This was performed by adding 50
µL of 2% BSA in PBS and transferring 50 µL of the scFvs into those ELISA plates,
making sure that the clone in a given well went to the same well in the ELISA plates.
Both plates were incubated for an hour and washed three times with 0.05% PBST.
After washing, 150 µL of 9E10 primary antibody (goat anti myc antibody, 1:1000) in
2% BSA in PBS were added to each well in both plates. These plates were then
incubated for an hour and washed three times with 0.05% PBST. Afterwards, 150 µL
of a secondary antibody (goat anti mouse with a tag, 1:1000) in 2% BSA in PBS was
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added to each well. These plates were incubated one last time for one hour and
washed three times with 0.05% PBST.
The last step was to perform the detection of the ELISA. For this, a TMB
(3,3’,5,5’-Tetramethylbennzidine) mixture was used to detect the antibodies. To
perform this detection, 100 µL of a 20:1 ratio of TMB-A:TMB-B was added to each
well. From there, the detection began when the colors of the wells changed from clear
to blue. The darker the blue, the more concentrated the scFvs are in the well. In order
to make sure that the experiment worked, all the positive control wells had to be blue,
all the negative control wells had to be clear and the wells on the positive control plate
had to be blue, while the wells on the negative control plate had to be clear. The first
signs of detection in the plates were found within the first five minutes. After 20 – 30
minutes, the reaction slowed down and the background started to come into play. At
this point, the experiment detection was stopped by adding 100 µL of Sulfuric Acid in
each well. This turned the solution from blue to yellow and allowed the experiment to
stop so that the OD of each well could be measured. To measure the OD, the plate
was placed in an ELISA reader (TECAN Sunrise) and the reader was set to measure
the OD at a wavelength of 450 nm, but have a reference wavelength at 620 nm. After,
the plates were read, the results were graphed and clones that worked well in the
experiment were chosen based on two factors: intensity and high positive:negative
ratio[145]. Once the clones are chosen, they are grown overnight in 5 mL 2YT medium.
After incubation, 80 µL of culture is added to a sterile vial, along with 20 µL of
glycerol, mixed together and stored at -80°C for further use in experiments. Diagrams
explaining the process are shown in figure 8-4.
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Figure 8-4: Diagram showing the ELISA steps (1: coating of streptavidin, 2: blocking
with 2% BSA in PBS, 3: addition of tau, 4: addition of scFv clones, 5: primary
antibody, 6: secondary antibody, 7: TMB, 8: sulfuric acid)
8.2.2. BStN Digest.
After the screening ELISA, the clones that gave off a high signal and aspect
ratio were chosen to be sequenced for possible antibodies. However, some screening
ELISAs can display multiple positive clones. These clones can be reduced by
selecting a minimum OD level in the ELISA. However, at times, there can be
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upwards to 20 clones within a given OD range. When this happens, it is necessary to
perform a BStN Digest. This digest breaks down the scFvs into smaller components
and sorts the components based on mass. It is used to find out if there are any
identical clones in the system. Once the digest is performed, the number of possible
binders is greatly reduced because it can be shown that for multiple picked clones,
they have the same structure and DNA makeup.
To perform the digest, the procedure is broken up into four parts: breakdown of
scFvs, building of the separation gel, separation of the scFvs and optical detection. To
begin the experiment, the scFvs have to be broken down. This starts with a master
mix to use in the Thermal Cycler (MJ Research PTC 200, MJ Research, St. Bruno,
QC, Canada) in order to perform a polymerase chain reaction (PCR). Each clone
needs the following amount of these ingredients to be in the vial for breakdown:


2 µL of 5X GoTaq Flexi Buffer



0.4 µL of Magnesium Chloride



0.2 µL of Deoxynucleotide Triphosphates (dNTPs)



0.5 µL of MHgIII_r Primer



0.5 µL of LacZpro_f Primer



0.05 µL of GoTaq Polymerase



6.35 µL of distilled water
A small amount of scFv is scraped and placed inside a vial with the master

mix. From there, the PCR is activated and the following program is used during the
process:
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1. 95°C for 2 minutes
2. 94°C for 20 seconds
3. 56°C for 15 seconds
4. 72°C for 90 seconds
5. Repeat steps 2 – 4 a total of 29 more times
6. 72°C for 3 minutes
7. End program at 16°C
From there, 3 µL of solution is transferred to a second vial that contains the
following:


0.5 µL of 10X Nuclear Extraction Buffer 2 (NEB2)



0.5 µL of 10X Bovine Serum Albumin (BSA)



0.2 µL of BstNI (10 U/µL)



0.8 µL of distilled water

From there, the PCR is activated and the following program is used during the
process:
1. 60°C for 1 hour
2. 65°C for 10 minutes
3. End program at 16°C
At the same time the agarose gel has to be assembled. To assemble the gel, the
following procedure is used. In a clean glass molding, the following mixture is added
in two parts. It is added until about halfway, hardened, and completely filled:
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1.55 mL of distilled water



3.2 mL of 30% Acrylamid mix



1.2 mL of 5X Tris/Borate/EDTA (TBE) buffer



60 µL of 10% Ammonium Persulfate (APS)



2.4 µL of Tetramethylethylenediamine (TEMED)
Both the chemicals used for the PCR and agarose gel came from New England

Bio Labs in Ipswich, MA. Slots are added during the making of the top layer, so that
the clones are easily inserted inside the gel. Once the samples have been prepared and
the gel has been hardened, the digest is then able to begin. 1 – 2 µL of dye is added to
each sample to where each line in the digest is and to give an estimate as to where the
samples have traveled down the gel. In total: 5 – 7 µL of sample was added to each
well as well as a 4 µL sample of marker it show where the size of each particles is
separated along the gel. To run the experiment after all the samples have been loaded,
the gel and casing is attached to a container, which is filled with 1% TBE Buffer
solution. An electrical charge runs through the gel at 300V and 50mA for 45 minutes
in order to pass the samples through the gel. After 45 minutes, the gel is removed, and
added to a petri dish with 40 µL of Ethidium Bromide (c = 10 µg/mL) 100 mL TAE
(Tris/Acetate/EDTA) Buffer and incubated at room temperature for 15 minutes. This
constitutes the developing stage so that the lines can be easily seen. After
development, the gel is placed in a UV scanner, where ultraviolet rays allow the bands
to be seen inside the gel. From there, one would be able to decipher which clones are
identical and which ones had some abnormalities in the DNA structure. From there,
the total number of possible clones can be decreased based on similar structures, as
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one will be able to see by way of DNA sequencing.
8.2.3. Titration ELISA
During the titration ELISA, each clone is placed into two different tests on the
same ELISA: to make sure that the scFv only binds to its proper antigen and that the
limit of detection for each scFv clone is found. The procedure for this ELISA is
similar to that of the screening ELISA, except for some differences during the addition
of the scFv clones and the antigens used to attach to the scFvs[145]. The experiment
starts with a 96 well micro titer plate, where 4 wells per clone is filled with 180 µL of
2xYT-AG medium. Each culture is reused from cryotubes that were prepared earlier
after the screening ELISA for each specific binder and each culture was placed in the
filled wells. One of the wells had a positive control inside so that it was to be shown
that the experiment functioned properly. This plate was incubated overnight at 37°C
at 800 RPM.
After overnight incubation overnight a second 96 well micro titer plate is used
for the growth of the clones. 170 µL of 2YT-AG medium is added to the same
locations as the first plate. 10 µL of the overnight culture is then added per well. This
plate is then incubated at 37°C at 800 RPM for 2 hours. Once incubation is
completed, the plates are spun down and the supernatant is decanted. 180 µL of 2YTASI medium is added per well and the plates are incubated overnight at 30°C and 800
RPM. At the same time, the ELISA plates are being prepared. The Costar ELISA
plates are coated with 100 µL Streptavidin (100ng/well), except for one well, which
was coated with 100 µL of MucI (1µg/well) to be used as a positive control. The
plates are incubated for 1 hour at room temperature. From there, the Streptavidin is
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discarded and each well was blocked with 2% BSA in 0.1% PBST. These plates are
then stored overnight at 4°C.
The following day, the plates are washed three times with 0.05% PBST. At this
point, the antigens added to the plate. Each antigen was added so that there was one
antigen per row. For each clone, two rows are used for the antigen the scFv should
bind to, one row is used for the antigen that the scFv should not bind to and one row
does not have antigen, in order to see if there was binding to the streptavidin. In each
well with antigen, add 100 ng of antigen is added to 100 µL of PBS. In the rows
where no antigen is added and the well with the positive control, only 100 µL of PBS
is added. The plates are then incubated for 1 hour and washed three times with 0.05%
PBST. In the meantime, a 96 well micro titer plate is used per ELISA plate for the
transfer of scFvs. In each well, 100 µL of 2% BSA in PBS is added. The overnight
culture is spun down and the supernatant is transferred in the following way: 100 µL
of supernatant for a specific clone is added to each well in the first column of that 96
well plate. After mixing, 100 µL of mixture in the first column is transferred to the
second column. After mixing, 100 µL of mixture in the second column is transferred
to the third column. This process is repeated for each column until the last column is
reached. Then, starting with the second to last column, 100 µL of mixture is
transferred from the micro titer plate to its exact column on the ELISA plate. This is
done by transferring the second to last column, then the third to last column, and so on
until the first column is transferred. This is done so that the results can be as accurate
as possible. In the last column of the ELISA plate, 50 µL of 2% BSA in PBS is added,
as well as 50 µL of the overnight culture for the positive control. These plates are then
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incubated at room temperature for 1.5 hours and washed three times with 0.05%
PBST.
The remaining steps are the same as for the screening ELISA. After washing,
150 µL of 9E10 primary antibody (goat anti myc antibody, 1:1000) in 2% BSA in PBS
were added to each well in both plates. These plates were then incubated for an hour
and washed three times with 0.05% PBST. Afterwards, 150 µL of a secondary
antibody (goat anti mouse with a tag, 1:1000) in 2% BSA in PBS was added to each
well. These plates were incubated one last time for one hour and washed washed three
times with 0.05% PBS.
The last step was to perform the detection of the ELISA. For this, a TMB
mixture was used to detect the antibodies. To perform this detection, 100 µL of a 20:1
ratio of TMB-A : TMB-B was added to each well. From there, the detection began
when the colors of the wells changed from clear to blue. The darker the blue, the more
concentrated the scFvs are in the well. In order to make sure that the experiment
work, all the positive control wells had to be blue, all the negative control wells had to
be clear and the wells on the positive control plate had to be blue, while the wells on
the negative control plate had to be clear. The first signs of detection in the plates
were found within the first five minutes. After 20 – 30 minutes, the reaction slowed
down and the background started to come into play. At this point, the experiment
detection was stopped by adding 100 µL of sulfuric acid in each well. This turned the
solution from blue to yellow and allowed the experiment to stop so that the OD of
each well could be measured. To measure the OD, the plate was placed in a machine
and the reader was set to measure the OD at a wavelength of 450 nm, but have a
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reference wavelength at 620 nm[145]. If the experiment worked, the intensity would
fade from left to right in the two rows where the antigen that is supposed to attach to
the scFv, while the other rows would give off no signal. From there, the best shown
clones would be then chosen to be sequenced to show the DNA structure and to see
any common areas in the structure or if they were identical.
8.2.4. DNA Sequencing
The final step for the whole experiment is the DNA sequencing. In this part,
the structure of each scFv is found and one can see if there is more than one clone that
can be used to detect antigens. To begin with the sequencing, an overnight culture is
first made by inserting a small amount of culture for a specific clone in a test tube
filled with 5 mL of 2xYT-AG medium. This test tube is incubated overnight at 37°C
at 250 RPM. The following day, the overnight culture is poured into a 1.5 mL reaction
cap, one milliliter at a time and centrifuged for 1 minute at 10X g (Eppendorf
Centrifuge 5415 D, Eppendorf, Hamburg, Germany). The supernatant is discarded
and the process is repeated until all the culture is used up and the pellet remained in
the reaction cap. The next part of the experiment used the peqGOLD Plasmid Mini
Kit (PeqLab, Erlangen, Germany) in order to extract the DNA. The first step is to
suspend the pellet completely in 250 µL of Solution I, which is mixed with Rnase.
Then 250 µL of Solution II is added and the cap is gently inverted until a clear lysate
formed. After that, 350 µL of Solution III is added and the cap is again gently inverted
until a white precipitate formed. The cap is then centrifuged for 10 min at 10X g. The
resulting supernatant is then transferred to a peqGold membrane (~750 µL) and
centrifuged for 1 minute at 10 X g. After centrifugation, 750 µL DNA Wash Buffer,
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which was mixed with ethanol, is added to the membrane and centrifuged for 1 minute
at 10 X g. This last step is repeated one more time. Then the membrane was dried by
centrifugation for 2 minutes at 10 X g. Following drying, 100 mL of elution buffer is
added to the membrane, centrifuged for 1 minute at 5X g and collected in a clean
reaction cap. This elution is stored at 4°C.
To prepare the elution for sequencing, new reaction caps containing the
plasmids must be sent to a GATC Biotech AG (Konstanz, Germany) for sequencing.
These reaction caps had to contain a plasmid concentration between 30 and 100
ng/µL, while the total volume had to be equal to 30 µL. To obtain this precise
concentration and volume, elution buffer was added to the specific volume of plasmid
to obtain the desired concentration at 30 µL of solution. The caps were shipped and in
a few days, the sequencing came back as a downloadable note file, which could be run
on VBASE2 (www.vbase2.org) to give the proper sequence for each scFv clone
Multalin (multalin.toulouse.inra.fr/multalin/) in order to see if multiple clones were
similar to each other, but how they lined up against each other.
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CHAPTER 9

FINDINGS

9.1.

Non-phosphorylated-Tau Protein
9.1.1. Screening ELISA

A450nm - A620nm

Tau [100 ng/well]
Streptavidin [100 ng/well]

Tau L1/L2

1

0,8
0,6
0,4
0,2
0
A1 A4 A7 A10 B1 B4 B7 B10 C1 C4 C7 C10 D1 D4 D7 D10 E1 E4 E7 E10 F1 F4 F7 F10 G1 G4 G7 G10 H1 H4 H7 H10

position (scFv clone)

Figure 9-1: Screening ELISA for Tau
The main objective for obtaining results with non-phosphorylated Tau is to
show what type of scFvs can be created with a version of Tau that was not only
healthy and did not immediately show the possible effects of phosphorylation, but also
that there was a baseline for detection, that strands of Tau could be found and not
render the experiment obsolete. After three panning rounds, 92 E. coli samples from
were collected, cultivated, had all possible amounts of scFvs extracted, and underwent
a screening ELISA. The results are as follows: Out of a possible 92 potential clones,
37 clones had an OD greater than or equal to 0.3. However, two of these clones also
had a positive signal:negative signal under 5. The reason that there needs to be a
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positive:negative ratio over 5 is that there is only streptavidin in the wells of the
negative control. This is to make sure that the scFvs will ONLY attach directly to the
antigen and not anywhere else, including the streptavidin. Out of the possible 35
clones, that could be of use, 31 had an OD greater than 0.5. However, to further show
that the amount of scFvs can be maximized, 11 had an OD greater than 0.8 and only 4
had an OD greater than 1.0. To show which clones were the best during this ELISA,
all clones that exhibited an OD greater than 0.8 were used in the following BStNI
digest.
A10

B3

C1

C2

D7

D8

D12

E4

E7
G9
H7
Table 9-1: Chosen clones for BStN digest for Tau

9.1.2. BStN Digest

Figure 9-2: BStN Digest of Tau clones from A10 through H7
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The use of the BStNI digest is to determine if there are any differences in the
makeup of each clone. Each scFv component is broken up into smaller fragments and
separated an agarose gel using electrophoresis. During the experiment, each
component is separated based on mass (the greater the mass, the higher up in the
column it would be), with a band showing the location of each particle. Although the
bands cannot be seen in the gel directly, they can be detected via UV light. For this
experiment, 11 clones were prepared and separated in the aforementioned gel. As a
result of this separation, there were 5 different sets of bands that could be used to
differentiate each scFv (A10-C2-D12-G8, B3-E1, D7-D8, D12-E7, H7, with C1 not
displaying any signal). However, in some cases, there seemed to be different
variations of intensities that corresponded with each clone, as shown with clones E7 &
G8. Also, on some of the clones, there appears to be an extra band near a specific
group of bands, which could mean an error in the process of splicing or a totally
different clone altogether. This was shown for clones D12 and E1, for example.
Because of these bands, 6 clones will go through DNA sequencing and a titration
ELISA.
A10

C1

D7

E4

E7

H7

Table 9-2: Chosen clones for Titration ELISA and DNA sequencing for Tau
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9.1.3. Titration ELISA

Tau L1/L2 Titration ELISA
1,2000
ALP13 A10 Tau L1
ALP13 A10 Tau L2
ALP13 A10 pTau L1
ALP13 A10 Strep
ALP13 C1 Tau L1
ALP13 C1 Tau L2
ALP13 C1 pTau L1
ALP13 C1 Strep

1,0000

OD

0,8000
0,6000
0,4000
0,2000
0,0000
0,01

0,1

1

10

100

Volume scFv (µL)

Figure 9-3: Titration ELISA of Tau against Tau (linkers 1&2), pTau (linker 1) and
Streptavidin for clones A10 and C1
Tau L1/L2 Titration ELISA
1,4000

ALP13 D7 Tau L1
ALP13 D7 Tau L2
ALP13 D7 pTau L1
ALP13 D7 Strep
ALP13 E4 Tau L1
ALP13 E4 Tau L2
ALP13 E4 pTau L1
ALP13 E4 Strep

1,2000
1,0000
OD

0,8000
0,6000
0,4000
0,2000
0,0000
0,01

0,1

1

10

100

Volume scFv (µL)

Figure 9-4: Titration ELISA of Tau against Tau (linkers 1&2), pTau (linker 1) and
Streptavidin for clones D7 and E4
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Tau L1/L2 Titration ELISA
1,2000
ALP13 E7 Tau L1
ALP13 E7 Tau L2
ALP13 E7 pTau L1
ALP13 E7 Strep
ALP13 H7 Tau L1
ALP13 H7 Tau L2
ALP13 H7 pTau L1
ALP13 H7 Strep

1,0000
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0,8000
0,6000
0,4000
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0,01

0,1

1

10

100
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Figure 9-5: Titration ELISA of Tau against Tau (linkers 1&2), pTau (linker 1) and
Streptavidin for clones E7 and H7
The purpose of the titration ELISA is to determine the intensity of specific
concentrations of each scFv clone, or the limit as to how intense the detection is. In
this experiment, with the binders for non-phosphorylated tau, we see that the most
concentrated samples for 4 clones show a standard OD of between 1.0 and 1.4. Only
one clone had one peptide at an OD of 0.4 and one clone had both peptides at around
0.2 at the maximum concentration. Because of this, these clones are not well fit to be
used for further experiments involving Tau. What is also worth noting is that the
detection signal is still strong (similar OD), even at 1/8 the concentration of scFvs.
After this is when the signal becomes weaker with decreasing concentration.
However, at an OD at 0.2, the intensity of this decreasing OD lessens and becomes
more gradual towards an OD between 0.03 and 0.1. This occurs at an scFv
concentration 1/64 – 1/128 the size of the original concentration. Therefore, we can
see that based on this observation, these scFv clones have a limit of detection at 1/128
the original concentration, with a high amount of detection starting at 1/8 the original
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concentration. Because of this, all six clones will be sequenced: A10, C1,D4, E4, E7
& H7.
9.1.4. DNA Sequencing:
With the DNA sequencing, the pattern of each attaching points on the scFvs for
both the heavy chain and the light chain are found and the antibody library can be
made for that specific scFv that attaches to the non-phosphorylated Tau. For this, it
was ideal to base the clone selection from a CDR comparison (due to an IP relevance,
the CDR comparisons cannot be shown, but the structure of the scFvs for both Tau and
pTau will be presented in section 9.5). Based on the results of the sequencing, only
three clones had full heavy and light chains that were similar: A10, C1& E4. Clone
E7 had the same heavy chain, but no light chain, which made it unsuitable for further
study. The other two clones, D7 & H7, were sequenced, but also had unfavorable
results. Clone D7 had a sequence that was completely different than the other three
clones, while clone H7 was missing completely. It was later re-sequenced, but the
light chain sequence was also missing. Also, it is important to note that even though
the light chain was missing for two of the clones, the heavy chain was still identical in
sequence as with the three best clones. In terms of choosing a clone, it was
determined that based on the ELISAs and sequence, that clone E4 will be used as the
biomarker against Tau.. However, even though clone D7 did not have a high signal in
the titration ELISA, because of the difference in the CDR comparison, this could be a
second possible candidate for the scFv against Tau.
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9.2.

Phosphorylated-Tau Protein
9.2.1. Screening ELISA

Tau [100 ng/w ell]
Streptavidin [100 ng/w ell]

pTau L1/L2

A450nm - A620nm
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Figure 9-6: Screening ELISA for pTau
The main objective for obtaining results with phosphorylated Tau is to show
what type of scFvs can be created with a version of tau that was phosphorylated. This
is because unlike non-phosphorylated tau, this type of tau is known as a signaler for
Alzheimer’s disease. After three panning rounds, 92 E. coli samples from were
collected, cultivated, had all possible amounts of scFvs extracted, and underwent a
screening ELISA. The results are as follows: Out of a possible 92 potential clones, 29
clones had an OD greater than or equal to 0.6. None of these clones had low positive
to negative control ratio, meaning that it is with the upmost confidence that these
clones will only attach to the antigen and not the streptavidin. Out of these possible 29
clones, that could be of use, 16 had an OD greater than 0.8, with the majority of these
clones within the same OD range. These clones were used in the following BStNI
digest.
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A2

A5

B7

B8

B9

B10

C3

C6

C12

E3

E11

F3

F5

G7

H4
H5
Table 9-3: Chosen Clones for BStN Digest for pTau

9.2.2. BStN Digest

Figure 9-7: BStN Digest of pTau clones B7 through H5
For the BStNI digest, 16 clones were prepared and separated in an agarose gel.
As a result of this separation, there were 5 different sets of bands that could be used to
differentiate each scFv (B7-B8-B9-B10-C3-C6-G7-H4, C12-E3, E11-F3, F5 & H5).
However, like in section 9.1.2, in some cases, there seemed to be different variations
of intensities that corresponded with each clone (C6 and G7 for example). Because of
these bands, 10 clones will go through DNA sequencing and a titration ELISA.
A2

A5

B3

B10

C3

E3
E11
F5
H4
H5
Table 9-4: Chosen clones for Titration ELISA and DNA Sequencing for pTau
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9.2.3. Titration ELISA
In terms of this round of the titration ELISA, this experiment had to be
performed twice. The first time, there was an issue with pTau L1. The scFvs were
binding properly to pTau L2 but not to pTau L1. It was then determined that the
peptides were old and contaminated during the course of the screening ELISA, with a
new set of peptides, the screening ELISA could resume and the results shown below
and on the next page display the actual final product.

pTau L1/L2 Titration ELISA
1,2000
1,0000

ALP14 B3 Tau L1
ALP14 B3 pTau L2
ALP14 B3 pTau L1
ALP14 B3 Strep
ALP14 B10 Tau L1
ALP14 B10 pTau L2
ALP14 B10 pTau L1
ALP14 B10 Strep

OD

0,8000
0,6000
0,4000
0,2000
0,0000
0,01

0,1

1

10

100

Volume scFv (µL)

Figure 9-8: Titration ELISA of pTau against Tau (linker 1), pTau (linkers 1&2) and
Streptavidin for clones A2 and A5
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pTau L1/L2 Titration ELISA
1,2000
1,0000

ALP14 A2 Tau L1
ALP14 A2 pTau L2
ALP14 A2 pTau L1
ALP14 A2 Strep
ALP14 A5 Tau L1
ALP14 A5 pTau L2
ALP14 A5 pTau L1
ALP14 A5 Strep
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Figure 9-9: Titration ELISA of pTau against Tau (linker 1), pTau (linkers 1&2) and
Streptavidin for clones B3 and B10
pTau L1/L2 Titration ELISA
1,0000
ALP14 C3 Tau L2
ALP14 C3 pTau L1
ALP14 C3 pTau L2
ALP14 C3 Strep
ALP14 H4 Tau L2
ALP14 H4 pTau L1
ALP14 H4 pTau L2
ALP14 H4 Strep
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Figure 9-10: Titration ELISA of pTau against Tau (linker 1), pTau (linkers 1&2) and
Streptavidin for clones C3 and H4
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pTau L1/L2 Titration ELISA
1,2000
1,0000

ALP14 E3 Tau L2
ALP14 E3 pTau L1
ALP14 E3 pTau L2
ALP14 E3 Strep
ALP14 E11 Tau L2
ALP14 E11 pTau L1
ALP14 E11 pTau L2
ALP14 E11 Strep
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Figure 9-11: Titration ELISA of pTau against Tau (linker 1), pTau (linkers 1&2) and
Streptavidin for clones E3 and E11
With a new set of antigens, the experiment was a success as the scFv clones
attached to both antigens (the phosphorylated ones), with the exception of clone B3
which did not bind to pTau L2. At the highest scFv concentration possible, the OD
values ranged between 0.8 and 1.2. However, there was a slight difference between
the result in the last experiment and the current experiment. In the last experiment, as
the scFv concentration decreased, the OD stayed relatively flat until it the
concentration reached 1/8 the original. At that point, the concentration started to
sharply decreased until it was about 1/64 the original, where it then leveled off. In this
experiment, as the concentration started to decrease, the OD also decreased. At the
original concentration, the OD was between 0.8 and 1.2. At 1/2 the original
concentration, the OD was between 0.55 and 1.1. The OD at 1/4 the concentration
was between 0.5 and 0.95. This steady decrease continued until the concentration was
1/128 the original concentration. Because of this observation, these scFv clones have
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a limit of detection at 1/128 the original concentration, but unlike the last experiment
where there is no increase in signal after 1/8 the concentration, there can be an
increase in signal as the scFv increases. Because of this, 10 clones will be sequenced:
A2, A5, B3, B10, C3, E3, E11, F5, H4 & H5.
9.2.4. DNA Sequencing:
Based on the CDR comparison, out of the possible 10 clones, only three clones
were bad. Clone B3 was missing part of the light chain, which made it unsuitable for
further study, which explains the titration curve, clone A2 was missing the light chain
and clone E11 was missing completely. On the other hand, the other seven clones that
were still intact had identical sequences, meaning that there was only one sequence for
this antigen. One other thing to note is that even though some scFvs were completely
missing the light chain, their heavy chains were identical to the rest of the suitable
clones. Based on these results, it was decided that clone B10 would be used as a
possible biomarker against pTau.
9.3.

Phosphorylated-Tau Protein Linker 1 with Competition
9.3.1. Screening ELISA

A450nm - A620nm

Tau [100 ng/well]
Streptavidin [100 ng/well]

pTau L1

1,2
1

0,8
0,6
0,4
0,2
0
A1 A4 A7 A10 B1 B4 B7 B10 C1 C4 C7 C10 D1 D4 D7 D10 E1 E4 E7 E10 F1 F4 F7 F10 G1 G4 G7 G10 H1 H4 H7 H10

position (scFv clone)

Figure 9-12: Screening ELISA for pTau L1 in competition with Tau L1
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The main objective for obtaining results with phosphorylated Tau is to show
what type of scFvs can be created with a version of Tau that was phosphorylated.
However, what is different with this experiment is that competition is used. During
competition, a second antigen is used in the panning process. While the target scFvs
are being detected in this step, another antigen is being used to remove other scFv's
that might cause interference. For this experiment, the main antigen being used for
detection is phosphorylated Tau with the first linker, with non-phosphorylated Tau
with the first linker being used as competition. This is done in order to remove any
binding to the non-phosphorylated Tau and the linker beforehand. After three panning
rounds, 92 E. coli samples from petri dishes with agar were collected, grown and had
all possible amounts of scFvs have been extracted, a screening ELISA was performed.
The results are as follows: Out of a possible 92 potential clones, 5 clones had an OD
greater than or equal to 0.1. None of these clones had low positive to negative control
ratio, meaning that it is with the upmost confidence that these clones will only attach
to the antigen and not the streptavidin. However, it should be noted that one clone
gave off a really high signal compared to the others (> 0.7), and was next to one of the
positive controls. This could mean that there might have been a chance for a possible
contamination. These 5 clones were used in the following BStNI digest.
G3

G4

G5

Table 9-5: Clones chosen for BStN digest for pTau L1
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G6

H11

9.3.2. BStN Digest

Figure 9-13: BStN Digest of pTau L1 with competition clones G3 to H11
For the BStNI digest, 5 clones were prepared and separated in the
aforementioned gel. As a result of this separation, there were 4 different sets of bands
that could be used to differentiate each scFv. There is only one pair of clones that
were similar: clones G5 & G6. The rest either varied in intensity in the bands (G4) or
exhibited an extra band that was not common among the other clones (G3). Also,
H11, the clone that exhibited a higher peak than the rest, was completely different than
the others in the digest. As a result of this, all five clones will be used in the titration
ELISA and DNA sequencing.
G3
G4
G5
G6
H11
Table 9-6: Clones chosen for Titration ELISA and DNA Sequencing for pTau L1
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9.3.3. Titration ELISA

OD

pTau L1 Titration ELISA
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0,1800
0,1600
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0,0600
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0,01

ALP15 G3 Tau L1
ALP15 G3 pTau L1
ALP15 G3 pTau L2
ALP15 G3 Strep
ALP15 G4 Tau L1
ALP15 G4 pTau L1
ALP15 G4 pTau L2
ALP15 G4 Strep

0,1
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ALP15 G5 Tau L1
ALP15 G5 pTau L1
ALP15 G5 pTau L2
ALP15 G5 Strep
ALP15 G6 Tau L1
ALP15 G6 pTau L1
ALP15 G6 pTau L2
ALP15 G6 Strep
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Figure 9-14: Titration ELISA of pTau with linker 1 with competition from Tau with
linker 1 against Tau (linker 1), pTau (linkers 1&2) and Streptavidin, without clone H11
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Figure 9-15: Titration ELISA of pTau with linker 1 with competition from Tau with
linker 1 for clone H11 against Tau (linker 1), pTau (linkers 1&2) and Streptavidin
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As shown by the titration graphs on the previous page, the experiment
performed well pTau L2, but not with pTau. This was explained in section 9.2.3.
Because of this, new peptides were prepared and the titration was performed again.

pTau L1 Titration ELISA
ALP15 G3 Tau L1
ALP15 G3 pTau L1
ALP15 G3 pTau L2
ALP15 G3 Strep
ALP15 G4 Tau L1
ALP15 G4 pTau L1
ALP15 G4 pTau L2
ALP15 G4 Strep
ALP15 G6 Tau L1
ALP15 G6 pTau L1
ALP15 G6 pTau L2
ALP15 G6 Strep
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Figure 9-16: Redo of Titration ELISA of pTau with linker 1 with competition from
Tau with linker 1 against Tau (linker 1), pTau (linkers 1&2) and Streptavidin, without
clone H11
pTau L1 Titration ELISA
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Figure 9-17: Titration ELISA of pTau with linker 1 with competition from Tau with
linker 1 for clone H11 against Tau (linker 1), pTau (linkers 1&2) and Streptavidin
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In this second run, it was a success as the scFv clones attached to both antigens
(the phosphorylated ones). At the highest scFv concentration possible, the OD values
for the clones, except for H11, ranged between 0.04 and 0.4. There was a decline after
this, but the signal was too weak to consider any further experiments with these
antibodies. However, the clone H11, the one that exhibited a high signal performed
well. The OD at the maximum concentration was around 0.8, with a steady decrease
as the concentration also decreased. At 1/64 the original concentration, the OD started
to level off towards an OD of zero. Because of this, only clone H11 underwent DNA
sequencing.
9.3.4. DNA Sequencing:
Based on the results of the CDR comparison, clone H11 displayed a complete
sequence. Moreover, compared to the previous experiment with no competition, the
DNA sequence was exactly the same as the other ones sequenced. Based on this
observation, this clone can be used with the others as a possible scFv to detect
phosphorylated Tau.
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9.4.

Phosphorylated-Tau Protein Linker 2 with Competition
9.4.1. Screening ELISA

A450nm - A620nm

Tau [100 ng/well]
Streptavidin [100 ng/well]

pTau L2

1
0,8
0,6
0,4
0,2
0
A1 A4 A7 A10 B1 B4 B7 B10 C1 C4 C7 C10 D1 D4 D7 D10 E1 E4 E7 E10 F1 F4 F7 F10 G1 G4 G7 G10 H1 H4 H7 H10

position (scFv clone)

Figure 9-18: Screening ELISA for pTau L2 in competition with Tau L2
Like back in section 9.3, this screening ELISA encompassed the use of
competition. Except this time, the peptides with linker 2 were used. After three
panning rounds, 92 E. coli samples from petri dishes with agar were collected,
cultivated, had all possible amounts of scFvs extracted and underwent a screening
ELISA. The results are as follows: Out of a possible 92 potential clones, 19 clones
exhibited an OD reading greater than 0.2. These clones were the best read clones out
of all the possible clones that were produced. However, with one of the clones, clone
F4, the negative control was abnormally higher than what it should have been. This
could either be a case where there was contamination in the negative control or there
was an unknown error during the running of the experiment. Nether the less, because
of this error, this one specific clone cannot be used in any further experiments.
Instead, the other 18 clones can be used for a BStNI digest.
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A3
E1
F2
H2

A6
B4
C3
C4
D1
E2
E3
E5
E6
F1
F3
F4
F5*
G5
H1
H4
H7
Table 9-7: Chosen clones for BStN digest for pTau L2(*Clone F5 had a higher
negative signal than positive)
9.4.2. BStN Digest

Figure 9-19: BStN Digest for pTau L2 with competition clones A3 through E1
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Figure 9-20: BStN Digest for pTau L2 with competition clones E2 through H7
In this digest, 18 clones were prepared and separated in the agarose gel. As a
result of this separation, most of the clones were similar in band length and distance.
However, some of the clones did experience a small brightness in the type of band
(clone E1, compared to D1), while other bands were just a little bit off from what the
majority of the bands (clone H7 compared to clone H4). As a result of this digest, 14
different clones will undergo a titration ELISA and DNA sequencing.
A3
A6
B4
C3
C4
D1
E1
E2
F1
F3
G5
H1
H2
H7
Table 9-8: Chosen clones for Titration ELISA and DNA sequencing for pTau L2
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9.4.3. Titration ELISA

pTau L2 Titration ELISA
0,6000
0,5000

ALP16 A3 Tau L2
ALP16 A3 pTau L1
ALP16 A3 pTau L2
ALP16 A3 Strep
ALP16 A6 Tau L2
ALP16 A6 pTau L1
ALP16 A6 pTau L2
ALP16 A6 Strep

OD

0,4000
0,3000
0,2000
0,1000
0,0000
0,01

0,1

1

10

100

Volume scFv (µL)

Figure 9-21: Titration ELISA of pTau with linker 2 with competition from Tau with
linker 2 against Tau (linker 2), pTau (linkers 1&2) and Streptavidin
Like the last experiments, the scFv clones attached well to the target antigen
(pTau L2), but not pTau L1. Not only that, but that same scFv also attached to one of
the negative controls, Tau L2. This was the control where the antigen was nonphosphorylated, but it used the exact same linker as before. Because of this, it is safe
to assume that these scFvs somewhat bind to the antigen, but there is binding at the
linker. A further titration ELISA was performed but it resulted in similar results,
except that the OD measurements were lower than before. Because of these reasons,
this experiment was not further investigated because the focus is only on scFvs that
attach directly to the antigen and nothing else.
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9.5.

Titration ELISA Using the Best scFv Clones against Tau, pTau and
Other Antigens

In these final experiments, the optimal scFv clones against Tau and pTau (Tau
clone E4 and pTau clone B10) underwent a titration ELISA against not only the forms
of Tau that were used, but also against other antigens. In a 96 well ELISA plate, the
following order was used for each antigen (from top to bottom): Non-Phosphorylated
Tau – Linker 1 (Tau L1), Non-Phosphorylated Tau – Linker 2 (Tau L2),
Phosphorylated Tau – Linker 1 (pTau L1), Phosphorylated Tau – Linker 2 (pTau L2),
Beta Amyloid 42 Fibrils (aß 42), Phosphorylated Fibronectin 1 – Linker 1 (pFN1 L1),
Phosphorylated Fibronectin 2a – Linker 1 (pFN2a L1), Streptavidin (negative control).
This is to make 100% sure that each scFv only binds to its own antigen and not any
others.

ALP13_E4 Titration ELISA
1,8000
1,6000
ALP13 E4 Tau L1
ALP13 E4 Tau L2
ALP13 E4 pTau L1
ALP13 E4 pTau L2
ALP13 E4 aß42
ALP13 E4 pFN1 L1
ALP13 E4 pFN2a L1
ALP13 E4 Strep

1,4000
1,2000
OD

1,0000
0,8000
0,6000
0,4000
0,2000
0,0000
0,01

0,1

1

10

100

Volume scFv (µL)

Figure 9-22: Titration ELISA for Tau scFv clone E4 against Tau (linkers 1&2), pTau
(linkers 1&2), aβ42, pFN1 (linker 1), pFN2a (linker 1) and Streptavidin
The ELISA that used the Tau scFv only bound to the non-phosphorylated Tau.
At the highest concentration possible, the OD measured between 1.3 and 1.55. This
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measurement was for the most part constant, even at 1/16 the original concentration.
At a lesser concentration, OD decreased substantially until it was 1/128 the original
concentration. At that point, the OD started to slowly level off towards 0.0. There
was no additional binding to any other antigen, with the exception of pTau L2, which
displayed a small amount of detection. This might have been caused by linker
binding, but it is small compared to the binding to the Tau. In terms of clone D7, this
titration ELISA was not performed as the signal back in the previous ELISA (see
section 9.1.3) was not high compared to clone E4.

Figure 9-23: Titration ELISA for pTau scFv clone B10 against Tau (linkers 1&2),
pTau (linkers 1&2), aβ42, pFN1 (linker 1), pFN2a (linker 1) and Streptavidin
The ELISA that used the pTau scFv only bound to the phosphorylated Tau. At
the highest concentration possible, the OD measured between 1.4 and 1.6. This
measurement was for the most part constant, even at 1/16 the original concentration.
At lesser concentration, OD decreased substantially until it was 1/1024 the original
concentration. At that point, the OD started to slowly level off towards 0.0. There
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was no additional binding to any other antigen.
To further compliment this, tables 9-9 and 9-10 below shows the fragment
structure of these three antibodies. This breakdown for the antibody fragments is as
follows: There are two types of chains: heavy and light. On the heavy chain, there are
three sections: variable (V), diversity (D) and joining (J). There are also two types of
light chains: kappa (K) and lambda (L). On either the kappa or lambda chains, there
are two sections: variable and joining. Fragments can either have a kappa chain or a
lambda chain, but not both. The naming scheme uses the above letters and numbers to
differentiate the segments
Antibdy Name
Antibody Type
Heavy Variable
Heavy Diversity
Heavy Joining
Light Variable
Light Joining

ALP13-E4
ALP13-D7
Non-Phosopho-Specific
IGHV5-51*01
IGHV1-46*01
IGHD3-22*01
IGHD5-5*01
IGHJ4*02
IGHJ4*02
IGLV3
IGLV1-47*01
IGLJ3*01
IGLJ3*01
Table 9-9: Structures for the scFvs chosen that bind against Tau

Antibdy Name
ALP13-B10
Phosopho-Specific
Antibody Type
IGHV5-51*01
Heavy Variable
IGHD1-26*01
Heavy Diversity
IGHJ3*02
Heavy Joining
IGLV2-8*01
Light Variable
IGLJ3*02
Light Joining
Table 9-10: Structures for the scFv chosen that bind against pTau
Some of the similarities between the three fragments include:


ALP13-E4 & ALP13-D7: Same joining segments for both the HJ & LJ



ALP13-E4 & ALP14-B10: Same HV segments



All three fragments have lambda structures for light chains

Other than these, these three are completely different fragments.
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CHAPTER 10

CONCLUSION

10.1. Discussion
This project effectively found two sets of scFv antibodies that are able to bind
to a certain Tau peptide. This was performed effectively by using phage display and
by harvesting E. coli cultures in order to extract these antibodies. Because of the
effects of phosphoylation, which is a side effect of Alzheimer's, these antibodies were
created in order to bind to both Tau and pTau. These antibodies were also shown to
have a high affinity to the antigen and could be detected in small amounts. Because of
these reasons, it was shown that creating these antibodies was a success.
Furthermore, it was also shown that only one of the same antibodies could be
formed based on the competition ELISA (pTau L1, not pTau L2). This is due to the
fact that there are antibodies that also bound to the linker that were also discovered. In
order to mitigate this, a fourth run would have to be performed with the same peptide,
but with different linkers, so that the proper antibodies could be obtained. Other than
this, it was shown that it was possible to obtain two different antibodies for Tau and
pTau respectfully. The structures for each was shown in section 9.5, tables 9-9 and 910.
As mentioned in the results section, scFv clones for both Tau and pTau were
found by using different antibody libraries and phage display. The majority of the
clones that were tested during the ELISAs performed well, with the exceptions of
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some clones during the DNA sequencing and the pTau – L2 with competition, where
the scFvs only attached to the linker. Based on the results found, scFv clones were
found that were able to detect pTau antigens and clones were found that detected Tau
antigens, both with specificity and with a high detection signal. However during the
course of these experiments, there were problems that had to be dealt with in order to
accurately show these results previously shown.
The majority of these errors occurred during the panning and the screening of
the scFvs. These errors were mostly random errors that were caused by not following
the protocols properly. These were either a time-related or temperature-related error
that resulted in the whole experiment being repeated over again. For example, if a
certain experiment was left out too long, the number of E. coli clones were either too
big or too many. One other problem occurred with temperatures, especially if a
certain experiment had to run overnight. As explained during the procedures, there
were only three temperatures that each experiment had to be incubated at: 4°C, 30°C
and 37°C. While no problems occurred at 4°C, the biggest issue was at 30 and 37°C.
Incubation at 37°C meant bacteria growth during panning rounds, while 30°C was
used to breakdown the E. coli to create new phages or to release scFvs into solution.
However during some experiments, samples that were supposed to be incubated at
30°C were actually incubated at 37°C. This was either due to human error, or to other
experiments being performed in the lab. This caused problems because there was no
detection or colonies after each experiment were completed, which meant that all of
these experiments had to be redone.
But one of the biggest errors during each experiment was during the
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amplification stage. In this stage, the newly made bacteria colonies had to grow from
on OD of 0.1 to an OD of 0.5. This was performed by scraping off the agar plate the
bacteria and placing between 0.3 and 0.5 mL in a solution of 2YT-AG. During this
section, it was important that no agar was also placed in this solution, as it would
hinder bacterial growth while in incubation. However, during this sequence there was
one problem that could cause the experiment to start over again. In a normal bacterial
growth, for every half hour elapsed, the OD would double. For example, at t=0, and
OD=0.1, at t=0.5h, OD=0.2 and at t=1h, OD=0.4. However, during this stage, the
growth was significantly different. What would happen is that there would be growth
for the first half hour, but after that, the OD would decrease dramatically. It would
decrease to a certain point either just above or just below the original OD. After that,
it would remain stagnant for about a few hours, before it would gradually rise up
again. Because of this, an experiment that could normally take between 1.5 and 2
hours, would actually take between 5 and 7 hours depending on the rise in the OD.
While this phenomenon was normal during the experiments, the problems usually
occurred when the OD fell below the original OD. When this happens, it shows that
there was something wrong with the amplification, which meant that the experiment
had to be redone.
Other errors in panning included measurements with the OD during incubation.
This was crucial because the growth in OD was not linear with time, but more
exponential. At times, if an experiment was being performed where incubation was
necessary, if the incubation was even 10 or 20 minutes longer than expected, the OD
would be too high for sufficient bacterial growth due to over-crowding and insufficient
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supply of food for the E. coli. However, if an experiment was stopped too short, then
there would not be enough E. coli to complete the experiment. To start each
incubation process, the acceptable OD range had to be in between 0.075 and 0.1, with
better results at 0.1. At the end of the incubation, the acceptable range had to be
greater than 0.45, but no more than 0.65, with 0.5 being in the acceptable range. But
since the bacterial growth during this time is not linear, it at times was hard to tell
when it was appropriate to end this experiment.
One other important bit of information during the panning rounds was that two
different protocols were used during the running of the experiments. The first
involved bacterial growth on agar plates, while the second involved bacterial growth
in micro titer plates. The first set of experiments was performed using the first
method. This method had some positive aspects while performing each experiment.
For instance, multiple samples after each panning round could be taken. This means
that because 100 microliters were needed of phage to run the next experiment, the
samples were collected in 1.5 – 2.5 mL samples. This meant that in case the
experiment went wrong, there was always backup available, so that the experiment did
not have to start over. On the other hand, this process was more labor intensive and
took at times about 6-8 days to complete three rounds.
The remainder of the experiments was performed using the method with micro
titer plates. This method not only cut back the time needed to create clones by 2 -3
days, but was also less labor intensive than the previously mentioned method.
However, the results were not generated until the end of the third panning round. In
the previous experiments, agar plates were used to grow bacteria colonies after each
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panning round. Since this occurred with larger volumes of solutions, separate vials
were needed to store the results from the previous experiments. This was to make sure
that even if the next panning round was not a success, there was extra phage left over
to redo the experiment so that it did not have to be started over again. However, in
this experiment, because small volumes of phage were used in each experiment, there
was not any room for error and there were no checks in between to make sure that the
experiments ran smoothly. All the results had to be found at the end of the third
panning round. If no colonies were present at the end, then the whole experiment had
to be repeated from the beginning.
In the previous experiments, it was shown that scFvs could be made for a
specific region of Tau Protein, in both phosphorylated and non-phosphorylated forms.
This is beneficial in that these antibodies can be used as a biomarker. However, there
can be more experiments that can further help the project. These experiments can be
explained below.
10.2. Further Work
The first experiment that can be done can be to create an scFv that can detect
both forms of this peptide of Tau. As shown in the previous experiments, only the
scFv made for non-phosphorylated Tau bound to non-phosphorylated Tau and the
same can be said for phosphorylated Tau. However, the reverse (Tau → pTau scFv
and pTau → Tau scFv) cannot work. This was shown with the final titration curves
above. A third antibody can be created that could detect both forms, but this could
require a larger stock antibody library and more than 4 rounds of panning in order to
successfully obtain these antibodies.
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The second experiment would be to obtain IgG from these scFvs. This could
either be performed by engineering the antibodies in a way that would allow for IgG
creation, or by performing it in the usual manners to obtain IgG. This would be by
introducing either the scFv or the peptide into a mammal and then extracting the
antibodies. This would be beneficial for performing assays in which tau needs to be
detected from a fluid and it needs something to attach to. IgGs work better because
they have a stabilizer in which they are able to attach to the well, whereas scFvs only
contain the parts which are supposed to attach to an antigen and maybe a detection
antibody.
One final group of experiments would be to find antibodies for the entire Tau
protein. As mentioned in the background, only about a dozen proteins exist that are
known to connect with certain Tau peptides. While this project only focuses on one
specific section, there are many different spots on the protein that have no antibodies
associated with it. Because phosphorylated Tau is broken off from the microtubules,
there are hundreds of peptides in spinal fluid that could be found. With this many
different peptides, it should be known that any different amount of peptides could be
in one solution and it is a lot more difficult to isolate one type. For this reason, it
would be better to at least find a few more scFvs that would be able to effectively
detect all known Tau peptides, both phosphorylated or not.
Further work will have to be performed in order to effectively either create IgG
antibodies and completely map the entire protein, but this will happen in the upcoming
years. However, it is safe to say that two new antibodies have been discovered that
would aid in detecting not only Tau protein, but one that is known to undergo
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phosphorylation. In conclusion, based on the above experiments and data, two scFv
antibody fragments have been replicated in order to attach to both Tau and pTau,
which would aid as a biomarker against Alzheimer's disease.
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APPENDIX
A.1: Masks for Photo Resists for the Channel – Side Molds

Figure A-1: Photo lithography masks for channel molds
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A.2: Mask for Photo Resist for the Molds for the Filter Holder

Figure A-2: Photo lithography mask for filter holder mold
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A.3: Protocol for HAR Photolithography for Silicon Wafer Molds[146]

Standard Operation Procedure for HAR Photolithography
Experiment Date:_________________

Hazardous Chemical: Sulfuric Acid, 96%
Hazard Identification: Corrosive.
Health effects: Causes severe skin burns. Causes severe eye burns. Causes burns of
the mouth, throat, and stomach.
Personal protection: Safety goggle, nitrile gloves together with trionic gloves, face
shield, wet chemical apron, and lab coat should all be worn.
Engineering Controls: Use the fume hood in the Wind Tunnel Lab in Kirk.
Handling and Storage: Keep container tightly closed in a cool, well-ventilated area.
Do not store above 23℃.
Stability and Reactivity: Stable. Avoid exposure to excess heat, combustible
materials, organic materials, moist air, water, oxidizers, amines, bases.
Hazardous Chemical: Hydrogen Peroxide, 30%
Hazard Identification: Strong oxidizer. Contact with other material may cause fire.
Health effects: Corrosive to eyes, skin, nose, throat and lungs. May cause irreversible
tissue damage to the eyes including blindness.
Personal protection: Safety goggle, nitrile gloves together with trionic gloves, face
shield, wet chemical apron, and lab coat should all be worn.
Engineering Controls: Use the fume hood in the Wind Tunnel Lab in Kirk.
Handling and Storage: Keep container tightly closed in a cool, well-ventilated
area. Do not store above 8℃. Separate from acids, alkalis, reducing agents and
combustibles.
Stability and Reactivity: Stable. Avoid exposure to excess heat, combustible
materials, organic materials, moist air, water, oxidizers, amines, bases, metals.
Hazardous Chemical: Methanol
Hazard Identification: Flammable.
Health effects: Hazardous in case of skin contact (irritant), of eye contact (irritant), of
ingestion, of inhalation. Slightly hazardous in case of skin contact (permeator). Severe
over-exposure can result in death.
Personal protection: Safety goggle, nitrile gloves, and lab coat should all be worn.
Engineering Controls: Use the fume hood in the Wind Tunnel Lab in Kirk.
Handling and Storage: Store in the yellow cabinet for the inflammables.
Stability and Reactivity: Stable. Avoid exposure to excess heat, ignition sources,
oxidizing agents, metals, and acids.
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Hazardous Chemical: SU8 Developer
Hazard Identification: Flammable. Flash point is 460℃.
Health effects: May be harmful if swallowed, inhaled, or absorbed through the skin.
Readily absorbed through the skin. No significant signs of any health hazard are
expected to occur through skin absorption. Irritating to eyes and respiratory tract. May
cause burning, tearing, redness or swelling. Vapor or mist is irritating to the eyes,
mucous membranes and upper respiratory tract. Prolonged and/or repeated exposure
can cause gastric or nervous system effects.
Personal protection: Safety goggle, nitrile gloves and lab coat should all be worn.
Engineering Controls: Use the fume hood in the Wind Tunnel Lab in Kirk.
Handling and Storage: Store in the yellow cabinet for the inflammables.
Stability and Reactivity: Stable. Avoid exposure to oxidizing agents, strong acids,
and strong alkali.
1st day

1. Cleaning: Add 75ml H2O2 and then 75ml H2SO4 sequentially to form piranha
solution. The substrate wafer is cleaned in the solution for 15 min (until no bubbles
are observed on the surface of the wafer) with gentle shaking. The wafer is then
soaked in distilled water for 5 mins (change to clean water and repeat 2 times ) with
gentle shaking.
2. Dehydration: Dehydrate the wafer at 200~220 ℃ for a minimum of 30 mins on hot
plate (No dehydration is needed when using AP300).
3. Adhesion improvement:
Method 1: After cleaning the silicon/glass wafer, spin SU-8 2002 for 25 sec. at
300rpm and 30 sec. at 3000rpm. The acceleration for low speed is usually set to
100rpm/sec, 300rpm/sec for high speed. The SU-8 2002 does not spread well on the
wafer. Repeat for multiple times until a desirable coating is observed.
Prebake at 65 ℃ for 1 min and softbake at 95 ℃ for 3 min. Over-expose without
photomask for 2 mins. Postbake at 65 ℃ for 1 min and 95 ℃ for 3 min. (Do not
develop it afterwards, this contaminates the wafer.)
Hard bake at 150 ℃ for 30 mins on hot plate.
Method 2: Blow the surface using clean nitrogen. After puddling 2-3ml AP300 on the
substrate, spin AP300 for 25 sec. at 300rpm and then 30 sec. at 3000rpm. Then, repeat
the spin coating to air dry the substrate. Make sure to put AP300 in perfectly sealed
Zip-Loc bag cushioned with nitrogen to protect it against moisture!!!
2nd – 3rd day
Temperature: _______________ Humidity: __________________
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4. SU8 preparation: After getting a new batch, loose the cap and heat photoresist at
an upright position at 50 ℃ in oven for 2 h. Don’t degas the bottle. Don’t pierce into
the resist as this may induce extra stress.
5. Spin coating: Align the wafer carefully with the chuck of coater. Blow the wafer
surface from center to edge with N2 gun. Next, spin SU-8 2050 for 45 sec at 300rpm
then 50sec at 600rpm (130-158 um layer). Remove large edge bead if necessary.
6. Planarization: Then, let it sit perfectly level for 1hr (relaxation time), so the
photoresist will “smooth out”. SU-8 has good self-planarization property.
7. Softbaking[1]: Make sure the hotplate is perfectly LEVELED before baking
the wafer. Then, ramp heat from 50 degrees to 95 degrees for 23 min at 2 ℃/min.
Bake for 3 hr at 95 ℃. Let cool to room temperature at 1 ℃/min.
Step 5-7 can be repeated if higher thickness film needs to be built. Add one extra
hour for baking at 95C when baking another layer. For instance, bake for 4 h at at
95℃ when baking the second layer. Bake for 5 h at at 95℃ when baking the third
layer, etc.
4th day
Optional Step (only for high aspect ratio):
Barrier Coating and Contrast Enhancement
1) Spin coat Barrier Coating 7.5 (ShinEtsuMicroSi, Pheonix, AZ) above the SU-8 at
1000rpm. Use more than anticipated, as it doesn’t spread well (this also
prevent substrate from sticking on the photomask. Air dry completely for 5
min. (enough time to spread at 300rpm, then fast ramp to 3000rpm, 60 s total).
2) Spin on Contrast Enhance Material 388SS (ShinEtsuMicroSi, Pheonix, AZ). Air
dry completely for 15 min.
8. UV Exposure: The Karl Suss MJB3-Broadband (3.5mW/cm2), 365nm i-line.
Make sure that there is no gap between photo mask and SU-8 surface. The gap would
result in widening of the patterns due to diffraction! Pay attention to the bubbles which
may also cause the gap.
UV exposure for 6 mins will work for 400um mold with barrier coat and Contrast
Enhance Material, only 2min one time with 1 min interval to allow surface cooling. [2]
USE HARD CONTACT. DON’T PRESS SOFT CONTACT BUTTON.
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Figure A-3: Diagram for UV light exposure for soft lithography mold creation
Tips on adjusting the alignment stage:
(1) the contact begin around 150 degree, fully contact at 170 degree. This is important
to make sure that the wafer is being hold properly, not to loose to cause gap, or
not to tight to stick on the photomask.
(2) Hold the outer silver ring when adjusting the stage. CW�lower, CCW�raise.
(3) Use razor to separate the wafer from mask carefully if wafer stick to mask.
Film Thickness:____300 μm____ ____100 μm___ _____50 μm_____
With CEM and BC: ___Y/N_____ ______________ ______________
Substrate material:___Silicon_____ ______________ _______________
Energy dosage required: _________ ______________ _______________
Estimated exposure time: 2.5+1+2.5 min ____2 min______ ____90 sec_______
Rinse in water (dissolving the Barrier Coat and lifting off the Contrast Enhance
Material) and air dry.
9. PEB[3]: ramp heat from 45 to 85 degrees at 2 ℃/min. Held for 40 min at 85 ℃. Let
it cool gradually to room temperature at 1 ℃/min.
10. Developing: Place the wafer face-down in the glass container. Set the shaker to
max speed 10 min in developer I (take the wafer out every 5 min and gently blow
dry with N2), 30 min in clean developer II (take the wafer out every 3 min and
gently blow dry with N2), and then 1min in IPA. Plasma could be used to clean
undeveloped residues from the mold. (Make sure use fresh solution for high aspect
ratio mold.)
Hard bake at 150 ℃ for 30 min (use 1 ℃/min as ramp to heat up and cool down).
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4th day
11. Channel Fabrication: (5:1 prepolymer/curing agent for high aspect ratio mold)
50+5g PDMS is typically enough for making 4 chips and one substrate for all.
For high aspect ratio PDMS pattern, more curing agent could be added (e.g. 1:5) to
the prepolymer.
Pour approximately 6g PDMS on wafer to form the first layer. Degas in the
vacuum oven. Bake at 60 ℃ for 30mins.
Add another 6g PDMS on wafer to form the second layer. Degas and bake at 60
℃ for 2.5 h.
For HAR PDMS patterns, degas 1 h for the 1st layer. Degas the 2nd layer as
usual and bake at 60 ℃ for 4.5 h.
12. Align PDMS to PDMS[4]: Bonding PDMS to PDMS can be done by spray a
liquid cushion of methanol after plasma treatment at 35psi for 3 mins. Do not do the
spray near a source of ignition, such as a hotplate. The alignment may be helped
by using a magnifier. Then, heat it on hotplate at 85 ℃ for 80mins. This method
allows aligning of different PDMS layers without immediate bonding.
Tips:
[1] Ramped heating reduce the tension in the film during the baking. It’s better to use
hotplate than oven. Extend prebaking and softbaking time longer, use a Petri dish to
cover the slide may avoid wrinkles and craters. The actual soft baking time ( e.g 1.5
hrs) is almost 2 times longer than the suggested soft baking time by the vendor in
order to make the SU-8 dried completely.
[2] Never illuminate the SU8 for to long periods. Energies of 200 mJ/cm2, heat the
SU8 at the interface with the photolithographic mask. This heating is responsible for a
hard skin formation at the surface of the SU8. Therefore, for thick layers and for high
exposure doses, the illumination should be done stepwise ( expose for 10 to 15
seconds, leave the system cool down for 60 seconds, illuminate again, etc ...).
It is important to note that the optimal exposure energy depends on the nature of the
substrate.
[3] Post exposure baking must be done gradually to prevent micro-cracks of mold due
to thermal tension.
[4] When aligning two PDMS patterns, grooves must be designed to allow methanol
evaporates.
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[5] Cross-linked SU-8 cannot be removed even by Piranha.
[6] The 2nd layer of photoresist will not level dimples on the 1st layer.
Troubleshooting:
1. Dimples. –a sign of surface/thermal tension (a) Caused by surface contamination,
can be resolved by cleaning in Piranha; (b) Caused by bubbles or residual tension in
SU-8, can be resolved by heating photoresist at 50 ℃ in oven for 2 h; (c) Presence of
micro particle in the resist, likely from air; (d) Due to uneven heating of surface, this
is most unlikely to happen; (e) High humidity won’t cause dimples, we have been
successful in obtaining “mirrored” film from 20-60% humidity at 25C.
2. Poor adhesion. Generally, glass has very poor adhesion to SU-8. Bare silicon has
medium adhesion to SU-8. Patterns wider than 200 μm should be fine on silicon. For
patterns <50 μm, adhesion promoting methods are needed, the following will help (a)
clean the wafer thoroughly with Piranha, (b) Use AP300, sputtered chromium film, or
SU-8 2002 as adhesion promoter, (c) over- expose the pattern.
3. Soft mold. (a) It could be that the resist film still “wet”, increasing softbaking or
PEK time. (b) under-exposure due to insufficient exposing time, less reflective
substrate, or thicker CEM and BC film. (c) high humidity, SU-8 uptakes moisture.
Written by: Peng Li
Microfluidic Lab, URI
Updated on Jun. 29, 2009
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A.4: Protocol for CRP Detection Tests[147]

Microfluidic Immunoassay Protocol for Detection of C-Reactive Protein
Experiment date: _________________
Temperature: _______________
Objective:
Important Note:
Equilibrate buffer to RT before experiments!
 Keep the channel wet by sealing Petridish with Parafilm during all processes.
 Don’t wipe the chip with tissue, always dry it with long-fiber cloth and keep the
surface free from particle.
 Always have a negative control and a positive control for each experiment.
 Make sure the surface isn’t in contact with fluorophores. It causes high
background.
 Flush the channels with PBS buffer and then aspirate them between steps.
Surface Functionalization:
1. All microchannels are coated with BSA (1.5mg/ml in PBS) for 244 min at RT.
2. The coated channels are then activated by 0.4% (v/v) glutaraldehyde in pure water
for 1h at RT.
3. Protein A (50g/ml in PBS) is incubated with the channel for another 1 h at RT.
Storage: stored at 4 °C in a buffer consisting of 10 mM Tris, 0.05% BSA, 0.05%
Proclin 300, and 5% glycerol.
Immunoassay:
ImmunoChips Functionalized on: ___________________
4. Take pre-functionalized chips out from the package. Flush the channels with 1X
PBS buffer.
5. Rabbit polyclonal IgG to C-reactive protein (CRP) in Protein A/IgG binding
buffer with concentrations shown in the table below is injected into channels and
incubated for 7 min at RT.
6. Flush the channels with PBS. Then, empty the channel. Make sure it is free of
residual liquid.
7. Inject CRP in PBS with concentrations listed in the table into channels. Incubate for
5 min at RT.
8. Flush the channels with PBS. Then, aspirate the channel. Make sure it is free of
residual liquid.
9. FITC labeled goat polyclonal IgG to CRP in PBS with concentrations shown in the
table below is injected into channels and incubated for 5 min at RT.
10. Wash channels by PBST (1x PBS+0.5l/ml Tween 20). Incubate 5 min during the
wash.
11. Refill channels with PBS and take image using exposure time 2.5 s and 84%.
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Schematic of Sandwich Immunoassay
rIgG to CRP: 1 mg/ml
(in Binding Buffer).
CRP: 2.13 mg/ml
gIgG to CRP: 1 mg/ml
Concentrations in Micro-channels（
g/ml）
1

2

3

4

5

rIg to
CRP
CRP

Microscope Setup:
0. Clean the glass slide and the 5x objective.
1. Brightness -0.50; Contrast 1.00; G.0.45 1.00.
2. Use Linearize for histogram (14 bit 16383).
3. Don’t press White Balance in fluorescence
mode. (Cyan 1.11 Red, Mag 1.41 Green, Yellow
0.48 Blue).
4. 1300×1030 RGB scanned color.
5. Index set to 0; Black reference enabled.
6. Best Fit set to 0%, disable Min/Max.
7. Push lever all the way in; shutter at 1st gear.

gIg to
CRP

Table A-1: Capture antibody, CRP and detection antibody concentrations example for
immunoassays

226

1

5

A.5: Example Graphs Taken from Fiber Optics for CRP Detection

Figure A-4: CRP detection at intensity = 5274 (concentration ~ 1.3 µg/mL in blood)

Figure A-5: CRP detection at intensity = 10256 (concentration ~ 3.4 µg/mL in blood)
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B.1: Protocol for Phage Display with Agar Plates (Translated from German)[143]

Panning Ab-libraries: Panning mit biotinylierten Oligopeptiden
Dissolve the Oliogpeptide in PBS with 5%DMSO.
Coat 100 ng Streptavidin in 100 µl PBS per Well overnight at 4°C. For each panning
round coat two wells on two separate Maxisorb Stripes! One well is for the
biotinylated Oligopeptide binding und second well is for the pre-incubation of the AbPhage library on top of streptavidin, in order to remove streptavidin binders!
Alternative: Coat 100 ng biotinylated Oligopeptides in PBS or NaHCO3 Buffer per
well overnight at 4°C direct on the plate. Check beforehand the Streptavidin-HRP
Conjugae, if the Oligopeptides bind on the plate!
Wash with PBST in the 3xELISA-Washer (Program "3 N"), to remove the unbound
Streptavidin.
Place 100 - 500 ng biotinylated Oligopeptides in 150 µl PBS in a Streptavidin Well
geben and incubate for 1 h at RT (not when the Oligopeptides are coated directly on
the plate!).
Wash with PBST in the 3xELISA-Washer (Program "3 N"). Fill the wells to
completely block with 2%MPBST. Incubate at RT for 2 h.
At the same time, block an empty Streptavidin well (without Antigens) per round with
Panning block for1 h. (when the Oligopeptides are coated directly on the plate, block
an empty well with panning block)
After pre-incubate the Ab-library (1x1011-1x1012 Ab-Phage, depending on the library),
or the amplified Phage in the previous panning rounds in 150 µl panning block for 1 h.
Transfer the Phage from the pre-incubation wells to the wells with the antigen, add
100 ng streptavidin (competitive assay from the previously used Streptavidin binders)
and incubate for 2h at RT.
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Remove the unspecific bounded phage in the ELISA-Washer (Program "10OBN" with
Nunc Maxisorbplatte, "10BONS2" with Nunc Maxisorb Stripes).
Elute the bounded Phagen with 200 µl 10 µg/ml Trypsin for 30 min at 37°C [with basic
Elution 150 µl 100 mM Triethylamin, 5 min at RT on the shaker (too long of an Incubation reduces the
infectionality of the phage). Neutralize the Phage with 150 µl 1M Tris HCl pH7.5. With acidic Elution:
150 µl HCl/Glycin 0,1 M pH 2,2, incubate 15 min on the shaker. Neutralize with150 µl Phosphate
buffer pH 7,6].

Innoculate 50 ml 2xTY-T mit XL1-Blue . Take the colony up O.D.600 0,5. Take 20 ml
and infect with 190 µl Phage, Incubate for 30 at 37°C. Centrifuge for 10 min at 4000
rpm (3220xg).
Titration Setup:
Infect 50 µl der XL1-Blue Kultur with around 10 µl 10-2 -10-8 (after each panning
round) Phage elution. Incubate for 30 min at 37°C and plate up the LB-Amp und
incubate overnight at 37°C (see Protocol Titration Setup).
--------------Dissolve the pellet in 250 µl SOB-GA und coat on an SOB-GA Agarplatte (15 cm
diameter). Incubate overnight at 37°C.
On the next day, clean the Bacteria off with around 5 ml TY-GA (use DrigalskiSpatula) and place in a Falcon.
Innoculate 50 ml 2xTY-GA mit 50-200 µl Bacteria (O.D. 600<0,1). Incubate the colony
at 37°C until the O.D.is between 0,4-0,5. Infect with 5 ml (~2,5*109 bacteria)
M13K07 a 1:20 ratio (5*1010 pfu) and incubate for 30 min at 37°C without shaking
and 30 min at 200 rpm.
Centrifuge the resulting bacteria at 4000 rpm (3220xg) for 5 min and place in Glycerin
stocks with 20 % Glycerin.
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In order to remove the glucose, (Phage will not build, if the Lac-Promotor is blocked),
pellet the bacteria at 4000 rpm (3220xg) for 10 min (Eppendorf 5810R, Rotor A-4-81).
Carefully resuspend the pellet in about 2xTY-AK and add in 30 ml 2xTY-AK in a
100 ml Erlenmeyer flask. Incubate overnight at 30°C and 250 rpm in the shaking
incubator.
Centrifuge the bacteria for 10 min at 4000 rpm (3220xg) at 4 °C in a falcon.
Place the supernatant in a new falcon (if the supernatant is still cloudy, centrifuge the
suspended bacteria again!) and precipitate the Phage particles with an additional 1/5
Volume PEG/NaCl. Mix the supernatant and incubate for 1 h on a shaker in ice.
Centrifuge for 1 h at 4000 rpm (3220xg) (Falcon) and 4 °C.
Remove the PEG-dissolved efficiently (Tube above roll of papertowels).
Resuspend the pellet in 500 µl Phage-Dilution Buffer and transfer to a 2 ml cap.
Centrifuge the rest of the bacteria at 13,000 rpm for 1 min and transfer the supernatant
to a 2 ml vial and incubate at 4°C or to begin the next panning round.
Chemicals and Compounds:


PBS pH 7,4 (8,0 g NaCl, 0,2 g KCl, 1,44 g Na2HPO4*2H2O, 0,24 g KH2PO4

per 1 l)


DMSO



50 mM NaHCO3, pH 9,6



Streptavidn (Applichem)



PBST (PBS+ 0,1% Tween 20)



2 % MPBST (2 % milk powder in PBST, kept fresh)



Panning block (1 % milk powder + 1 % BSA in PBST, kept fresh)



10 µg/ml Trypsin in PBS



100 mM Triethylamin
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Phosphate buffer pH 7,6 (6 mM NaH2PO4, 50 mM Na2HPO4)



HCl/Glycin 0,1 M pH 2,2



1 M TrisHCl pH 7.5



2xTY-Medium pH 7,0 (1,6 % Tryptone, 1 % wheat extract, 0,5 % NaCl)



2xTY-T (2xTY + 50 µg/ml Tetracyclin)



2xTY-GA (2xTY + 100 mM Glucose + 100 µg/ml Ampicillin)



2xTY-AK (2xTY + 100 µg/ml Ampicillin + 50 µg/ml Kanamycin)



Mg-solution 2 M (1 M MgCl, 1 MgSO4)



SOB Medium pH 7,0 (2 % Tryptone, 0,5 % wheat extract, 0,05 % NaCl, sterile

after autoclaving, before using 20 mM Mg-solution addition)


SOB-GA (SOB + 100 µg/ml Ampicilin + 100 mM Glucose)



2 M Mg-Lösung (1 M MgCl2 + 1 M MgSO4)



Ampicillin (100 mg/ml Stock)



Kanamycin (10 mg/ml Stock)



2 M Glucose (filtered sterile)



Glycerin 87%, autoclaved



PEG/NaCl (20% (w/v) PEG 6000 und 2,5 M NaCl)



Phage Dillution Buffer (10 mM TrisHCl pH7,5, 20 mM NaCl, 2 mM EDTA)

Organisms:


VCS-M13 or M13K07 Helper phage or Hyper phage (Kanamycin-Resistance)



XL1-Blue MRF' (Tetracyclin Resistance) (Amber Suppressor Mutated (sup E))



Phage bank Glycerol stock
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Hint: XL1-Blue can be grown up to O.D. 0.5 und then kept on ice until infection (FPili remains at 4°C)
Materials and tools:


Filtertips



50 ml Falcon



2 ml screw on vial



Immunotubes or Microtiter 8 row plates (250-300µl per well) (Nunc Maxisorb)



Microtiter plates or Stripes with bound Streptavidin



Petridish 15cm diameter



Eppendorf 5810R, Rotor A-4-81

Work schedule for a panning round:
Day 0: Antigen coating
Day 1: Panning, Titration of the eluted phage, overnight growth of the eluted Abphage
Day 2: Overnight growth and amplification of the eluted phage
Day 3: PEG-Precipitation of the phage, Titration of the amplified phage + antigen
coating
Day 4: Evaluation of the titration, next panning round
M.Hust 11/16/05
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B.2: Protocol for Phage Display with Micro Titer Plates (Translated from German)[144]

Panning Ab-libraries: Panning in Immunotubes (MTPs)
Coat the well with the antigen (5 µg Protein should be used for the first panning
round, 0,5-5 µg or a constant 5 µg for the following rounds): Dissolve the protein in
150 µl 1xPBS or NaHCO3-buffer (preferred) and place in a well. Incubate overnight at
4°C. (with biotinylated antigens, coat 200 ng Streptavidin in 150 µl NaHCO3-buffer
overnight at 4°C and wash away the next day the Streptavdin with the Washer and
incubate the biotinylated Antigen for 45 min at RT in 50 µl PBS).]
Remove the antigen solution.
Completely fill in order to block the wells with 2%MPBST. Incubate at RT for 2 h.
Wash with PBST in a 3xELISA-Washer (Program "3 N").
At the same time, block completely an empty well (without antigens) per round with
panning block for1 h.
Then pre-incubate 1x1010-1x1012 scFv-Phage from the library (with HAL7/8 around
2,5x1011), or the amplified Phage from the previous panning round in 150 µl panning
block for 1 h.
Transter the phage from the pre-incubation wells into the wells with the antigen and
incubate for 2h at RT.
Remove the not or partially bound Phage in the ELISA-Washer (Program "10OBN"
with Nunc Maxisorb plate, "10BONS2" with Nunc Maxisorb Stripes). The number of
the washing repeats is based on the number of the panning round (ex. 2x wash with 2nd
panning round).
Elute bound scFv-Phage with 200 µl 10 µg/ml Trypsin for 30 min at 37°C.
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Innoculate 50 ml 2xTY-T mit XL1-Blue. Let the colony grow until O.D.600 = 0.5. Add
20 ml and infect with 200 µl eluted scFv-Phage in a 50 mL Falcon, incubate for 30
min at 37°C for 10 min.
Centrifuge at 4000 rpm (3220xg).
Titration setup of the eluted phage:
Plate 200 µL of the infected bacteria (10-2) und plate again 20 µL for the dilution in
PBS und around 100 µL (10-4 - 10-6). Incubate overnight at 37°C (see protocol
Titration setup).
---------------

Dissolve the pellet in 250 µl 2xTY-GA und spread on a 2xTY-GA Agar plate (15 cm
diameter). Incubate overnight at 37°C.
The next day, suspend the bacteria with around 5 ml 2xTY-GA (use DrigalskiSpatula) and transfer into a falcon.
Innoculate 30 ml 2xTY-GA in a 100 mL flask with 50-200 µl bacteria (O.D. 600<0,1).
Let the colony grow at 37°C until the O.D. is around 0,4-0,5. 5 ml (~2,5*109 bacteria)
infect with M13K07 in a 1:20 ratio (5*1010 pfu) incubate for 30 min at 37°C without
shaking und 30 min at 200 rpm.
Centrifuge the suspended bacteria at 4000 rpm (3220xg) for 5 min and place in
Glycerin stocks with 20 % Glycerin.
This step is common, but not necessary!
--------------In order to remove the glucose, (Phage will not build, if the Lac-Promotor is blocked),
pellet the bacteria at 4000 rpm (3220xg) for 10 min (Eppendorf 5810R, Rotor A-4-81).
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Carefully resuspend the pellet in about 2xTY-AK and add in 30 ml 2xTY-AK in a
100 ml Erlenmeyer flask. Incubate overnight at 30°C and 250 rpm in the shaking
incubator.
Centrifuge the bacteria for 10 min at 4000 rpm (3220xg) and 4 °C in a Falcon (if the
supernatant is still cloudy, centruge the suspended bacteria again!). Take twice 1 mL
supernatant (~1x1012 Phagen/mL), store at 4°C, or bzw. Directly add 100 µL + 50 µL
panning block for the next panning round. Titrate the amplified phage to the control
(see protocol: Titration steps).
This step of the process is optional:
Place the supernatant in a new falcon (if the supernatant is still cloudy, centruge the
suspended bacteria again!) and precipitate the Phage particles with an additional 1/5
Volume PEG/NaCl. Mix the supernatant and incubate for 1 h on a shaker in ice.
Centrifuge for 1 h at 4000 rpm (3220xg) (Falcon) and 4 °C.
Remove the PEG-dissolved efficiently (Tube above roll of papertowels).
Resuspend the pellet in 500 µl Phage-Dilution Buffer and transfer to a 2 ml cap.
Centrifuge the rest of the bacteria at 13,000 rpm for 1 min and transfer the
supernatant to a 2 ml vial and incubate at 4°C or to begin the next panning round (see
protocol: Titration steps).
Chemicals and solutions:


PBS pH 7,4 (8,0 g NaCl, 0,2 g KCl, 1,44 g Na2HPO4*2H2O, 0,24 g KH2PO4

per 1 l)


50 mM NaHCO3, pH 9,6



PBST (PBS+ 0,1% Tween 20)



2 % MPBST (2 % milk powder in PBST, kept fresh)



Panning block (1 % milk powder + 1 % BSA in PBST, kept fresh)



10 µg/ml Trypsin (Sigma T-0303) in PBS
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100 mM Triethylamin



Phosphate buffer pH 7,6 (6 mM NaH2PO4, 50 mM Na2HPO4)



HCl/Glycin 0,1 M pH 2,2



1 M TrisHCl pH 7.5



2xTY-Medium pH 7,0 (1,6 % Tryptone, 1 % wheat extract, 0,5 % NaCl)



2xTY-T (2xTY + 50 µg/ml Tetracyclin)



2xTY-GA (2xTY + 100 mM Glucose + 100 µg/ml Ampicillin)



2xTY-AK (2xTY + 100 µg/ml Ampicillin + 50 µg/ml Kanamycin)



2xTY-GA Agar plate (2xTY-GA + 1,5% Agar)



Ampicillin (100 mg/ml Stock)



Kanamycin (10 mg/ml Stock)



2 M Glucose (filtered sterile)



Glycerin 87%, autoclaved



PEG/NaCl (20% (w/v) PEG 6000 und 2,5 M NaCl)



Phage Dillution Buffer (10 mM TrisHCl pH7,5, 20 mM NaCl, 2 mM EDTA)

Material und Tools:


Filtertips



50 ml Falcon



2 ml screw on vial



Immunotubes or Micro titer 8 row plate (250-300µl per well) (Nunc Maxisorb)



Streptavidin Immunotubes/MTPs/Stripes (Nunc)



Petri dish 15cm diameter



Eppendorf 5810R, Rotor A-4-81
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Tecan Columbus ELISA Washer



MTP shaker Vortemp56 (Labnet) oder Thermo Shaker PST-60HL-4

(Lab4You)
Organisms:


M13K07 Helper phage oder Hyper phage (Kanamycin-Resistant)



XL1-Blue MRF' (Tetracyclin Resistant) (Amber Suppressor Mutated (sup E))



Phage bank Glycerol stock

Hint: XL1-Blue can be grown up to O.D. 0.5 und then kept on ice until infection (FPili remains at 4°C)
Arbeitsablauf für eine Panningrunde:
Work schedule for a panning round:
Day 0: Antigen coating
Day 1: Panning, Titration of the eluted phage, overnight growth of the eluted Abphage
Day 2: Overnight growth and amplification of the eluted phage
Day 3: PEG-Precipitation of the phage, Titration of the amplified phage + antigen
coating (optional)
Day 4: Evaluation of the titration, next panning round
M.Hust 09/12/11
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B.3: Number of Colonies Obtained for Each Panning Round
104
105
106
Average*
Too Many
153
7
153 X 105
Tau Colonies
Table B-1: Tau E. coli colonies after third panning round (panning in micro titer
plates)
104
105
106
Average*
Too Many
Too Many
330
---Tau Colonies
Table B-2: pTau E. coli colonies after third panning round (panning in micro titer
plates)
104
105
106
Average*
31
1
1
20.5 X 104
Tau Colonies
Table B-3: pTau L1 with competition from Tau L1 E. coli colonies after third panning
round (panning in micro titer plates)
104
105
106
Average*
2
0
0
1.0 X 104
Tau Colonies
Table B-4: pTau L2 with competition from Tau L2 E. coli colonies after third panning
round (panning in micro titer plates)
* The average values were taken from the average between the 104 and 105 counts.
This was performed with the formula ((104 coefficient) + 10 x (105 coefficient)) / 2.
The resulting coefficient is multiplied by 104 to obtain the average result.
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